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Titre : Prévention de la transmission du VIH de la mère à l'enfant au Mozambique: 
engagement dans les soins et défis programmatiques de la stratégie B+  
En 2015, l’Organisation Mondiale de la Santé a mis en œuvre des nouvelles lignes directrices 
sur la prévention de la transmission de la mère à l'enfant (PTME) du VIH recommandant à 
toutes les femmes enceintes et allaitantes séropositives, d'initier la trithérapie antirétrovirale à 
titre de traitement à vie (option B+). Cependant, il existe de plus en plus d'inquiétudes quant à 
l'efficacité de cette stratégie pour réduire réellement la transmission verticale du VIH à la 
lumière des défis programmatiques de sa mise en œuvre ; on observe en particulier des niveaux 
sous-optimaux de suivi dans les soins chez le couple mère/enfant en Afrique sub-Saharienne. 
Notre thèse vise à évaluer, d’un point de vue de santé publique, l’engagement dans les soins du 
couple mère/enfant en prenant l’exemple du Mozambique, pays connu pour avoir l'une des 
prévalences du VIH les plus élevées au monde. Nous analysons, plus particulièrement trois 
aspects importants de l’engagement dans les soins : les résultats du programme PTME avec une 
attention toute particulière sur la rétention des femmes enceintes séropositives initiant la 
trithérapie antirétrovirale et la couverture du dépistage du VIH chez l’enfant exposé ; les 
interventions visant à améliorer ces résultats et les méthodes de mesures de rétention dans les 
soins et leurs impacts programmatiques.  
Nous observons dans ce contexte mozambicain une couverture élevée du dépistage du VIH, 
une amélioration significative de la couverture du traitement antirétroviral au cours du temps 
et une meilleure acceptation du traitement chez les femmes enceintes séropositives. Cependant, 
la rétention dans les soins à la fin de la première année du traitement antirétroviral chez les 
femmes enceintes VIH+ et la couverture du dépistage du VIH chez les nourrissons exposés 
restent sous-optimales. Nous concluons que les interventions visant à améliorer l’engagement 
dans les soins du couple mère-enfant doivent être systématiquement encouragées. Enfin, nous 
soulignons la grande hétérogénéité des définitions des indicateurs utilisées dans les différents 
programmes de PTME. 
Ce travail met en évidence les lacunes dans l'engagement du couple mère-enfant dans les soins 
pour la PTME et ses conséquences sur l'élimination virtuelle de la transmission vertical du VIH. 
Nous soulignons également l’importance d’une approche consensuelle pour mesurer les 
indicateurs clés afin de permettre des comparaisons à l’échelle nationale et internationale. Les 
efforts visant à suivre les femmes sous traitement tout au long de leur vie, en veillant à ce que 
leurs nourrissons exposés au VIH reçoivent les soins attendus jusqu'à ce que leur statut VIH 
définitif soit déterminé, constituent la pierre angulaire de l’obtention d'une génération sans Sida 
pédiatrique d'ici 2030. 
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Title: Prevention of mother-to-child transmission (PMTCT) of HIV in Mozambique: 
engagement in care and programmatic challenges for the B+ strategy  
In 2015, the World Health Organization published new guidelines for the prevention of mother-
to-child transmission (PMTCT) of HIV and recommended that all seropositive pregnant and 
breastfeeding women be provided with lifelong anti-retroviral therapy (ART) (option B+). 
However, there are rising concerns about the effectiveness of the strategy in truly reducing the 
number of vertical HIV transmissions; there are indeed programmatic challenges related to its 
implementation; in particular, the sub-optimal levels of engagement in care of mother/infant 
pairs observed mainly in sub-Saharan Africa. The aim of the present thesis was to discuss, from 
a public health perspective, the programmatic challenges of engagement in care under option 
B+ strategy, with the example of Mozambique, a country known to have one of the highest HIV 
prevalence figures in the world. More specifically, we focused on three important aspects of 
engagement in care: PMTCT outcomes with a special focus on maternal ART retention and 
HIV infant testing uptake; interventions aimed at improving these PMTCT outcomes and 
methods of measurements of retention in care with their potential programmatic impact. We 
observed a high uptake of HIV testing, significant improvement in ART coverage over time 
and a better acceptance of ART at initiation in HIV+ pregnant women. Retention in care by the 
end of the first year of ART in HIV+ pregnant women and HIV testing coverage in HEI remain 
sub-optimal. Therefore, interventions to improve the mother-infant pair’s engagement in care 
should be systematically promoted. Finally, we underscore the considerable heterogeneity of 
definitions of outcomes used across various PMTCT programs.  
This work has highlighted the gaps in optimal engagement care of the mother-infant pair and 
its consequences on achieving virtual elimination of MTCT of HIV. We also highlighted the 
importance of having a consensus approach to measure PMTCT programme outcomes to allow 
national and international comparisons. Efforts to retain women under lifelong ART, ensuring 
their HIV-exposed infants receive the expected PMTCT services at the right moments along 
the continuum until final HIV status is determined, is the cornerstone of achieving an AIDS-
free generation by 2030. 
Key words: PMTCT, HIV, option B+, engagement in care, retention, Mozambique 
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Glossary  
 
Antiretroviral Therapy Standard antiretroviral therapy (ART) consists of the combination of 
antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop 
the progression of HIV disease. ART also prevents onward transmission 
of HIV, reduces morbidity and mortality in people living with HIV.  
Engagement in care Patient engagement in his/her’s own health, care and treatment. 
Specifically, engagement in HIV care refers to a patient who is actively 
engaged in and receiving regular HIV care, by a dynamic navigation 
through the complete spectrum of HIV care and treatment with the final 
goal of achieving and maintaining viral suppression. 
HIV continuum of care  The HIV continuum of care defines the dynamic and bidirectional 
relationship that exist between steps or stages of HIV medical care that 
people living with HIV go through from initial diagnosis to achieving the 
goal of viral suppression.  
HIV treatment cascade The HIV treatment cascade depicts prevalence estimates for discrete 
steps along the HIV care continuum from HIV diagnosis through viral 
suppression. The cascade is outcome-oriented: it begins with 
quantitative estimates of prevalent HIV cases, successive bars illustrating 
the subsequent steps of HIV diagnosis, linkage to care, retention in care, 
antiretroviral therapy (ART) receipt, and plasma viral suppression.  
HIV testing yield The proportion of clients undergoing HIV testing who test positive 
Option B and B+ strategies Strategies used for the Prevention of Mother to child transmission of HIV.  
Option B recommends ART for all HIV-infected pregnant and lactating 
women beginning in the antenatal period and continuing throughout the 
duration of breastfeeding. At the end of breastfeeding those who do not 
yet require ART for their own health would discontinue ART and continue 
to monitor their CD4 count, eventually re-starting ART when the CD4 falls 
below 350 cells/mm3.  
Option B+ recommends life-long ART for all pregnant and breastfeeding 
women living with HIV regardless of their CD4 count.  
Prevention of Mother to Child 
Transmission (PMTCT) of HIV 
Prevention of mother-to-child transmission (PMTCT) of HIV comprise a 
set of interventions to prevent the vertical transmission of HIV from the 
HIV-infected women to her HIV-exposed infant. Effective preventive 
interventions are provided during the periods of pregnancy, labour, 
delivery, and breastfeeding.  
Unmet need for family planning  Percentage of women of reproductive age, either married or in a union, 
who have an unmet need for family planning. Women with unmet 
need are those who want to stop or delay childbearing but are not using 
any method of contraception. 
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1 General introduction 
1.1 HIV/AIDS epidemic in East and Southern Africa 
1.1.1 Epidemiology of the HIV epidemic  
By the end of 2018, there were an estimated 37.9 million people living with HIV (PLHIV) 
worldwide. Of these, more than a half (20.6 million, 54%) were living in East and Southern 
Africa (Figure 1.1) [1]. This high-burden region also bears the highest numbers of new 
infections, with 47% of 1.7 million new infections estimated worldwide. Of the 20.6 million 
PLHIV in East and Southern Africa, 1.1 million were children less than 15 years of age. Most 
of these children were infected by their HIV-positive mothers during pregnancy, childbirth, or 
breastfeeding. By the end of 2018, a total of 310,000 people died from AIDS-related illnesses, 
bringing the total number who have died from AIDS-related illnesses since the start of the 
epidemic to 17.5 million in the region.   
Remarkable efforts have been made over the past two decades in reducing HIV-associated 
morbidity, mortality, transmission, and stigma as well as in improving the quality of life of 
PLHIV. In East and Southern Africa, new HIV infections and deaths decreased by 28% and 
44%, respectively, owing largely to the investments, commitments, and innovations used to 
respond to the HIV epidemic.  
 
 
 Figure 1.1: Number of people living with HIV/AIDS worldwide, all ages, 2018 
 
 
Source: UNAIDS, AIDSinfo, 2018 [1] 
 
 
 
 
 
 
million PLHIV 
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1.1.2 The paradigm shifts in the approach to antiretroviral treatment scale-up 
Since 2000, there has been a growing evidence that PLHIV who are virally suppressed cannot 
transmit the virus to their sexual partners [2]. Three major studies undertaken between 2007 
and 2016 in more than 20 different countries confirmed the absence of sexual transmission of 
the virus from virally suppressed HIV-positive patients to their seronegative partner [3–5].  
Early initiation of antiretroviral treatment (ART) and Pre-exposure prophylaxis (Prep) using 
ARV drugs for HIV prevention can achieve significant reduction in the number of HIV 
transmission and accelerate the response to the HIV epidemic. As treatment services are scaled-
up, rather than focusing on a single time point, a more longitudinal assessment of engagement 
in care was needed to better measure the outcomes of ART programs. In this context, the 
priority was then shifted to monitor progress along the HIV continuum of care by measuring 
patients receiving services at each step of the HIV care cascade.  
With the ultimate goal of HIV care and treatment programs being to end the HIV epidemic by 
2030, three major approaches all coherent with this new vision, have been promoted by the 
international community: United Nations Program on HIV/AIDS (UNAIDS)’ 90-90-90 targets, 
WHO’s ‘Test and Treat’ strategy and the Prevention Access Campaign’s ‘U=U’ campaign.  
 
The 90-90-90 HIV care cascade  
In 2014, ambitious targets were set by UNAIDS 
and its partners, known as the ‘90-90-90’ 
treatment target. It aims that by 2020, 90% of all 
PLHIV should know their HIV status; of those 
tested HIV-positive, 90% will receive sustained 
ART; and of those receiving ART, 90% will 
have viral suppression (Figure 1.2). If these 
targets were met, at least 81% of all PLHIV 
would be on treatment, 73% of all PLHIV would 
be virally suppressed. New HIV infections and 
HIV-related deaths would be reduced to less than 
500,000. Statistical modelling has suggested that 
achieving these targets by 2020 could lead to the 
end of the AIDS epidemic by 2030.   
 
Figure 1.2 : Key Fast Track Targets 
Source: UNAIDS 2014 [6] 
 
However, the current status of the 90-90-90 cascade in East and Southern Africa falls short of 
the expected targets. At the end of 2018, 85% of the estimated 20.6 million PLHIV knew their 
status, 79% were on ART and 87% of PLHIV on ART had suppressed viral loads, making the 
achievement of the target at ‘85-79-87’ (Figure 1.3). This is a significant improvement 
compared to previous years and compared to the global figures for the same year (‘79-78-
86’)[1].  
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Figure 1.3: Progress towards 90-90-90 target, Eastern and Southern sub-Saharan Africa, 2015 to 
2018.   
 
 
Source: UNAIDS, AIDSinfo, 2018 [1]; note: the lighter colour in the bars correspond to the estimated number of 
missing to PLHIV to reach the 90-90-90 targets. 
 
The ‘Test and Treat’ strategy and the new WHO 2018 ART guidelines 
WHO recommended in 2016 the ‘Test and Treat’ (T&T) strategy, in which all children, 
adolescents, and adults, including all pregnant and breastfeeding women, living with HIV 
should be provided with lifelong ART regardless of CD4 cell count, as a way to decrease 
community viral load and to reduce the rate of new HIV infections[7].  The preferred first-line 
regimen was tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) (or emtricitabine, FTC) 
+ efavirenz (EFV).  
Recent studies have demonstrated an increase in the levels of pre-treatment ARV drug 
resistance in low- and middle-income countries ranging from 3% to 30%, with higher rates of 
resistance observed for NNRTI-based regimens mainly due to sub-optimal viral suppression 
[8–11]. In response, WHO issued guidelines recommending that countries with pre-treatment 
resistance to EFV or nevirapine (NVP) at or above 10% should urgently consider revising their 
first-line regimens [12] ; and in 2018, a dolutegravir (DTG)-based regimen was recommended 
as the preferred first-line regimen [13]. The drug has shown an improved safety profile 
compared with EFV in randomized studies [14–16] and also has a high barrier to development 
of drug resistance [17,18]. In addition, DTG has been found to be effective for pregnant women 
and was also found in breast milk, resulting in significant plasma concentration in infants and, 
thus, a potential important drug to reduce mother-to-child transmission (MTCT) of HIV [19]. 
However, an observational study in Botswana, the TSEPAMO Study, reported in 2012 a 
potential safety risk for developing neural tube defects among infants born to women who were 
taking DTG at conception [20,21].  
Since then, several studies have provided additional safety data of DTG in pregnancy[22–26]. 
An observational cohort study in Botswana of 1,729 pregnant women showed similar rates of 
adverse birth outcomes (including stillbirth, neonatal death, preterm birth) in both women 
receiving dolutegravir-based ART and those receiving efavirenz-based ART in pregnancy[23]. 
A systematic review of 1,200 pregnant women treated with DTG reported similar percentages 
of adverse birth outcomes and congenital abnormalities compared to historical control studies 
85% 
79% 
87% 
million PLHIV 
million PLHIV 
know their HIV status 
million PLHIV 
receiving ART 
million PLHIV 
have suppressed VL
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of HIV-positive women[24]. After an extended period of surveillance, new findings from the 
TSEPAMO study reported that prevalence of neural-tube defects associated with DTG 
exposure at conception declined from 0.94% to 0.30% of deliveries although still significantly 
higher than the 0.10% observed among women receiving non-dolutegravir ART [27] (ref). By 
mid-2019, based on these results, caution was still recommended by WHO when providing 
DTG-based ART regimens in adolescent girls and women of childbearing age. Consistent and 
reliable contraception method is recommend to be systematically provided for them to avoid 
potential neural tube defects among newborns [13]. 
 
The ‘U=U’ campaign  
In 2016, the official ‘Undetectable=Untransmittable’ (U=U) campaign was launched by the 
Prevention Access Campaign, which has since then been endorsed by more than 60 countries 
worldwide. The ‘U=U’ campaign has been an important message of 2017 to fight the HIV 
epidemic and to promote the ‘Test and Treat’ strategy as its pillar for achievement of the 
UNAIDS’s 90-90-90 target by 2020.  The campaign has already been successful in influencing 
national HIV treatment policies, public opinions, and encouraging more and more people living 
with HIV to seek treatment [2].  
However, implementing these new approaches has important implications for programme 
priority-setting, funding and service delivery, especially in high HIV burden countries. As more 
people are expected to start ART earlier, the burden on health facilities is expected to increase, 
which could lead to reduced quality of services and increased risk of patients’ dropping out of 
care.  
  
1.2 Prevention of Mother-to-Child Transmission (PMTCT) of HIV  
1.2.1 What is PMTCT of HIV? 
Mother-to-Child Transmission (MTCT) of HIV is one of the leading causes of HIV 
transmission in children. It can occur during pregnancy, delivery or breastfeeding (Figure 1.4). 
In the absence of any intervention, MTCT rates range from 25% to 40% among infants who 
were breastfed.  Over a half of infants vertically infected with HIV would die before the age of 
2 years [28,29]. Maternal viral load is a strong predictor of the risk of transmission regardless 
of timing of transmission. The rate can be reduced to less than 5% when women achieve viral 
suppression[30–33] through various interventions put in place during the periods of pregnancy, 
labour, delivery, and breastfeeding, including ARV treatment for the mother which will be 
discussed in further detail.  
 
Figure 1.4: Timing of Mother-to-Child transmission and transmission risk estimates in the absence of 
ARVs for PMTCT  
Early (<28 we) Late (³28 we)  Late (6-24 mos) Early (0-6 mos) 
PREGNANCY 
10-25% 
LABOR & DELIVERY 
 
35-40% 
BREASTFEEDING 
35-40% 
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In resource-poor settings where formula feeding is not a viable option due to lack of access to 
clean water, women living with HIV are recommended to exclusively breastfeed (rather than 
mixed feeding), providing that they are on ART. The revised 2016 WHO guidelines recommend 
exclusive breastfeeding for the first six months of life, followed by continued breastfeeding 
with introduction of appropriate complementary foods thereafter [34].  
WHO recommends an early infant diagnosis (EID) using HIV virologic testing for HIV-
exposed infants (HEI) between 4 and 8 weeks of age. Another HIV test should be done at 18 
months of age and/or when breastfeeding ends to provide the final infant diagnosis. Infant ARV 
prophylaxis varies according to mother's course of ARVs and the infant feeding method: once-
daily nevirapine or twice-daily zidovudine from birth to 4 to 6 weeks of age. In addition, all 
infants who are found to be positive for HIV should be immediately initiated on treatment[7]. 
Besides improving mothers’ survival, PMTCT protects HIV-exposed children from infection 
and decreases infant morbidity and mortality[35].  Thus, in a global effort to significantly 
contribute to achieving the Millennium Development Goals (MDGs) in reducing child 
mortality by two-thirds between 1990 and 2015 (MDG 4) and reducing maternal mortality rate 
by three-quarters between 1990 and 2015 (MDG 5), two major turning points in PMTCT care 
occurred since 2010: the call for a ‘Global Plan Towards the Elimination of New HIV Infections 
Among Children by 2015 and Keeping Their Mothers Alive’ in 2011 and the recommendation 
for providing ART for HIV-positive pregnant and breastfeeding women, also called the Option 
B+ strategy in 2012.  
 
 
1.2.2 UNAIDS’ call for a virtual elimination of MTCT (eMTCT) of HIV 
In 2009, during the week of the World Health Assembly, UNAIDS called for a virtual 
elimination of MTCT of HIV by 2015. At the 2011 United Nations High Level Meeting on 
AIDS, world leaders presented the UNAIDS-crafted ‘Global Plan Towards the Elimination of 
New HIV Infections Among Children by 2015 and Keeping Their Mothers Alive’ [36].  
It covered all low- and middle-income countries but focused on the 22 countries1—including 
Mozambique—with the highest estimated numbers of pregnant women living with HIV and 
that were home to nearly 90% of pregnant women living with HIV in need of services.  
Barriers still exist to attain the complete elimination of MTCT (e.g. late maternal HIV 
diagnosis, insufficient ART access or adherence, ARV-resistant virus strains, maternal/infant 
ARV toxicities). In addition, although intensive efforts are ongoing for the development of a 
vaccine, HIV-1 curative strategies are still in their infancy stage [37]. Therefore, the virtual 
elimination - and not the complete elimination – of MTCT of HIV has been recognised and 
accepted by UNAIDS and partners. For this reason, the ‘Global Plan’ called for a 90% reduction 
in the number of new HIV infections among children, a 50% reduction in the number of AIDS-
related maternal deaths, a reduction of final MTCT rates to 5% or less among breastfeeding 
women, and to 2% or less among non-breastfeeding women by 2015. 
To achieve these goals, four prongs were identified with specific targets for each of them 
(Figure 1.5). Prongs 1, 2 and 3 are necessary to reach the first target of reducing new child 
infections while only prong 3 will affect the second target to lower the transmission rate. 
 
 
1 Angola, Botswana, Burundi, Cameroon, Chad, Côte d’Ivoire, Democratic Republic of the Congo, Ethiopia, 
Ghana, India, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, South Africa, Swaziland, Uganda, 
United Republic of Tanzania, Zambia and Zimbabwe. 
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Figure 1.5:  Targets for each of the four prongs in the Global Plan Towards the elimination of new 
HIV infections among children by 2015 and keeping their mothers alive  
Source: Joint United Nations Programme on HIV/AIDS, UNAIDS 2011 [36] 
 
Similar to UNAIDS’ 90-90-90 target, the key principles of success of this plan was that the 
mother/infant pair is now seen as a unique entity that should be followed up for a longer 
continuum of care engagement with other essential health and non-health services provided.  
 
 
1.2.3 Evolution of WHO treatment guidelines for PMTCT from 2005 to 2015 
Since 2001, great progress has been made to provide pregnant and breastfeeding women with 
a more efficacious and simplified ARV regimen to prevent vertical transmission of HIV from 
the mother to her exposed infant while offering her improved treatment for her own health 
(Figure 1.6). In 2010, WHO guidelines recommended two options, Options A and B, for HIV-
positive pregnant women with CD4 cell counts of 350 or less to start lifelong ART using a 
triple-combination regimen [38]. Under Option A, women receive antenatal and intrapartum 
ARV prophylaxis along with an ARV postpartum ‘tail’ regimen to reduce risk of drug 
resistance, while infants receive postpartum ARV prophylaxis throughout the duration of 
breastfeeding. Under Option B, all HIV-positive pregnant and lactating women are offered 
ART to continue throughout the duration of breastfeeding. At the end of breastfeeding, those 
women who do not yet require ART for their own health would discontinue treatment, and 
would continue to have their CD4 count monitored, eventually re-starting ART when the CD4 
falls below 350 cells/mm3. 
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Figure 1.6:  Evolution of WHO treatment guidelines for PMTCT from 2005 to 2015  
 
Note: Option A and Option B were offered if CD4 count > 350 cells/mm. The recommended first-line ART for 
lifelong treatment was a once-daily regimen of EFV/TDF/3TC.  
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In 2013, WHO released a ‘programmatic 
update’ to its 2010 guidelines 
recommending countries to phase out 
Option A and replace it with either 
Option B or Option B+ to provide HIV-
positive pregnant women with lifelong 
ART regardless of their CD4 count and 
WHO staging[39]. Options B and B+ 
provide the advantages of offering all 
HIV-positive pregnant women the same 
triple-combination regimen. An 
important benefit of Option B+ is that it 
can lower the risk of HIV transmission to 
male partners since being on ART will 
make women less infectious. Option B+ 
should also reduce the risk of MTCT of 
HIV in subsequent pregnancies.  
 
From a programmatic standpoint, this 
makes drug procurement, distribution, 
and prescribing more straightforward. Furthermore, when considering PMTCT-related costs 
and child infections, Option B+ is the most cost-effective strategy compared with Option A and 
averts more child infections compared with Option B [40]. Thus, in 2015, WHO recommended 
that all pregnant women be provided with Option B+ [7].  
 
For many countries, the simplicity of Option B+ was a ‘game changer’ in efforts to prevent 
MTCT of HIV, its main outcome being progress made in maternal ART coverage. By the end 
of 2017, all priority countries except Nigeria had a national Option B+ coverage above 80% 
(Figure 1.7).  
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Figure 1.7:  Share of pregnant women who receive antiretroviral therapy, by end of 2017. 
Percentage of pregnant women with HIV who receive antiretroviral therapy for PMTCT 
Source: Our World in Data, World Bank, UNAIDS estimates 2017 [41] 
 
1.2.4 Current PMTCT situation and challenges 
The introduction of highly efficacious ARV regimens and rapid expansion of comprehensive 
services over the past decade have contributed to remarkable results, especially in the Southern 
and Eastern Africa (SEA) region where PMTCT efforts have yielded the greatest achievements. 
There has been a significant increase in ARV coverage in HIV-infected pregnant women from 
61% in 2010 to 92% in 2018 (figure 1.8) due to the expansion of PMTCT services. This has 
translated into similar increase the in number of pediatric infections averted from 110,000 to 
160,000 children during that same period (figure 1.9). Since 2010, estimated rate of MTCT 
decreased by 50%, reaching 9.24% [IdC95%: 7.6 - 12.5%] (by 18 months post-partum) at the 
end of 2018 (figure 1.8). Still this rate represents an estimated 84,000 newly infected children 
in 2018 in the SEA region due to the significant numbers of pregnant women who acquire HIV 
infection during pregnancy or the postpartum period who are not diagnosed and offered 
antiretroviral medicines and due to the low coverage of early infant testing (estimated at 68% 
[95%CI: 56 - 91%] in 2018)[42]. 
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Figure 1.8 :  PMTCT coverage (%) and MTCT rate (%) in Eastern and Southern Africa, 2018  
 
  Source: UNAIDS, AIDSinfo, 2018 [1]  
 
Figure 1.9: Estimated number of new HIV child infections vs.  number of new infections averted due 
to PMTCT, Eastern and Southern Africa, 1990-2018 
. 
Source: UNAIDS, AIDSinfo, 2018 [1]  
 
Programmatic challenges to Option B+ implementation are numerous in resource limited 
settings. Although a large proportion of HIV-infected pregnant women have access ART in 
ANC, retaining them in care and ensuring their adherence to treatment remain a challenge, 
especially during the postpartum period. While more than 75% of pregnant women were 
reported to adhere to ART during pregnancy, only 53% did so during the postpartum period 
due to inadequate follow-up and support provided to mothers during the breastfeeding 
period[43–46]. Therefore, approximatively half of all new HIV infections among HEI now 
61 72 80 82 88 90 90 93 92
18
16
15
13
12
11 11
10
9
0
2
4
6
8
10
12
14
16
18
20
0
10
20
30
40
50
60
70
80
90
100
2010 2011 2012 2013 2014 2015 2016 2017 2018
M
TC
T 
Ra
te
 (%
)
PM
TC
T 
co
ve
ra
ge
 (%
)
PMTCT coverage MTCT rate
61 72 80 82 88 90 90 93 92
18
16
15
13
12
11 11
10
9
0
2
4
6
8
10
12
14
16
18
20
0
10
20
30
40
50
60
70
80
90
100
2010 2011 2012 2013 2014 2015 2016 2017 2018
M
TC
T 
Ra
te
 (%
)
PM
TC
T 
co
ve
ra
ge
 (%
)
PMTCT coverage MTCT rate
M
TC
T 
Ra
te
 (%
)
PM
TC
T 
co
ve
ra
ge
 (%
)
Page 27 of 188 
 
 
 
occur during breastfeeding. Reasons behind non-adherence to PMTCT services can be various. 
Some pregnant women are reluctant to take ARV drugs while they feel healthy[47,48], or due 
to fear of disclosure or stigma[49–51]. Possible drug side effects can also lead to non-adherence 
and dropping out of care[48,52]. Some women gradually stop taking ARV drugs after giving 
birth due to other competing priorities, such as child care[53,54]. Perinatal depression is a 
common condition of pregnancy and the postpartum period but remain frequently undiagnosed 
in MCH services as it is not part of the standard of care in most sub-Saharan African 
countries[55]. Nevertheless, it has been reported that perinatal depression can occur in nearly 
50% of women enrolled in MCH services and can lead poor PMTCT outcomes, including 
dropping out of care[56–58]. Some mothers after giving birth change residency and self-transfer 
to another health facility close to their family in-law and are considered lost to follow-
up[50,59]. 
Virologic testing for HEI is not consistently available due to low geographical coverage and 
often accessible only in high volume centralized provincial or district hospital.  When it is 
available, virologic testing is often time-consuming with challenges in transport of samples to 
centralized laboratories and potential delays in the return of results. In SEA region, only Malawi 
reach an EID coverage of > 95% in 2018. Other countries in the region have an average of 68% 
EID testing coverage [1].  
The introduction of Option B+ and the interrelationship between ANC, post-natal care, ART, 
and child care services have highlighted important gaps in the PMTCT cascade monitoring [60]. 
While aggregated and cross-sectional data are used to construct the PMTCT cascade, women 
and children are not tracked across services, especially in population with high mobility and 
settings with weak health information systems[61].  
 
1.2.5 Country validation criteria for eMTCT 
Although the overall goal of reducing new HIV infections among children by 90% by 2015 was 
not met, remarkable achievements in terms of PMTCT services expansion, ART coverage and 
number of pediatric infections averted, have built the momentum and opened the pathway for 
efforts to be sustained by the international community in reaching virtual elimination of MTCT 
of HIV and make good on the commitment to deliver an AIDS-free generation.  In May 2016, 
the dual elimination of MTCT of HIV and syphilis has been identified as a global public health 
priority2. Therefore, a set of criteria for eMTCT country validation for the dual elimination of 
HIV and syphilis were defined [62]:  
- Impact criteria for HIV: fewer than 50 cases per 100,000 live births, a transmission rate 
below 5% if mothers are breastfeeding and below 2% if they are not breastfeeding for at 
least 1 year;  
- Process criteria at service delivery level: 	³ 95% of pregnant women to receive antenatal 
care (ANC); ³ 95% of pregnant women to receive HIV and syphilis testing in pregnancy; 
³ 95% of pregnant women diagnosed with HIV or syphilis to receive treatment.   
In addition, WHO requires that eMTCT of HIV and syphilis processes and indicators are 
achieved within a context of human rights, gender equality, and community engagement.  
To date, five countries and several island states and territories have reached eMTCT of HIV3. 
For example, Thailand was the first Asian country to receive WHO validation of the eMTCT 
 
2  Impact targets must be met for at least 1 year prior to eMTCT validation assessment 
3 Armenia, Belarus, the Caribbeans (Anguilla, Antigua and Barbuda, Bermuda, Cayman Islands, Montserrat and Saint 
Kitts and Nevis), Cuba, Thailand and Malaysia which was proclaimed by WHO in October 2018 
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of HIV-1 (see Case study box) [63]. With an adult prevalence of 1% and 440,000 PLHIV in 
2017, Thailand is the only country thus far with a generalized epidemic to achieve 
eMTCT[62,64]. Compared to Mozambique, Thailand had a lower HIV prevalence rate among 
pregnant women, a higher ANC coverage and strong public health infrastructures. In addition, 
the country had a self-reliant national budget, a strong engagement of nongovernmental and 
civil society partners, and a robust prevention of MTCT monitoring program.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case study: eMTCT in Thailand 
1) HIV generalized epidemic since the early 1990s 
Adult (15-49) HIV prevalence (2017) = 1%; 440,000 of PLHIV 
ANC coverage (2015) = 98.3% (at least one ANC visit) 
Introduction of option B+ in 2014 (with exclusive breastfeed for at least 6 months) 
Estimated MTCT rate declined from 24.2% in 1994 to 1.9% in 2015 
2) eMTCT validation in May 2016 (for HIV & Syphilis)  
3) Programme and country attributes towards eMTCT:  
A. Near universal healthcare access 
    i.99.9% of Thai citizens have government supported insurance 
    ii. Additional 1.4 million non-Thai migrants have health insurance 
B. All PMTCT services (ANC, screening and treatment for HIV and syphilis) financed 
through national budget with free access for migrants 
C. Routine antenatal screening for syphilis for more than 30 years 
D. Routine antenatal screening for HIV for approximately 20 years 
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1.2.6 Start Free, Stay Free, AIDS Free 
The ‘Global Plan’ was recognized as one of the greatest public health achievements of recent 
times. Building on its remarkable success, the international community called in 2016 for a 
‘Start Free, Stay Free, AIDS Free’ Super-Fast-Track framework and accelerated 
implementation plan to reduce the number of new HIV infections among children as well as 
increase the number of children with HIV on treatment [65]. The framework establishes three 
blocks of programme activity that are closely 
interrelated:  
• START FREE: by preventing new HIV 
infections among children during 
pregnancy, birth and throughout the 
breastfeeding period; 
• STAY FREE: by preventing new HIV 
infections among adolescents and young 
women as they grow up; 
• AIDS FREE: by providing HIV treatment, 
care and support to children and adolescents 
living with HIV. 
Of particular interest for PMTCT of HIV is the first 
block ‘START FREE’ which recommends full programme scale to reach the following targets: 
1) reduce the number of children (aged 0–14) newly infected annually to less than 40,000 by 
2018 and 20,000 by 2020; 2) Reach and sustain 95% of pregnant women living with HIV with 
lifelong HIV treatment by 2018. The elimination of new HIV infections among children can be 
achieved only if these ambitious targets are reached. These targets are complementary to 90-
90-90 targets but are to be achieved in a shorter time frame. To reach these targets, countries 
must ensure that at least 95% of pregnant women living with HIV receive Option B+ PMTCT 
services by 2018 and that these women are retained in care during the breastfeeding period.   
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1.3 HIV epidemic in Mozambique  
1.3.1 Country profile 
The Republic of Mozambique, one of the largest 
southern African countries (799,380 km2 in size), has 
2,300 kilometers along the Indian Ocean on its eastern 
coast. The country borders with Tanzania, Malawi, 
Zambia, Zimbabwe, South Africa, and Swaziland. 
Approximately 70% of the population of 28.9 million 
(2017 census) live and work in rural areas [66,67].  
Nampula is one of the 11 provinces of Mozambique.  
Located in the Northern region, it had an estimated 
population of 6.1 million habitants in 2017, representing 
a 50% increase since 2007. Nampula is the most 
populous province of the country with 74.8 people/ km2 
for a surface of 81,606 km² - almost 30 times higher 
than the national average of 2.55 people/km2 [41]. 
Zambézia is a province located in the central region of 
Mozambique. It is the second largest province after 
Niassa (105,008 km2) and second most populous after 
Nampula (5,110,787 habitants and population density 
population of 48,7 people/km2). Zambézia’s population 
increase was 31% since 2007. Both provinces have a 
majority of women: 52% in Nampula and 53% in 
Zambia [68].    
Mozambique is considered a low-income country, and more than half of its people continue to 
live below the poverty line. With an annual population growth of 3%, and additional challenges 
in recent years including a regional drought in 2016, increasing debt, decreased external 
investment, and declines in exports, the economic growth of the country has slowed even 
further. The annual gross domestic product (GDP) growth decelerated to 3.7% in 2017, down 
from 6.7% in 2016 and well below the 7% GDP growth achieved on average between 2011 and 
2015 36.  In 2016, Mozambique was among the bottom eight countries in the UNDP’s world 
Human Development Index (HDI) report, ranking 181 out of 188 [69]. 
Two-thirds of the population is 24 years of age or younger, mostly unemployed and dependent 
on the older third [67,71]. Life expectancy at birth has improved and is currently 58 years [66]. 
The adult literacy rate increased from 27.1% in 1980 to 58.8% in 2015 and is improving at an 
average annual rate of 22.15% [73]. Despite these improvements, Mozambicans, especially in 
the rural areas, are still affected by an epidemiological profile dominated by the three major 
communicable diseases, HIV, malaria and tuberculosis, and by persistent poor living 
conditions, such as high food insecurity, low levels of educations, poor access to safe water and 
poor sanitation.  
Women in Mozambique are highly vulnerable. Gender inequality in Mozambique remains a 
major challenge in the access to health services. The Gender Inequality Index synthesises 
gender-based inequalities in three dimensions—reproductive health, empowerment, and 
economic activity—on which Mozambique ranks 138 of 160 countries [69]. Since 2010, the 
government of Mozambique is committed to achieving the MDGs [74]. Despite the reduction 
between 1997 and 2003 [75,76], the maternal mortality ratio in more recent years has been 
stagnant and still unacceptably high (489/100,000 live births in 2015), compromising the 
achievement of the MDG target (Figure 1.10) [77].  Exposure to the risk of maternal death is 
still high due to several factors, among which is the overall fertility rate of 5.3 children per 
million people 
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woman, slightly lower than in 2011 (5.9). Teenage pregnancy also remains unacceptably high 
and increased from 38% in 2011 to 46% in 2015, with the risk of death among pregnant 
teenagers four times higher than for women above the age of 20. Other factors contributing to 
the high rates of maternal mortality are low utilization of family planning (FP) services, low 
antenatal care (ANC) coverage (at least four visits), and low institutional delivery. Although 
use of modern contraceptives increased from 14% in 2003 to 25% in 2015, it still remains low, 
and 23% of married women have unmet needs for family planning. Similarly, ANC coverage 
(at least four visits) was estimated at 55%, a slight increase from 2011 (53%), and seven of ten 
births (73%) were attended by skilled personnel [78,79]. Recent national MCH program data 
from 2018, report a decrease in the ANC coverage (at least 4 visits) of 49% and a slight 
improvement in institutional delivery coverage of 87%.  
Child health indicators show remarkable and consistent progress in recent years. Mortality rates 
for children under 5 years of age decreased by more than 100% between 1997 and 2011 (Figure 
1.11). However, the decrease in neonatal mortality is occurring at a slower pace, requiring 
special attention considering that approximately 81% of these deaths occur during the first week 
of life and 32% of them on the first day. In the last decade, there has been an improvement in 
the immunization level, with vaccination coverage increasing from 63% in children aged 12 to 
23 months completely vaccinated in 2003 to 65% in 2015.  
 
 
Figure 1.10: Maternal Mortality Ratio, Mozambique 1995-2015. 
Maternal mortality ratio is the number of women who die from pregnancy-related causes while pregnant or within 
42 days of pregnancy termination per 100,000 live births. 
Source: Our world In Data, World Bank, data source from World Health Organization, 2015 [80] 
 
 
 
 
 
 
 
per 100,000 live 
births 
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Figure 1.11: Child Mortality Rate, Mozambique, 1960-2015. 
The child mortality rate measures the share of children that die reaching the age of 5.  
Source: Our world In Data, World Bank, data source from World Health Organization, 2015 [80] 
 
 
 
1.3.2 Epidemiological trends of HIV infection 
Mozambique has a generalized HIV/AIDS epidemic (i.e. HIV prevalence exceeds 1% of the 
general adult population). In 2013, a mode of transmission study was conducted using data 
from INSIDA, DHS2011 and the different IBBS surveys from 2011-2012 [81]. Transmission 
of HIV occurred through stable heterosexual relationships (25.6%), people with multiple 
heterosexual sex partners (22.6%), regular partners of people with multiple heterosexual sexual 
partners (21.6%) and clients of female sex workers (FSW) (18.4%). Among the children, the 
principal mode of transmission was mother-to-child transmission of HIV. Until 2016, 
HIV/AIDS was the main cause of deaths in the country, as reported by the Global Burden of 
Disease[82].  
Mozambique has one of the highest adult (ages 15-49) prevalence rate in the East and Southern 
African region: 12.6% estimated in 2018[1]. Because of the population growth and the 
significant expansion of ART coverage between 2010 and 2018, the absolute number of PLHIV 
has increased from 1.8 to 2.2 million amidst a drop-in incidence of 7% and a steady reduction 
in the number of deaths by 16% (Figures 1.12 and 1.13).  Nevertheless, Mozambique was the 
third country of the East and Southern African region to have the highest incidence rate (5/1,000 
population) behind Lesotho and Eswatini and the second country to have the highest AIDS-
related deaths (54,000 deaths) behind South Africa [1].  
 
 
 
 
 
of children £ 5 
years old
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Figure 1.12: Prevalence, new cases, and deaths from HIV, Mozambique, 1990-2018. 
Total number of deaths from HIV/AIDS (not including deaths from tuberculosis), new cases of HIV 
infection per year, and total number of people living with HIV. The total number of people living with 
HIV is measured in tens. 
 
Source: UNAIDS, AIDSinfo, 2018 [1] 
 
 
Figure 1.13: HIV Prevalence among adults (aged 15-49 years), Mozambique, 1990-2018. 
 
Source: UNAIDS, AIDSinfo, 2018 [1]  
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The HIV prevalence varies significantly by geographic location, age, and gender. The country’s 
southern region still registered the highest prevalence, particularly Gaza Province (23.9%), 
Maputo Province (22.2%), and Maputo City (16.9%) [1], which could partly be explained by 
circular migration of migrant labor between these provinces, South Africa, and Swaziland. The 
risk factors in the region include inequality, transactional sex, and casual partnerships [79]. The 
central region including Sofala (15.6%), Manica (13.3%), Zambézia (14.1%), and Tete (5.3%) 
remains the second most affected. This region is a major transport corridor with numerous 
hotspots. Zambézia accounts for 420,000 PLHIV, representing 19% of the country’s PLHIV 
population, while the northern region’s lower prevalence is partially explained by higher rates 
of circumcision due to local social-cultural norms and the presence of Voluntary Male 
Circumcision services offered by partners (Figure 1.14). 
Of the total number of PLHIV, 140,000 (6.4%) are children aged 0 to 14 years. Women 
comprise 1.2 million (60%) of the 2 million adult PLHIV with a higher HIV prevalence rate 
(15%) then in men (9.9%). Prevalence peaks among women aged 35 to 39, while incidence is 
highest among the vulnerable group of adolescent girls and young women aged 10 to 24. For 
males, prevalence also peaks between ages 35 to 39, while incidence is highest between ages 
20 to 29 . This implies possible sexual networking among older males and young girls and 
subsequent spread within marriages and other concurrent relationships [79]. The age and sex 
variations in HIV prevalence underscore the need to integrate interventions targeted to 
adolescent girls, young women, and their male partners as well as for intensified efforts for 
increased male involvement, early treatment initiation using the “Test and Treat all” strategy 
and close follow-up and retention in care.  
 
Figure 1.14: HIV Prevalence among adults (aged 15-49 years), by provinces, Mozambique, 2018. 
Source: UNAIDS, AIDSinfo, 2018 [1] 
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1.3.3 National HIV response efforts 
The HIV response in Mozambique is coordinated by the National Control Programme for STI-
HIV/AIDS at the Ministry of Health of Mozambique - MOH (Ministério de Saúde de 
Moçambique - MISAU) and the National AIDS Council (CNCS) with support from key 
stakeholders and partners including UNAIDS, the United States Presidents’ Emergency Plan 
for AIDS Relief (PEPFAR), the Global Fund (GF), additional bilateral and multilateral partners, 
and civil society. Approximately 95% of the HIV response is funded through external donors, 
and 5% through domestic funding resources.    
Several national plans have guided the HIV response, the most recent of which are:  
• The ‘National Plan for Accelerating the Response to HIV/AIDS (2013-2017)’ 4 based 
on the UNAIDS’ call for accelerating the response for HIV/AIDS [83].  The Plan’s goal 
was to achieve substantial reductions in HIV transmission, with targets including: 80% 
of eligible HIV-infected adults and children receiving treatment, 50% reduction in new 
infections, and reduction in MTCT of HIV to less than 5% by 2015. The evaluation of 
the plan’s achievements was, however, mixed: 55% of HIV-infected patients were 
receiving ART by then end of 2018, stagnant annual number of new infections, and an 
estimated 18% of MTCT of HIV (Figure 1.15) [85]. 
• The ‘National Strategic Plan for the HIV/AIDS response (PEN IV 2015-2019)’ [86]. 
This HIV Strategic Plan provides a combined response for the provision of prevention, 
care, and treatment services and mitigation of the consequences of HIV tailored to the 
social context and conditions of the country. Its three main goals are to reduce the 
mortality due to HIV by 40% in 2019, reduce the number of new infections by 30% by 
2019, Reduce the rate of HIV transmission from mother to child to <5 % by 2019. 
Outcomes to achieve these three goals were set out.  
• The ‘Political Declaration of HIV 2016-2020’: specific national care and treatment 
targets were revised to align with UNAIDS 90-90-90 targets and to reach an AIDS free 
generation by 2030. The new targets included: reduce the number of new infections by 
50% by 2020, reduce the mortality caused by HIV infection by 37% by 2020 and 
increase the ART coverage to 81% by 2020.  
 
 
4 Originally developed for the years 2013-2015 and subsequently extended to the year 2017. 
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Figure 1.15: Target achievements of the ‘National Plan for Accelerating the Response to HIV/AIDS 
(2013-2018), Mozambique. 
 
Source: Spectrum 5.754 (2018); figure extracted from National HIV programme report, Ministry of 
Health, 2018 [85]. Note: with the implementation of ‘Test and Treat’ strategy, eligible patients are 
defined as all HIV-positive patients.  
 
 
In addition, over the past 5 years, national treatment guidelines were revised to reflect the 
changes in international policy recommendations to scale-up availability of ART and viral load 
(VL) monitoring for PLHIV (Table 1.1). These include increasing the ART eligibility threshold 
from a CD4 cell count of less than 350 cells/μL to a CD4 cell count of less than 500 cells/μL, 
with universal access for specific populations, phased implementation of the ‘Test and Treat’ 
strategy, and routine VL implementation for all districts implementing the T&T strategy.  The 
T&T strategy was piloted in 12 high-burden districts in late 2016. The expansion continued to 
reach all districts by December 2018, reaching the objective of nationwide coverage within the 
scheduled timeframe.   
 
 
 
 
 
 
 
 
 
 
 
ACHEIVEMENTS 
IN 2018 
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Table 1.1 : National Antiretroviral Therapy ART-eligibility Guidelines from 2013 to 2017, Mozambique 
Ministry of Health (MISAU). 
 
 
WHO stage 
CD4 cell count not 
available 
CD4 cell count available 
2013 through 2016 
 I/II Do not initiate ART Initiate ART if CD4≤ 350 cells/μL 
 III Initiate ART Initiate ART independent of CD4 count 
 IV Initiate ART Initiate ART independent of CD4 count 
2016* through 2017 
 I/II Do not initiate ART Initiate ART if CD4≤ 500 cells/μL 
 III Initiate ART Initiate ART independent of CD4 count 
 IV Initiate ART Initiate ART independent of CD4 count 
2018 All patients : ‘Test and Treat strategy  
Source: National HIV/AIDS treatment guidelines, Ministry of Health (MISAU), 2018 [87]. Abbreviations: WHO, 
World Health Organization; ART, antiretroviral therapy.  
*The ‘Test and Treat’ (T&T) strategy started to be implemented in a phased way in August 2016.  
 
These efforts have led to a remarkable scale-up of HIV services in Mozambique over the past 
7 years (Figure 1.16). In 2018, 89% of the 1,455 health facilities in the country offered ART, 
up from 72% in 2016. However, there remains a large gap in access to ART service, with only 
56% of PLHIV in need of ART actually receiving it[1]. 
 
Figure 1.16: Trends in the number of health facilities providing ART services, Mozambique (2003-
2018) 
 Data source: extracted from the National HIV/AIDS program, Ministry of Health, 2019 report [85] 
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1.3.4 The 90-90-90 cascade  
In Mozambique, the testing and treatment cascade is based on a combination of the information 
provided by the Spectrum estimates (number of PLHIV), the 2015 Indicator survey on 
immunization, malaria and HIV/AIDS in Mozambique (IMASIDA) data (percentage who 
knows their status; percentage virally suppressed) and the routine monitoring of ART (number 
of HIV-positive patients on ART). Figure 1.17 shows this cascade for the period 2015-2018, 
including the gaps (in lighter color in the bars) remaining to reach the 90-90-90 targets: by end 
of 2018, 72% of the estimated 2.2 million PLHIV knew their HIV status; of those diagnosed 
with HIV, 77% were on ART. Viral load testing is not yet done routinely in all PLHIV in 
treatment. Availability of testing capacity is still limited, and priority is given to patients with 
treatment failure. Therefore, routine viral load testing coverage is insufficient for national level 
estimates of PLHIV who are virally supressed. However, the 2015 IMASIDA survey, reported 
that only 59% of patients on ART were virally suppressed[79].  
The major gap is in the first ‘90’ for HIV diagnosis. HIV testing and counselling (HTC) services 
are widely available in the country and are implemented in all levels of the healthcare system—
primary, secondary and tertiary, and in clinical settings either via routine opt-out testing (e.g. 
in high risk paediatric clinics, inpatient wards, TB, ANC, Voluntary Male Medical 
Circumcision (VMMC) services, surgery, blood bank clinics, or emergency care unit) or via 
testing of symptomatic patients (e.g. in adult outpatient care, well -child care, urgent care and 
dentistry). Despite high HTC service coverage, HTC is still a weak component of the 
Mozambique HIV prevention strategy. Women are accessing HTC services more than men 
through essentially MCH services, although testing coverage is low for both groups. Based on 
IMASIDA data, 29% of women and 19% of men were tested in the last 12 months and had 
received their test results. Strong stigma and discrimination persist against people infected with 
HIV which has been reported as a barrier to HIV testing and counselling [88–90]. Expanding 
community testing through self-testing with facilitated referral to health services are known to 
increase uptake of HTC and linkage to care, especially in men and high-risk individuals[91]. 
However, community HTC is only being implemented at sub-national levels by organizations 
funded by PEPFAR, Global Fund, and the private sector. Some community HTC activities are 
specifically targeted to FSW, men who have sex with men (MSM), adolescent girls and young 
women (AGYW) and prisoners through focused projects. Index case testing strategy is also at 
sub-national scale whereby index cases are identified at the health facility, and with the consent 
of the index case, HTC services are offered to their sexual partners and children with age under 
10 years (who have not been tested before). Self-testing has not yet been implemented in the 
country.    
Of those HIV-infected, only an estimated 77% were actually receiving ART reflecting the great 
ART service expansion started in 2013 and the simplification of eligibility criteria. In addition, 
ART coverage is highest among adult women (64%) probably due to the systematic screening 
in MCH services and the introduction on Option B+ in 2013. The ART coverage among 
pediatric patients is low (60% of the estimated children 0-14 years living with HIV), most 
probably due to the low number of HIV-exposed children accessing HIV services and who are 
tested and initiated on ART (see section 1.3.5 ‘PMTCT overview’). 
According to IMASIDA, only 59% of HIV-infected patients receiving ART are virally 
suppressed. The three major factors contributing to low VL testing coverage are the high LTFU 
rate within the first year of ART initiation, the absence of routine VL testing and the weak 
supply chain systems in the country. Indeed, from 2015 to 2018, the retention at 12-months 
post-ART initiation has been stagnant at 68% for adults and 70% for children. The absence of 
increase in retention rates is due to the over-saturation of high-volume sites offering ART: 75% 
of patients receiving ART are actually followed in only 20% of health facilities offering ART 
services in the country [85]. Consequently, a decrease in quality of care and insufficient 
Page 39 of 188 
 
 
 
resources to correctly follow-up patients and missed appointments leads to high drop-outs rates. 
Most health facilities use targeted VL only for pregnant women, children under 5 years of age, 
and suspected treatment failures. In addition, lack of human resource capacity and weak 
systems for cold chain management, warehousing, and transportation contribute further to sub-
optimal VL testing services. Implementation of routine VL is planned to be introduced 
progressively along with the ‘Test and Treat all’ strategy but will require significant health 
systems strengthening to respond to the increased demand.   
 
Figure 1.17: HIV testing and treatment cascade, Mozambique,2015- 2018  
Source: UNAIDS, AIDSinfo, 2018 [1] 
 
 
1.3.5 PMTCT overview 
Key National Strategies  
The PMTCT program in Mozambique first started in 2002 in 8 health facilities. In 2004, the 
program was then integrated in the ‘2004-2008 National Health Plan’ and in 2006, PMTCT 
services were offered in MCH consultations offering Option A to all pregnant women and their 
HEI (national guidelines 2010).   
According to UNAIDS, Mozambique contributes to 8.2% of new pediatric infections globally 
in 2009, ranking third of the 22 countries that most contribute to the global burden of new HIV 
infections after Nigeria and South Africa. To accelerate the response, Mozambique endorsed in 
2011 the ‘Global Initiative for the Elimination of Vertical Transmission 2012-2015’, 
constituting radical change in the prevention paradigm to eliminate MTCT of HIV in children 
while ensuring the mother/infant pair’s survival. It is in this context that the country reviewed 
its PMTCT targets to align with those of the ‘National Plan for Accelerating the Response to 
HIV/AIDS (2013-2017)’: reducing MTCT to less than 5% and increasing PMTCT coverage to 
90% by 2015. To better respond to this challenge, the MOH developed the ‘National Plan of 
the Elimination of Vertical Transmission of HIV 2012-2015’, providing guidelines to more 
effective PMTCT interventions, including introduction of Option B+ strategy, task shifting of 
HIV care and treatment to Mother and Child Health (MCH) nurses, improving family planning 
and HIV service integration, enhancing community support and tracing [92].  
 
 
72% 
56% 
No routine data 
available 
IMASIDA 2015 = 59% 
 2.2M PLHIV 
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Option B+ recommendations  
Option B+ was rolled out nationally at the beginning of 2013. PMTCT services are offered free 
of charge via a ‘One-stop model’ and ‘Test and Treat’ approach in which ART consultation is 
performed by nurses trained in both MCH and PMTCT guidelines. In the ‘Test and Treat’ 
approach, a pregnant woman is counselled and tested for HIV at first ANC visit and if found 
HIV+, she would initiate ART during the consultation. Thus, HIV care and treatment services 
were integrated into MCH services. All HIV-positive women who become pregnant are referred 
from the ART clinic to MCH services to receive PMTCT.  
First-line treatment was one daily fixed-dose combination of Tenofovir/Lamivudine/Efavirenz. 
Monthly clinical follow-up was done during the first six months of ART, then bi-monthly 
during breastfeeding until 12 months of treatment and bi-annually thereafter until end of 
breastfeeding. ART counselling and drug pickup was done monthly. Routine viral load (VL) 
monitoring was recommended at 3 and 12 months after ART initiation and annually thereon. 
HEI received daily dose of Nevirapine from birth until 6 weeks postnatal and were followed 
monthly during the first year, then bi-monthly until final HIV serostatus was determined. 
Exclusive breastfeeding was recommended for at least the first 6 months post-partum. The first 
virologic test (DNA PCR HIV test) was recommended between 1 and 2 months post-partum 
and if result was negative and infant was still being breastfed, HIV test should be repeated 2 
months after breastfeeding cessation. The mother-infant pair was followed in MCH services 
until the final HIV status of the exposed infant was determined [87]. 
After final testing of the HIV-exposed infant is completed in the MCH sector, HIV-positive 
mothers (and her child if tested positive) are transferred to ART clinics for follow-up. Health 
facilities are supported by community health workers who assist in counselling and community-
based care for PMTCT, however no official community outreach guidelines are available.   
 
Achievements  
The PMTCT program in Mozambique succeeded in a steady scale up and improvement of 
services. PMTCT services are provided at primary and secondary health centres as well as 
tertiary referral hospitals.  Health facilities providing ART also provide Option B+, whereas 
health facilities without ART services continue to provide Option A. By the end of 2018, 
PMTCT was rolled out to almost all health facilities (93%) in the country, and 93% of these 
1,520 PMTCT facilities was applying Option B+ (corresponding to 97% of all facilities 
providing ART) [85]. 
Since first implementation of PMTCT services in the country in 2002, population coverage has 
increased markedly with higher proportions of women knowing their HIV status and receiving 
ART since the introduction of Option B+. By the end of 2018, 98% of pregnant women enrolled 
in ANC knew their HIV status, 8% of these were HIV-positive and 94% of those tested HIV-
positive were on ARVs of any kind for PMTCT, of whom 99% were receiving ART.   
Due to the increase in PMTCT service coverage, its integration into MCH services and the 
introduction of Option B+, a total of 127,500 new child infections have been averted since 2010 
and the annual number of new infections among children decreased from 28,000 in 2010 to 
16,000 in 2018 (Figure 1.18). In addition, monitoring efforts have been made by the MOH in 
2015, with the revision of the monitoring and evaluation tools to provide a paper-based registers 
allowing better capture the longitudinal follow-up of mothers enrolled in the programme.     
Early infant diagnosis has expanded, reaching 92% of health facilities providing PMCT services 
by end of 2018. However, diagnosis coverage remains low. Program data from 2018 show that 
of the 91,776 HEI that reached at-risk child consultation before 8 weeks of age, 71,754 (78%) 
had a polymerase chain reaction (PCR) HIV test at less than 8 weeks of age [85]. If we consider 
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as a denominator the estimated number of HIV-positive pregnant women in the same period, 
only 66% of HEI received an EID test at less than 2 months of age (Figure 1.20).   
 
Figure 1.18: Trends in number of new HIV child infections vs. number of new infections averted due to 
PMTCT, Mozambique 2002-2018. 
 
Source: UNAIDS, AIDSinfo, 2018[1] 
 
 
Figure 1.19: Trends in percentage of HIV-exposed infants tested in Early Infant Diagnosis (EID) care, 
Mozambique 2002-2018. 
 Source: UNAIDS, AIDSinfo, 2018[1]. 
 
 
The National Strategic Plan (Plano Estratégico Nacional) PEN IV 2015-2019 and the Political 
Declaration 2016-2020 called to reduce the MTCT rate of HIV to <5% by 2020. According to 
Spectrum estimates, the MTCT of HIV rate has significantly declined from 19% in 2013 to 
17% in 2016, and further increased to 15% in 20185 (Figure 1.21). Nevertheless, accelerated 
efforts are to be made if the <5% target is to be reached within a 3-year period.  
 
 
 
 
5 Modelling estimates of MTCT of HIV includes the breastfeeding period.  
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Figure 1.20: Trends in Mother-to-Child Transmission of HIV, Spectrum modelling estimates, Mozambique 
2000-2017 
 
Source: UNAIDS, AIDSinfo, 2018 [1]  
 
Challenges  
Efforts to prevent MTCT of HIV have been slowed by several socio-cultural barriers and health 
system challenges in Mozambique. The persistent low levels of knowledge of HIV in 
Mozambican hampers the level of engagement in care of PMTCT clients.  In 2015, the 
IMASIDA survey reported low levels of comprehensive knowledge of HIV among the 15-49 
years old (31% among men and 30% among women)[79]. For women, the 2009 INSIDA and 
the 2011 DHS  showed similar percentages, indicating no improvements made over the 
years[78,93]. Only 54% of women and 50% of men knew that HIV could be transmitted from 
mother-to-child through breastfeeding and that administration of antiretrovirals could reduce 
the risk of transmission. Male partner involvement in ANC has also been low, with only 48% 
of male partners reported to have been tested in ANC in 2017[94]. 
Due to the expansion of ART and PMTCT services across the country, public health facilities 
have faced a significant increase in patient volume, even more so since the progressive 
implementation of the ‘Test and Treat all’ strategy which started in late 2016[94]. The lack of 
human resources along with insufficient formative supervision may have led to decrease in 
quality of care. Consequently, treatment drop-out rates among pregnant and breastfeeding 
women were high: in 2018, the national HIV program reported a 12-month retention rate of 
65%, much lower than the rate for adults (excluding pregnant women of 70%) [85].  
The number of National laboratory sites have increased from 347 in 2015 to 406 in 2018 but 
with still a low coverage: 25% of all health facilities in the country. Most laboratories are 
located in a centralized area, at provincial or district level hospitals with long distance specimen 
transport. They often run with only one technician in weak infrastructures (i.e. small and 
inadequate layout), and cold chain problems are recurrent. In addition, the laboratory 
information system is, in 90% of the cases, paper-based which limits timely reporting of results 
back to the patient.    
Currently in Mozambique, the national health information system continues to be paper-based 
using a cross sectional approach: compilation of data from the registers to produce monthly 
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reports are done manually at each MCH entry point; tracking of mother–infant pairs across 
different MCH services within the same health facility and across various health facilities is 
lacking. The cross-sectional approach of data compilation does not account for patient 
movement across the health sector. This occurs when the mother moves from ANC to maternity 
for delivery and then to post-partum care, leading to inaccurate or incomplete reporting of 
patient engagement in care throughout the pregnancy, delivery and breastfeeding period.   
Page 44 of 188 
 
 
 
2 Importance of engagement in care for PMTCT programs 
The WHO refers to patient’s engagement in care as ‘the process of building the capacity of 
patients, families, care givers, as well as health care providers, to facilitate and support the 
active involvement of patients in their own care, in order to enhance safety, quality and people-
centeredness of health care service delivery’ [95]. This definition applies to high, middle and 
low-income countries and to all types of diseases.  
Specifically, engagement in HIV care refers to a patient who is actively engaged in and 
receiving regular HIV care, by a dynamic navigation through the complete HIV care continuum 
with the final goal of achieving and maintaining viral suppression[96]. Therefore, engagement 
in HIV care is vital to PLHIV and too often confused with ‘retention in care’ viewed as a patient 
present in care at a certain time point. We know that the proportion of patients diagnosed with 
HIV infection but not engaged in medical care is distributed heterogeneously across the care 
continuum: some may have been diagnosed but did not successfully linked to care, other may 
have linked and initiated ART but subsequently dropped out of care – either never returned 
after the first visit or after a certain period of time and, some may be reengaging in care 
elsewhere. Thus, engagement in HIV care is dynamic, allowing people to cycle in and out of 
HIV treatment over the course of their life with HIV.  
For PMTCT programmes, engagement in care implies the client is seen as dual entity composed 
by the HIV-positive women and her HIV-exposed infant. Therefore, the potential benefits of 
ART encompass improving long-term maternal health and reducing MTCT risk, both linked to 
maternal viral suppression. Furthermore, to achieve eMTCT of HIV at least 95% of pregnant 
women should receive the required service delivery at each step of the PMTCT cascade. In this 
context, engagement in care for the women during the pre-natal phase and for the mother-infant 
pair during post-partum are of paramount importance to guarantee important milestones of 
PMTCT care such as rapid maternal viral control before delivery, EID testing at 6-8 weeks and 
final HIV infant testing at 12-18 months post-partum (Figure 2.1)[97,98]. Furthermore, 
compared to previous PMTCT regimens (Options A or B), lifelong ART provided to pregnant 
women under Option B+ has the additional public health benefit of guaranteeing viral 
suppression for subsequent pregnancies while keeping mothers alive[99]. Thus, disengagement 
from PMTCT care share the common consequence as for the general ‘Test and Treat all’ 
approach of poor viral control for the HIV-positive women but adds-in the failure of elimination 
of MTCT of HIV. 
Factors that influence engagement in PMTCT care can be complex and multilevel, such as 
individual characteristics (e.g., age, sex, education, marital status), disease characteristics (e.g., 
clinical staging, immunological and virologic stages), pregnancy/birth characteristics 
(physiological changes of pregnancy and post-partum,  HIV- and/or ART-related concerns, 
adverse pregnancy or birth related outcomes, post-partum depression), characteristics of the 
setting (e.g., type of provider, type of services available) and cultural norms. Therefore, 
improvement of just one of these factors would have little effect on the ultimate goal of viral 
suppression and eMTCT. This underscores how imperative it is to recognize engagement in 
PMTCT care as a comprehensive approach as it guarantees efficient and effective passage of 
mother-infant pairs through the care continuum[100].  
Originally, Option B+ was introduced in PMTCT programs to allow a simplification of 
treatment regimen across the entire adult population, a simplification of clinical and laboratory 
follow-up for pregnant and breastfeeding women while offering a cost-effective alternative to 
previous preventive ARV regimen. Thus, women initiated on ART under Option B+ would 
have better levels of engagement in care compared to those non-pregnant and non-breastfeeding 
and initiated on ART for their own health as the perceived benefit of Option B+ is both for their 
new-born and for their maternal health. As explained earlier, the timing of ART initiation along 
the PMTCT cascade of care is of paramount importance and can be influenced by various 
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system and individual factors. Women initiating lifelong ART during pregnancy would have 
better levels engagement in PMTCT care then women initiating late during the breastfeeding 
period as we can hypothesize that the latter group are less likely to be retained in regular care 
because they seek and access MCH services only in the port-partum period. We also discussed 
previously in chapter 1.2, that maternal viral load is a strong predictor of risk of vertical 
transmission. Thus, in the absence early ART initiation, these breastfeeding women are at 
higher risk of MTCT as risk of HIV transmission during pregnancy and delivery can reach up 
to 40% in the absence of ARVs for PMTCT [30–33].  
In a resource limited setting such as Mozambique, intervention to improve women’s 
engagement in long-term PMTCT care starting during pregnancy is of paramount important if 
the approach of Option B+ strategy is likely to succeed in reaching the global public health 
target of reducing MTCT rate to less than 5% [62].  
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Figure 2.1: Processes of engagement in care for HIV+ women for ART treatment and eMTCT success, 
in low- and middle-income countries. 
This figure demonstrates the dynamic and multi-directional nature and relationship of various steps of the Option B+ PMTCT 
care cascade and how a woman and her HIV-exposed infant move along the care continuum. Source:  Figure adapted from 
Mugavero et al. ‘The State of Engagement in HIV Care in the United States: From Cascade to Continuum to Control’. Clinical 
Infectious Disease 2013 [96]. Abbreviations: ANC: antenatal care; ART, antiretroviral therapy; EID: early infant diagnosis; HIVT: 
HIV testing; eMTCT: elimination of mother to child transmission of HIV.  
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3 Justification and objectives of the PhD thesis 
3.1 Justification of the thesis 
With rapid expansion of Option B+ PMTCT services, the main challenge is to ensure effective 
follow-up of the mother/infant pair. Indeed, sub-optimal levels of engagement in care for the 
HIV-infected mother leads to ART non-adherence, the increase risk of unsuppressed viral load, 
and the need to switch to more expensive second- and third-line treatment regimens after first-
line treatment failure. Without optimal viral suppression in the mother, the HEI is also at higher 
risk of HIV infection through vertical transmission. At a public health level, the risk is to 
undermine programme effectiveness, waste precious resources, and see the emergence of drug 
resistant strains of HIV. It is therefore crucial to engage the mother and her HEI as early as 
possible along the continuum in sustainable manner. 
Based on the programmatic challenges faced under Option B+, especially the high rates of 
women drop-outs and low infant testing coverage in numerous resources limited settings, a 
review of recent evidence of types of interventions tested to improve maternal ART retention 
and infant testing would be useful for programme managers and policy makers to strengthen 
their PMTCT programmes and improve outcomes for mothers and their children. 
When first implemented in Mozambique, the Option B+ strategy had the potential to improve 
ART access for pregnant women, mothers, and their children. In addition, having the same 
regimen for all women would simplify messages delivered to patients, providers, and 
communities about the necessity to adhere to ART for life once started. The strategy would also 
provide a more comprehensive approach, as ART and PMTCT services are integrated with one 
another.  
Despite such promises, the estimated MTCT rate remains high (15% in 2018) in Mozambique 
and raises concerns about the effectiveness of the strategy in truly reducing vertical HIV 
transmission. Low retention in care has been identified in Mozambique as a threat to achieve 
the 90-90-90 targets and the virtual elimination of vertical transmission of HIV[84].  Identifying 
where progress has been made in the PMTCT cascade and where gaps still remain would help 
to provide insights on where to focus efforts to reach the ‘last mile’ for virtual elimination of 
MTCT by 2020.  
For women and children enrolled in PMTCT programmes, attendance at the clinic at a certain 
time point is often considered as full retention over this period. However, regularity of 
attendance is an important parameter to take into consideration if we are to evaluate the quality 
of engagement in care. As for Mozambique, where routine health information systems fail to 
capture patient-based viral load testing results, regular attendance at scheduled visits is a good 
indicator of levels of engagement in care for women initiating ART under Option B+. Exploring 
different measures of retention considering the level of attendance of scheduled visits during 
follow-up could help better measure women’s engagement along the continuum of PMTCT 
cascade of care. 
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3.2 Objectives of the thesis 
3.2.1 General objective  
The thesis aims to highlight, from a public health perspective, the programmatic challenges of 
engagement in care for the Option B+ strategy in sub-Saharan Africa, with the example of 
Mozambique, a country known to have one of the highest HIV prevalence in the world. To 
assess the level of engagement in care of the mother/infant pair, this work focused on three 
programmatic aspects of PMTCT Option B+ strategy: PMTCT outcomes with a special focus 
on maternal ART retention and HIV infant testing uptake; interventions aimed at improving 
these PMTCT outcomes and methods of measurements of retention in care with their potential 
programmatic impact.  
 
3.2.2 Objectives of the thesis 
Specific objectives of the thesis are to:  
1. Quantify risk of attrition associated with reason for ART initiation (ART initiation 
under Option B+ versus ART initiation for own health) in a PMTCT program in 
Mozambique; 
2. Describe interventions aimed at improving PMTCT outcomes in programs offering B+ 
strategy with a special focus on maternal ART retention and HIV infant testing uptake; 
3. Evaluate the impact of various definitions of ‘retention in care’ on the programmatic 
interpretation of PMTCT Option B+ strategy. 
 
A framework has been elaborated to provide an overall picture of the thesis work, to visualize 
how the three analyses proposed respond to the three objectives, how they relate to one another 
and how they fit into the overall problematic of engagement in care under PMTCT Option B+ 
strategy (Figure 3.1).  
To respond to the first objective, an empirical analysis of routine data from the first 4 years of 
PMTCT Option B+ program implementation in Mozambique was conducted to analyse annual 
trends in PMTCT program outcomes. This study focused on the ANC cascade of pregnant 
women enrolled in PMTCT and women retention in care 12 months after ART initiation.  
To respond to the second objective, a systematic review focused on interventions to improve 
ART retention and infant testing was conducted. This systematic review aims to synthesis types 
of interventions tested and discuss the heterogeneity of measurements metrics used to define 
both retention on ART and infant testing uptake and their impact on the effects of interventions.  
To respond to the third objective, a comparative analysis using 6 different definitions of 
‘retention in care”, was performed to highlight the variability of measurement metrics and 
discuss their impact on estimating level of engagement in care of HIV-positive women enrolled 
under Option B+ in Mozambique.  
Based on the results of this thesis work, innovative strategies to improve engagement in care of 
the mother-infant pair (MIP) at each step of the PMTCT Option B+ care cascade are proposed 
considering the Mozambican context. The proposed strategies focus on providing solutions to 
the gaps identified in the care continuum with the goal of achieving the “last mile” for eMTCT 
of HIV in Mozambique.  
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Figure 3.1: Prevention of mother-to-child transmission (PMTCT) of HIV in Mozambique: engagement in care and programmatic challenges for the B+ Strategy: the thesis 
framework.   
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4 Institutional setting for the PhD 
4.1 ICAP at Columbia University  
Founded in 2004 at Columbia University’s Mailman School of Public Health, ICAP is one of 
the world’s largest implementation and technical assistance providers for HIV and related 
health programs and a global leader in research and public health. To date, ICAP has supported 
HIV prevention, care, treatment, and related services at more than 6,000 sites across 30 
countries in Africa, the Caribbean, and Southeast and Central Asia, as well as in the United 
States.  
ICAP’s technical expertise and experience span over three broad health-related areas: 1) service 
delivery and service-delivery-strengthening activities, including PMTCT, HIV/AIDS care and 
treatment, Tuberculosis/HIV integration, integration of PMTCT and Maternal Child 
Health/Reproductive Health, laboratory strengthening, infrastructure development, workforce 
development, treatment adherence, and support for PLHIV and their families; 2) training, 
clinical service mentorship programs, and development of training materials, and use of 
distance education; and 3) monitoring, evaluation, and research.  
With support from PEPFAR, ICAP’s technical assistance and support has resulted in nearly 32 
million individuals being tested for HIV—including over 8.6 million pregnant women tested in 
ANC; nearly 2.4 million people have received HIV care and 1.46 million have received ART 
at ICAP-supported health facilities.  
 
4.2 ICAP in Mozambique 
ICAP has supported the transformational scale-up of HIV prevention, care, and treatment 
services in Mozambique as a major technical support partner to the MOH since 2004.  
ICAP supported some of the first ART clinics in the public sector in Mozambique and has 
played a key role in each stage of the HIV response, including the effort to decentralise and 
expand HIV care and treatment services. Since 2004, more than 300 health facilities in five 
provinces (Nampula, Zambézia, Inhambane, Maputo, and Gaza) have benefited from ICAP’s 
comprehensive technical and operational support.  
From 2012 to 2017, ICAP was the leading partner in Zambézia province, supporting 7 out of 
17 districts, and was the main implementing partner in Nampula province, supporting all 21 
districts. In addition, Zambézia was identified as one of the MOH’s priority provinces due to 
its high HIV prevalence and population size. 
In 2013, ICAP supported PMTCT sites in Nampula and Zambézia for the transition from Option 
A to Option B+ by providing in the first 18 months of programme implementation training for 
more than 280 MCH nurses on Option B+ and ART, extending in-service training to all sites 
shortly after transition, purchasing additional equipment (e.g. file cabinets) to support patient 
monitoring activities, and re-enforcing the monitoring and evaluation system to capture specific 
ART information for pregnant and breastfeeding women enrolled in Option B+ while 
improving the quality of the data.  
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Photo 1: A normal day at the Zimpeto Health Centre (patients waiting area for consultation & 
pharmacy drug pick-up), Maputo, Mozambique 2016 (photo credit: ICAP Mozambique). 
 
 
Photo 2: Outpatient consultations, Mulaha Expansão Health centre, Nampula, Mozambique 2014 
(photo credit: ICAP Mozambique). 
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4.3 My role at ICAP in Mozambique and related work for the PhD thesis 
From August 2012 to August 2016, I was the Strategic Information and Monitoring and 
Evaluation (SI and M&E) Director for ICAP Mozambique. Based in Maputo capital city, I was 
responsible for managing a total of 40 staff at central and provincial levels (Zambézia and 
Nampula). The M&E team was composed of a reporting officer, M&E officers in charge of 
each clinical area, m-health officer and senior database managers at the central level, and teams 
of M&E officers and data entry officers at provincial levels.  Research teams were composed 
of a research coordinator, field research supervisors, interviewers, and data entry officers.  
The main objective of the SI and M&E unit is to provide relevant, up-to-date, and high-quality 
information from efficient routine health information systems and operational research studies. 
The evidence-based results produced are used to monitor and assess the progress of 
implemented activities to improve patient care.    
Over the 4-year period, we have made great progress in implementing more efficient health 
information systems to produce reliable data for decision-making both in M&E and research 
(Table 4.1). In 2013, we implemented a new health information system, DHIS2 (District Health 
Information System Software 2), an open-source health management data platform that 
provides aggregated health facility data for routine reporting purposes [101].  This system 
enabled us to significantly improve the completeness and accuracy of the data ICAP reported 
on a quarterly basis to the MOH, Centre for Disease Control and Prevention (CDC) in 
Mozambique, and ICAP headquarters in New York. ICAP was one of the first organizations to 
develop an electronic patient-level data (ePLD) system in Mozambique. To re-enforce the 
quality of the routine data reported, in collaboration with the MOH and other implementing 
partners, we implemented routine data quality assessment runs on a quarterly basis. See 
paragraph below for more detailed description of the ICAP’s health information system (HIS).  
I initiated my PhD part-time in 2014, while working at ICAP Mozambique on a full-time basis. 
During that period, the programme faced many challenges in implementing Option B+ strategy, 
among which one was maintaining women engaged in care throughout the PMTCT cascade. 
Collecting routine information on pregnant HIV-positive women enrolled in PMTCT and 
initiating ART in more than 80 supported sites with patient-level data was a unique opportunity 
to understand the underlying programmatic challenges faced and to provide programme 
managers and clinicians practical recommendations to improve quality of care provided to the 
mother and her HIV-exposed infant.   
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Table 4.1 : Summary of key SI and M&E activities that have been implemented, 2012- 2016, ICAP, 
Mozambique. 
Area   Activities performed  
(2012 – 2016) 
M&E supervision  Key M&E activities implemented:  
- Migration from Excel individual district files to DHIS2 national Health Information 
System (1st PEPFAR funded partner in Mozambique) 
- Expansion from 5 to 8 central M&E officers 
- Hiring of 2 new provincial M&E managers 
- Expansion from 12 to 30+ M&E officers/data Officers 
- Creation of an annual M&E workplan (previously non-existent) 
- Creation of the SI Unit annual logic framework (previously non-existent) 
- Support of implementation of clinical specific strategies to improve pre-ART and ART 
retention: ACT initiative, SMS, i-DART  
- Patient level data analysis of patient enrolled on community support groups  
CDC funded Strategic 
Information award (5-
year project) 
Implementation of 2 new PEPFAR funded projects. L Ahoua was the project manager 
1) OpenMRS MCH module project  
2) National HIV tools revision project  
 Research activities  
   
‘Engage 4 Health’ study. L Ahoua was the ICAP-Mozambique research director.  
Implementation science study using a two-arm cluster site-randomised design to 
determine the effectiveness of a combination intervention strategy (CIS) using (1) point-
of-care (POC) CD4 count testing, (2) accelerated ART initiation for eligible individuals, and 
(3) SMS reminders for linkage to and retention in care—as compared to the standard of 
care (SOC) in 2 provinces Mozambique [102–104].  
‘Discrete Choice Experiment’ study. L Ahoua provided the technical support for field 
study implementation.  
Discrete choice experiment in Ethiopia and Mozambique to identify health system 
characteristics preferred by HIV-infected women to promote continuity of care [105].  
‘Prep phase I ’ study.  L Ahoua was the ICAP-Mozambique research supervisor 
A cross-sectional study to assess the willingness of migrant miners and female partners of 
miners to take short-term pre-exposure prophylaxis (PrEP) for prevention of HIV 
acquisition in Gaza Province, Mozambique [106]. 
‘Prep phase II ’  study.  L Ahoua was the ICAP-Mozambique research supervisor 
A prospective cohort study to evaluate the feasibility, acceptability, and adherence with 
short-term PrEP among female sexual partners of migrant miners in Mozambique 
[107,108]. 
 
M&E: Monitoring and Evaluation; DHIS: District Health Information System Software 2; HIS: Health Information System; 
ACT: Accelerating Children's HIV/AIDS Treatment (ACT) Initiative; i-DART: Intelligent Dispensing of Antiretroviral 
Treatment; MCH: maternal and child health; PrEP: pre-exposure prophylaxis.  
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4.4 ICAP Mozambique Health Information system  
4.4.1 District Health Information System (DHIS) version 2.21 
General overview 
The DHIS2 is ICAP’s principal internal Health Information System (HIS). The system was 
implemented in 2013. Figure 4.1 summarises the data and communication flow of the HIS in 
ICAP Mozambique from peripheral to central level, including the various data sources and 
process utilized for collecting, verifying, analyzing and reporting programme indicators.  The 
MoH paper-based report forms are collected by the M&A Officer from the satellite team (i.e. 
ICAP district based staff overseeing of 1 or 2 districts) on a monthly basis and computerized 
by the data officer directly into the system for the following clinical programs: MCH/PMTCT, 
HIV counselling and testing, Gender Based Violence, nutrition, positive prevention, post-
exposure prophylaxis, HIV/ART, tuberculosis, laboratory, pharmacy, voluntary male 
circumcision. DHIS2 data entry forms were regularly updated to reflect latest changes in the 
national guidelines and paper-based tools.   
To ensure timeliness of data collection, ICAP’s M&E staff performed data entry into DHIS2 
directly on site at the HF or at the district health directorate (also called the M&E Satellite). 
Data verification for coherence, completeness and consistency is done at each level of the HIS 
with regular feedback to the lower levels for corrections. This is an ongoing process where 
clinical and M&E teams both from ICAP and the MOH are involved. Immediately after data 
entry, internal data quality checks (DHIS’ run validations rules) have been embedded in the 
electronic forms to guaranty a minimum of data quality. ICAP’s M&E staff works in close 
collaboration with the MOH district M&E officer to take immediate corrective actions for any 
errors on the monthly reports. Participation of the clinical team in reviewing the monthly 
statistics are organized with ICAP’s and MOH’s staff to ensure correct interpretation of clinical 
data during the on-site review process, to discuss/resolve any problems with the clinical staff 
and to know what are the M&E challenges encountered during data collection that can help 
interpret better the programs’ performances.   
One of the main challenges is the constant changes in indicators to be reported (definition, age 
and sex desegregations, etc.…) and the absence of MOH tools for some programmatic areas 
(resulting in creation of parallel reporting systems) which made the data collection process 
tedious and time consuming.  This is tackled by reviewing and updating all DHIS2 forms on a 
quarterly basis before each reporting period. Another challenge is the limited technical capacity 
of the health facility staff in correctly filling the paper-based registers and monthly reports. For 
this purpose, ICAP’s clinical and M&E staff re-enforce on-site mentoring to improve correct 
completion of the registers and forms during site supervision visits. Focus is given to high 
volume sites and sites where data quality and completeness are the most problematic.  
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Figure 4.1: Data and communication flows for ICAP’s Heal Information System (HIS), 2013-2017, 
Mozambique 
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ANC/PMTCT data 
For the second work of the PhD, I extracted the ANC/PMTCT variables from DHIS2 (table 
4.2). These variables are from the ANC clinic monthly reports forms which are based on 
longitudinal cohort-based follow-up registers (figures 4.2 and 4.3). Pregnant women who come 
for their first ANC visit are registered and given a unique identification number, sequential 
number based on the site code, date of registration and consecutive enrolment number. This 
unique identification number is captured in her health passport. The national MCH program 
recommendation is for a pregnant woman to remain in care in the ANC health facility where 
she first enrolled, to deliver at the maternity ward of that health facility or at the corresponding 
referral maternity closest by and then to come back to the original facility for post-partum care 
[87]. If a pregnant woman attends more than one facility in the area, her unique identification 
number from her health passport is used and she is enrolled as a follow-up pregnant woman (as 
opposed to a new enrollee). A woman receives a new ANC number for each new pregnancy. 
Therefore, subsequent pregnancies are not linked to one another. 
If she is already on ART at enrolment, her unique HIV identification number is also registered. 
This number is also based on sequential number using the health facility code, HIV service 
code and a sequential enrolment number (see section ‘4.4.2 Electronic Patient Level data 
(ePLD)” below for more details). 
The MCH nurses provides integrated care for all pregnant women including diagnosis and 
treatment for nutrition support, syphilis and other sexual transmitted diseases, malaria 
prophylaxis, vaccination, tuberculosis prophylaxis or treatment continuation and PMTCT care. 
If a pregnant woman is newly tested HIV-positive in ANC, an individual patient file will be 
opened, a new HIV patient code will be attributed, and she will register at HIV care clinic 
although she will still be followed-up in ANC under the ‘one-stop model’ approach for Option 
B+, until final diagnosis of her HIV-exposed infant is obtained. The patient file is the same as 
for any HIV-positive patient enrolled in HIV care and treatment service (see section ‘4.4.2  
Electronic Patient Level data (ePLD)” below for more details). HIV-related laboratory results 
and pharmacy records are linked through the patient’s HIV patient code.   
 
Table 4.2 : List of the variables and correspondent data elements used for the PhD work and their 
definition, ICAP Mozambique 2013-2017.   
 
Name of variable DHIS data element 
Total number of pregnant women 
enrolled during the reporting period CPP.CONDUTA.1- Total das 1as Consultas 
Pregnant women with unknown status at 
ANC entry SMI.CPN.FA.1- Número de MG HIV Desconhecidas a entrada 
Pregnant women HIV+ at ANC entry CPN_ Positivos a Entrada  
Pregnant women HIV counselled and 
tested with test results positive CPN_ Aconselhados e Testados_Primeiro Teste Positivo 
Pregnant women HIV counselled and 
tested with test results negative CPN_ Aconselhados e Testados_Primeiro Teste Negativo 
Pregnant women HIV+ initiated sdNVP 
Only 
SMI.CPN.FA.5- Número de Mulheres Grávidas que Inicia NVP dose 
única 
Pregnant women HIV+ 
initiated biprophylaxis (AZT+NVP) 
SMI.CPN.FA.7- Número de Mulheres Grávidas que Inicia 
biprofilaxia (AZT+NVP) 
Pregnant women HIV+ initiated ART SMI.CPN.FA.8- Número de Mulheres Grávidas Inicia o TARV 
Pregnant women HIV+ already on ART @ 
1st visit  SMI.CPN.FA.6- Número de Mulheres Grávidas Em TARV a entrada 
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Figure 4.2: ANC paper-based register, Mozambique 2013-2017. 
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Figure 4.3: ANC Health Facility monthly report form, Mozambique 2013-2017.  
 
   PROVINCIA: ______________________________________________________________________________ 
   DISTRITO: ________________________________________________________________________________ 
   UNIDADE SANITÁRIA: ______________________________________________________________________ 
  
 
 MOD - SIS - B01 - B            MÊS ________________  
         
 RESUMO  MENSAL DA UNIDADE SANITÁRIA – SMI  - CONSULTA PRÉ-NATAL 
   Implementa a Opção B+? SIM NÃO    
         
 Indicadores/Características TOTAL 
1 
1ª
s 
co
ns
ul
ta
s 
Total das 1as Consultas   
2 
Id
ad
e 
 
Mulheres grávidas com idade entre 10 a 14 anos   
3 Mulheres grávidas com idade entre 15 a 19 anos   
4 Mulheres grávidas com idade entre 20 a 24 anos   
5 Mulheres grávidas com idade ≥ a 25 anos    
6 
Idade 
Gestacional  Mulheres grávidas com menos de ou igual 12 semanas na primeira consulta   
  Para os indicadores a seguir colher as informações de todas as mulheres que tiveram a 1ª consulta 6 meses atrás 
7 
Co
or
te
 6
 m
es
es
 
Total de mulheres grávidas inscritas no período (Total da COORTE)   
8 Total de mulheres grávidas que fizeram a 4 ou mais consultas pre-natais   
9 
N
ut
riç
ão
 
Mulheres grávidas com Ganho < 1.5 Kg/mês a partir do 2º trimestre   
10 Mulheres grávidas que tiveram Desnutrição aguda grave (DAG)   
11 Mulheres grávidas que tiveram Desnutrição aguda moderada (DAM)   
12 Mulheres grávidas que iniciaram e/ou receberam suplementos nutricionais   
13 Total Gestantes com Desnutrição aguda curadas   
14 Total Gestantes com Desnutrição aguda que abandonaram    
15 Mulheres gravidas que receberam desparasitante   
16 Mulheres grávidas que receberam a 3ª dose (ou mais) Sal ferroso com Ac Fólico   
17 
Co
or
te
 6
 m
es
es
 
IT
S  
Mulheres grávidas com diagnóstico sindrómico para ITS   
18 Mulheres grávidas com tratamento sindrómico para ITS   
19 Mulheres grávidas testadas positivas para sífilis   
20 Mulheres grávidas testadas negativas para sífilis   
21 Mulheres grávidas que receberam 3ª dose de tratamento de sífilis   
22 Parceiros que receberam  tratamento de sífilis   
23 
H
IV
 
Mulheres grávidas HIV positiva a entrada   
24 Mulheres grávidas testadas HIV negativas durante a CPN   
25 Mulheres grávidas testadas HIV positivas durante a CPN   
26 Parceiros testados negativos na CPN   
27 Parceiros testados positivos na CPN   
28 Mulheres gravidas que Iniciaram  CTZ   
REPÚBLICA DE 
MOÇAMBIQUE 
MINISTÉRIO DA SAÚDE  
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29 Mulheres grávidas em TARV a entrada   
30 Mulheres grávidas cuja profilaxia final foi Monoprofilaxia (NVP)   
31 Mulheres grávidas cuja profilaxia final foi Biprofilaxia (NVP+AZT)   
32 Mulheres grávidas que iniciaram TARV durante a gravidez   
33 
Co
or
te
 6
 m
es
es
 
Malária 
Mulheres grávidas que receberam 2 doses de TIP   
34 Mulheres grávidas que receberam 4 ou mais doses de TIP   
35 Mulheres grávidas que receberam Rede Mosquiteira (REMTIL)    
36 Mulheres grávidas com diagnostico laboratorial de malária   
37 Mulheres grávidas que receberam tratamento para malária   
38 
Prevenção 
HPP Mulheres grávidas que receberam Misoprostol   
39 
VAT 
Mulheres grávidas que receberam 1ª Dose VAT   
40 Mulheres grávidas que receberam 2ª-5ª dose VAT   
41 
Tuberculose 
Início de Profilaxia com INH   
42 Início de Tratamento para Tuberculose   
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4.4.2 Electronic Patient Level data (ePLD)  
From 2013 to 2017, the number of HFs providing HIV care and treatment services increased 
from 110 to 218 in both Namupla and Zambezia. To follow the expansion of HIV care services, 
ICAP expanded its ePLD system coverage from 35% (38/110) of HFs with HIV/ART services 
to 40% (87/218) during that same period. High volume sites with more than 500 PLHIV active 
on ART, adequate infrastructure and electricity power were the priority sites. This represented 
a coverage of 67% of PLHIV currently receiving ART by the end of 2017.  
When a patient is found to be HIV-positive, he/she is referred to the HIV care and treatment 
service to register, receive a new HIV unique identification number and open a clinical file 
(Figures 4.4 and 4.5). The unique HIV identification number is a sequential code based on the 
health facility code, HIV service code and a sequential enrolment number. This unique 
identification number should only be given once in a lifetime. National guidelines recommend 
to systematically check if the patient has been previously enrolled in HIV care and treatment 
service using the HIV identification code before opening a new file, but this can only be verified 
within the same site as there is no health information system linking data from different health 
facilities. After the first clinical visit, the information from the patient file is entered 
retrospectively in the ePLD by data entry clerks using the unique identification number. 
Laboratory and pharmacy results are linked with the patient file through this number. From 
thereon, for each subsequent visit at the health facility, information on clinical visit, pharmacy 
drug pickup, counselling session and/or laboratory results are retrospectively updated in the 
ePLD. For each reporting period, ePLD data is extracted to produce specific HIV program 
indicators by the M&E staff. 
When PMTCT Option B+ was implemented, the ePLD was modified to capture information on 
pregnant and breastfeeding women: gestational age at ART initiation and if the woman was 
initiating ART for PMTCT (status ‘pregnant’ or ‘breastfeeding’ at ART initiation). No other 
MCH specific variables were captured in the ePLD.  
The first ePLD system used MS Access database then, in 2014, we progressively switched to 
an open source patient level data system, Open Medical Record System (OpenMRS) to align 
with other implementing partners in the country and with the MOH’s new national guidance on 
M&E systems. In 2016, we developed in collaboration with other partners the specific MCH 
OpenMRS module for specific patient-level monitoring of the mother/infant pair enrolled under 
Option B+. The tool produced was to be piloted in 2017 in a three Option B+ sites with an 
expansion scheduled for late 2018/beginning of 2019. Unfortunately, the project was stopped 
due to cut of funds.  
The two main challenges with the ePLD system are first the low expansion of the electronic 
system compared to that of HIV care and treatment service expansion (especially in Zambézia), 
due to various internal (logistics, infrastructure renovations, etc…) and external (security, lack 
of ownership of the MOH, etc…) constraints. Second, is the absence of linkage between various 
site level databases making it impossible to track the patients who silently transfer to another 
site or who re-engage in care after a certain time of absence at the same site or at another site. 
Duplicate patient records are however tracked on a quarterly basis at ICAP central level by the 
M&E team once all ePLDs are merged together using the following data elements: sex, age (or 
date of birth), outcome status (i.e. death, transferred-out, alive, stopped treatment), date of 
outcome status, date of enrolment, last date of visit. If a duplicate is found, data is reviewed on 
a case by case basis and if applicable, merged into one single patient follow-up file using the 
first HIV patient identification number.   
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Figure 4.4: MOH Patient file, admission form and follow-up form, Mozambique 2013-2017 
 
 
Referido de - UATS, SMI, TB, enfermaria, outro serviço(especifique)______________       
ARVs tomados anteriormente 
(S/N) ARV tomados anteriormente   
Data 
 
  Nenhum 
     
  
  ARV no PTV (CPN/Post-Parto)? __/__/___ 
 
Onde? ________ ARVs ________ 
  Fez ARV mas sem transferência __/__/___ 
 
Onde? ________ ARVs ________ 
 
Data TARV - Coorte (Mês / Ano) _________/_______ 
      
Transferido em TARV de ________________________  
___/___/____ 
ARVs _________________________ 
1.
ª 
Li
nh
a 
___/___/____ 
 Início do regime ARV inicial de 1.ª linha ________________ 
No início do 
TARV 
  Peso __________   Gravidez  ______   Não   Sim           
Estadio da OMS _____   CD4 (N.º / %)  
________                      
Substituição dentro da 1.ª linha                             
___/___/____  Novo Regime________________ Porquê? _________________        
___/____/____  Novo Regime________________ Porquê? _________________       
2.
ª 
Li
nh
a 
Mudança para a 2.ª linha ( ou substituição dentro da 2.ª linha) 
___/___/____ Novo Regime________________ Porquê? _________________ 
____/___/___ Novo Regime________________ Porquê? _________________ 
Estado de Permanência 
Interrupção do tratamento ARV - Suspensão ou Abandono do tratamento 
Suspensão ou 
Abandono 
  Suspensão   Suspensão   Suspensão   Suspensão 
  Abandono   Abandono   Abandono   Abandono 
Data                                               
Porquê                                             
Reinício- Data                                       
 
                                                  
                Data                         
Transferido para        ___/___/____ Para onde _______________________ 
 
  
Falecido           ___/___/____                         
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Figure 4.5: MOH Patient file, follow-up form, Mozambique 2013-2017 
 
 
 
 FICHA DE SEGUIMENTO DE HIV PARA 
ADULTOS  
 
Preenche o nº do Livro, Página, e Linha onde o doente foi registado no Livro 
de Registo  
Pre-TARV depois da inscrição, e no Livro de Registo TARV depois do início 
TARV 
Nome: __________________________________     Idade:_____________   
Sexo:____  
NID :   
Nº do Livro Pre-TARV: ________ Pag:________ 
Linha:________ 
      
Data de Nascimento: 
____/____/____ 
Nº do Livro TARV:        ________ Pag:________ 
Linha:________ 
  
Transferido de outra Unidade 
Sanitária? Sim       Não  
Datas das Consultas (d-m-a)                   
Altura: ______(M)                                        Peso (kg)                   
Índice de Massa Corporal (IMC):(kg/m2)                   
Apoio Nutricional (ANUT)                   
Temperatura (°C)                   
Tensão Arterial (TA)                   
Gravidez - DUM:____/____/____; DPP:____/____/____    
PTV ou TARV? 
                  
LABO
RATÓ
RIO
 
Data de Processamento do CD4 (d-m-a)                   
CD4 (/mm) / CD4 (%)                   
Carga Viral (CV)                   
G. Brancos (GB) Está só num 
quadrado 
                
Neutrófilos (N) (/mm3 e %)  Está só num 
quadrado 
                
Linfócitos (L) (/mm3 e %)  
Está só num 
quadrado                 
Hemoglobina (HgB) (g/dL)  
Está só num 
quadrado                 
Provas hepáticas - ALT/AST (U/L) Está só num 
quadrado 
                
Glicémia (GL) (g/dL) 
Está só num 
quadrado                 
Ureia (UR) (mg/dL) / Creatinina (CR) (mmol/L) 
Está só num 
quadrado                 
Outros (Amilase, Teste gravidez, Urina II, 
Plaquetas...) 
Está só num 
quadrado 
                
ESTÁDIO DA OMS (I, II, III, IV)                   
Outros Diagnósticos                   
In
fe
cç
õe
s 
O
po
rt
un
ist
as
 
Rastreio de ITS (Tem sintomas sugestivas para ITS)?  S               N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
Rastreio de TB (Tem sintomas sugestivas para TB)?  S               N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
Resultado da Investigação para TB de BK e/ou RX? 
(POS/NEG) 
POS         NEG 
POS         
NEG 
POS         
NEG 
POS         
NEG 
POS         
NEG 
POS         
NEG 
POS         
NEG 
POS         
NEG 
POS         
NEG 
TTT de TB (veja Cartão de TB) 
Data de Início:______________; Data de 
Fim:_______________ 
S               N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
Profilaxia com Cotrimoxazol - TPC 
Data de Início:_______________;Data de 
Fim:________________ 
S               N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
Profilaxia com INH - TPI 
Data de Início:_______________; Data de 
Fim:_______________ 
S               N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
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Aconselhado para Adesão aos Cuidados S               N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
TA
RV
 
Para Cada Esquema ARV: Início (I) / Continuação (C) / Continuação com Intolerância (CI) / Reinício (R);  
Interrompeu por: Efeitos Sec. (ES) / Não Aderente (NA) / Iniciativa do Doente (PAC) / Outras (discriminar); Mudança de Regime: Tuberculose (TB) / Gravidez (GR) 
/ Falência Terapêutica (FT); Anemia (A); Outros (discriminar) 
Data de Elegibilidade para iniciar o TARV: ___________ ; Data de Início de TARV:___________ ; Data de Reinício de TARV:___________  
Médicamentos ARVs:                   
                    
                    
                    
Efeitos Secundários do Tratamento (Ver códigos abaixo)                   
Aderente ao TARV: S               N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
S               
N 
DATA DE PRÓXIMA CONSULTA:                   
DATA DE PRÓXIMO CONTROLO DE CD4                   
REFERIDO PARA outro sector clínico: 
(TB, PTV, Apoio Psicosocial - AP, Planeamento familiar - PF, 
Internamento - I; etc.) 
                  
REFERIDO PARA serviços comunitários:  
(Cuidados Domiciliários (CD), Grupos de Apoio (GA), etc) 
                  
Saídas - Suspenso ao TARV (S); Transferido para (T); 
Abandono (A); Óbito (O) 
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4.5 Data Quality assessment (DQA) 
Data Quality Assessments (DQA) has been elaborated by the MOH in collaboration with the 
Implementation partners’ Strategic Information (SI) working group in 2014. The pilot was 
tested in 2015 with an official phased national roll-out in 2015/2016.  
The DQA is done in a nationally representative sample of 30 randomly selected health facilities, 
stratified by province and size of health facility. It verifies the quality of reported data by 
quantifying concordance between data recorded in the source documents and data reported in 
the electronic database. Specific standard operating procedure (SOP) and Excel spreadsheet 
have been created for this purpose. Data collection is done by ICAP’s M&E provincial and 
district level staff in collaboration with their MOH counterparts. 
Specifically, a cohort of 30 randomly selected HIV-positive patients initiating ART over a 3-
month period, 12 to 15 months prior to the DQA assessment, is identified using the patient files, 
patient registers and pharmacy files. Then for those patients, information in the ePLD is 
compared to monthly reports. According to national guidelines, a concordance between both 
data sources >90% is considered as “good quality”, between 90% and 80% as “medium quality” 
and <80% as “bad quality”. After each exercise, data is analysed and a data quality 
improvement plan is elaborated at site level to be implemented and monitored during the next 
reporting period.  
Figure 4.6 illustrates the DQA results for ePLD database comparing data in the database to the 
patient files. The sample included 30 sites randomly selected annually for the years 2015, 2016 
and 2017. Because of enhanced M&E mentoring, regular on-site trainings and supervisions of 
M&E officers, the overall concordance increased from an average 73% in 2015 to 87% in 2016 
to 96% in 2017. 
 
Figure 4.6: DQA annual results for ePLD for random sample of HIV-positive patients currently 
receiving ART, ICAP supported sites, 2015-2017.   
  
Nevertheless, the main challenge for DQAs is the ownership of the exercise by the MOH staff 
at provincial and district level. Support for the monitoring of the quality improvement plan at 
site level is re-enforced through regular site visits by the ICAP staff.  
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Photo 3: ICAP Strategic Information and M&E team members, Mozambique, 2016 (photo credit: ICAP 
Mozambique) 
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5 Results 
The following chapter presents results of the PhD original research. It is articulated in three 
parts: (1) a cascade analysis and a retrospective cohort analysis to evaluate annual trends of 
outcomes in HIV-infected pregnant women initiating ART under Option B+ in the first 4 years 
PMTCT program implementation in Mozambique, (2) a systematic review of interventions to 
improve maternal ART retention and testing uptake of HEI under Option B+ strategy in low 
and middle income countries, and (3) a retrospective cohort analysis of HIV-infected pregnant 
women initiating ART using six different definitions of ‘retention in care’ to evaluate the 
operational impact of these definitions on PMTCT Option B+ programme outcomes. 
 
 
5.1 PMTCT care cascade and risk of attrition in the first 4 years following 
Option B+ implementation in Mozambique 
5.1.1 Introduction and methodology 
In 2013, ICAP Mozambique was one of the first PEPFAR funded implementing partners to 
provide enhanced support to the MOH to roll-out Option B+ in Zambézia and Nampula 
provinces. ICAP provided technical assistance for task-shifting of ART from clinician to nurses 
while integrating HIV care and treatment within MCH services using a one-stop model of care. 
These activities allowed a rapid scale-up of Option B+ and ART coverage: the number of ART 
sites providing Option B+ increased from 81% (78/96) in 2013 to 98% (117/120) of health 
facilities in 2014 in Nampula and 91% (85/93) in 2013 to 96% of health facilities (137/143) in 
2014 in Zambézia. As mentioned previously, ICAP Mozambique was one of the pioneers in 
collecting patient-level HIV/ART data using electronic patient tracking system and was the first 
organization in the country to implement DHIS2 as its heath information system for monitoring 
all its service delivery related activities.  
After 4 years of program implementation, we had the unique opportunity to analyze the 
program’s performance highlighting programmatic gaps and persistent challenges of retaining 
HIV-positive women in care in Zambézia and Nampula, two of the highest HIV burden 
provinces in the country. This study is a combination of two distinctive analyses: 1) the PMTCT 
ANC cascade of care using aggregated facility-level data from DHIS2, 2) factors associated 
with attrition in HIV-positive women initiating ART during the Option B+ era using patient-
level data.  
To describe the annual trends of the PMTCT Option B+ program, the ANC cascade was 
disaggregated by year of ART initiation from 2013 to 2017.  For the retrospective cohort 
analysis using patient-level data, we hypothesised that not returning to care after the first visit 
was more likely to be related to patient’s reluctance to initiate ART whereas non-retention 
might be related to sub-optimal quality of care. Under this hypothesis, we characterized to types 
of attrition: 1) no follow-up (NFU) and 2) not retained in care.  
Figure 5.1 summarizes the statistical analysis conducted for both types of attrition in the 
retrospective cohort analysis.  
 
The manuscript was submitted to the TMIH journal on the in June 2019, accepted in September 
2019 (with comments to be addressed).  
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Figure 5.1: Methodological details of the retrospective cohort analysis of HIV+ women initiating ART in HIV care and treatment health facilities, Nampula and Zambézia, 
Mozambique.  
 
 
 
 
 
 
 
 
 
HFs: Health facilities; NFU: no follow-up; LTFU: lost to follow-up; PFaCTS: Programme and Facilities Characteristics Tracking System.   
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Abstract 
Objective: To evaluate the effectiveness of the prevention of mother-to-child transmission (PMTCT) Option 
B+ programme in two provinces with high human immunodeficiency virus (HIV) burden in Mozambique over 
the first four years of programme implementation.  
Methods: We assessed the PMTCT cascade in antenatal care (ANC) from July 2013 to December 2017 using 
facility-level data and performed a retrospective cohort analysis with patient-level data. We compared the 12-
month antiretroviral therapy (ART) retention rates between women with HIV infection who initiated ART under 
Option B+ (‘B+ pregnant’) and those non-pregnant and non-breastfeeding who initiated ART for their own health 
(‘own health’).  
Results:  A total of 916,280 pregnant women enrolled in ANC. The proportion of women with a documented 
HIV status increased from 93% in 2013 to 96% in 2017. The proportion of those tested HIV-positive decreased 
from 8% to 6% while that of those HIV-positive on ART increased from 42% to 95%. Of the 44,377 HIV-positive 
women included in the retrospective cohort analysis, 35% were lost to care. ‘B+ pregnant’ women initiating ART 
in 2015 were less likely to have no follow-up (NFU) compared to ‘own health’ women starting ART during the 
same period (adjusted odds ratio: 0.77, 95% confidence interval [CI]: 0.64-0.94, P=0.01). There was no statistical 
difference between the two groups during the other years in which ART was initiated. Of those returning for care 
after their first visit (N=39,801), the ‘B+ pregnant’ women showed a higher risk of non-retention than the other 
group (adjusted hazard ratio: 1.14, 95% CI: 1.03-1.25) when ART was initiated in 2013. The risk decreased during 
the subsequent years, with no difference observed between the groups.  
Conclusion: PMTCT Option B+ programme scale-up has yielded positive results, including the 
achievement of high HIV testing and ART initiation rates in ANC. Challenges still remain, however, in 
improving immediate engagement in care and long-term retention. Seeking alternative service delivery 
models to support existing health systems and prevent defaulters is required to achieve the UNAIDS 95-95-
95 targets for PMTCT in Mozambique. 
 
Keywords: PMTCT; Option B+; attrition; retention; cohort analysis; retrospective study 
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Introduction 
Mozambique’s HIV prevalence is one of the highest in the world, with 12.5% of the adult population (aged 15-
49) living with HIV in 20171. In 2011, the country endorsed the ‘Global Initiative for the Elimination of Mother-
to-Child transmission’ (eMTCT) policy, in which ambitious antiretroviral therapy (ART) coverage targets were 
set for HIV-positive pregnant women (100%) and for the Mother-to-Child Transmission (MTCT) rate of HIV 
(5%), to be achieved by 2020 2–4. To achieve these targets, the country officially adopted the prevention of mother-
to-child transmission (PMTCT) Option B+ strategy in 2013; as part of this, lifelong ART was initiated among 
pregnant and breastfeeding women found to be HIV-positive at their first visit to mother and child health (MCH) 
services, regardless of gestational age, CD4 cell count and/or clinical staging5.  
This new strategy has led to the expansion of ART coverage, which is among the key successes of Option B+6. 
However, emerging studies from the early years of B+ implementation indicate poor retention rates among women 
who had initiated ART under the new strategy. In Central Mozambique, less than 45% of women were retained 
at 90 days following ART initiation 7,8. Another study also suggested that women with ART initiation under 
Option B+ were significantly likelier to be lost to follow-up in the first year or have no follow-up after their first 
visit than those who initiated ART for their own health9. These reports suggest poor levels of engagement in care 
among women under universal ART, raising concerns pertaining to the effectiveness of the strategy, not only in 
terms of maternal ART outcomes, but also the programme’s success in achieving eMTCT HIV targets. Since the 
introduction of Option B+ in 2013 in Mozambique, few studies have evaluated the progress made in the 
implementation of the strategy; in particular, the remaining gaps in the continuum of PMTCT care have not been 
investigated.  
We evaluated the PMTCT Option B+ strategy in two of the most highly populated provinces of Mozambique  
Nampula and Zambezia  between 2013 and 2017. More specifically, we aimed to estimate the progress in the key 
indicators related to the PMTCT cascade in pregnant women enrolled in antenatal care (ANC) services under 
Option B+. We also aimed to assess whether women with ART initiation under Option B+ had an increased risk 
of attrition compared to those who initiated it for their own health. 
 
Methods  
PMTCT programme in Mozambique  
In Zambezia and Nampula, the Option B+ programme was officially initiated in July 2013 with the ‘one-stop-
model’ and ‘test and treat’ approach, wherein pregnant or lactating women with HIV had access to HIV care and 
treatment within MCH services. ART is provided by MCH nurses. Pregnant and breastfeeding women living with 
HIV are followed-up in MCH services until the final HIV status of the exposed infant is determined; once this 
status is confirmed, these women are referred for follow-up HIV care and treatment services. Women have 
monthly clinical visits during the first six months after ART initiation followed by bi-monthly visits until 12 
months, and bi-annual visits thereafter until the end of breastfeeding. ART counselling and drug pickup are 
performed on a monthly basis. Routine viral load (VL) monitoring is recommended at 3 and 6 months after ART 
initiation and annually thereon. First-line treatment is a once-daily fixed-dose of the 
tenofovir/lamivudine/efavirenz combination. HIV-exposed infants receive a daily dose of nevirapine from birth 
until 6 weeks postnatally and are followed-up on a monthly basis during their first year, then bi-monthly until the 
final HIV serostatus is determined.  
For non-pregnant and non-breastfeeding women, the ART initiation criteria changed overtime (Supplemental 
Digital 1). Between 2013 and 2016, adults with World Health Organisation (WHO) stage I/II disease and a CD4 
count <350 cells/μL and those with WHO stage III/IV disease irrespective of CD4 count were deemed eligible for 
ART initiation. From 2016 to 2017, the CD4 threshold was changed to 500 cells/μL5. A phased implementation 
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of the ‘test & treat all’10 approach was initiated in late 2016 in 12 high-burden districts; this was then scaled up to 
reach 65 districts by December 2017.   
 
 
Study design, data collection and statistical analyses 
We included data from 86 Ministry of Health facilities providing HIV care and treatment in Nampula and 
Zambezia that were receiving technical support from ICAP at Columbia University through funding from the 
United States President’s Emergency Plan for AIDS Relief*. 
PMTCT cascade in ANC 
For this assessment, we used existing ANC aggregated data from facility reports and those captured through 
ICAP’s aggregate database using DHIS211. Simple statistics were calculated and expressed in number and 
proportions (%) for the following indicators: number of pregnant women enrolled in ANC; proportion of pregnant 
women with a documented HIV status at the first ANC visit; proportion of HIV-positive pregnant women at the 
first ANC visit; and proportion of HIV-positive pregnant women receiving ART. For this analysis, we included 
all pregnant women enrolled in ANC between the July 1, 2013 and December 31, 2017. The indicators have been 
disaggregated by year of ART initiation from 2013 to 2017 to highlight the potential evolution in programme 
implementation. 
Risk of attrition analyses 
For the assessment of attrition risk, we performed a retrospective cohort analysis using data from an electronic 
patient-level database (ePLD). We also used data from the Program and Facilities Characteristics Tracking System 
(PFaCTS) round 8 (May 2015). This is an ICAP facility-level survey conducted every two to three years to gather 
information on the characteristics of health facilities and their services at ICAP-supported sites 12,13. Data from 
the ePLD and PFaCTS were merged by a facility code to allow for the analyses of the potential effects of facility-
specific characteristics on the risk of attrition in each patient. 
Our main exposure variable was patient group, for which patients were categorised into two groups based on their 
pregnancy status and ART eligibility criteria: (1) ‘own health’, if women were neither pregnant nor breastfeeding 
and ART was initiated based on national eligibility criteria; (2) ‘B+ pregnant’, if women were pregnant at the time 
of ART initiation. The outcome event was attrition, which was divided into two types of losses: (1) No follow-up 
(NFU), corresponding to women who never returned to the health facility after the first visit in which ART was 
prescribed and (2) Non-retention, corresponding to women who dropped out from care after the second visit, due 
to death (documented date of death) or those lost to follow-up (LTFU, defined as not having been seen for a period 
of 30 days or longer prior to the 365th day since ART initiation). We hypothesised that while the NFU cases were 
likelier to be related to patients’ reluctance to initiate ART, non-retention may have been related to a sub-optimal 
quality of care.  
We included women enrolled in HIV services who initiated ART any time between July 1, 2013 and December 
31, 2016. We included data from follow-up until December 31, 2017. Women were excluded if their HIV status 
was not confirmed or they had missing information on pregnancy status and eligibility criteria for ART initiation 
 
*US Centers for Disease Control and Prevention (CDC) under PEPFAR, through cooperative agreements: Building Mozambican 
Capacity to Implement Quality HIV/AIDS Prevention, Care and Treatment in the Republic of Mozambique under PEPFAR 
(CA#U2GPS002756); Technical Assistance to the Ministry of Health for HIV Services and Program Transition  in the Republic of 
Mozambique under PEPFAR 9CA#1U2GGH000424);  Supporting Sustainable Implementation of HIV and TB Services for Epidemic 
Control in The Republic of Mozambique (CA# NU2GGH001944). 
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since this information was used to classify patients into groups. We also excluded a small number of breastfeeding 
women who had been previously enrolled in HIV care but who initiated ART only after July 2013 (n=280) due to 
specific characteristics related to the timing of diagnosis and duration of follow-up in HIV care, which did not 
allow for comparability.  
The patients’ baseline characteristics were described as frequencies for categorical variables and median for 
continuous variables and were compared by patient group using Chi-square and Wilcoxon tests. For biological 
and immunological measurements, we used the most updated data within the range of 90 days prior to or 30 days 
after ART initiation. A patient retained in care was defined as being alive and present in care at 12 months 
following ART initiation or any time after. Women transferred to another facility were right-censored at the date 
of transfer. The Kaplan-Meir method was used to estimate the probability of retention in care at 12 months after 
ART initiation for each patient group, with differences in crude estimates assessed by a log-rank test.  
To assess the risk of having an NFU status at 12 months after ART initiation, we used logistic regression models 
with the cluster effect on the facility. For the risk of non-retention at 12 months after ART initiation, we used Cox 
proportional hazard models with random effects accounting for the clustering of patients in the same health 
facility. For both models, we explored the association between the patient group (‘B+ pregnant’ vs. ‘own health’) 
and outcome (NFU or non-retention), adjusting for socio-demographic, clinical, immunological and facility-
related characteristics. Covariates were first selected based on prior knowledge on associated predictors, which 
were tested in the univariate analysis. Multivariable models were then constructed. Final models were obtained 
using a backward elimination procedure. We systematically tested the interaction between the year of ART 
initiation and patient group in both models as we hypothesised that the Option B+ programme may have evolved 
in a certain manner over the four-year period and influenced the association between patient group and attrition. 
Adjusted odds ratios (aORs) and adjusted hazard ratios (aHRs) were reported with their 95% confidence intervals 
(CIs). We performed a sensitivity analysis to assess whether the exclusion of health facilities with missing 
information on facility-related characteristics had any effect on the results. All statistical analyses were performed 
with Stata version 14.0 (Stata Corp., College Station, TX, USA). 
 
Ethical approval  
This study was part of the ‘Analysis of existing aggregate data included in routine reports generated by ICAP-
supported HIV and other health programmes in Mozambique’ study and the ‘Identifying Optimal Models of HIV 
Care and Treatment’ collaboration, which were approved by the Mozambican National Ethics Committee and the 
Columbia University Medical Center IRB. Additional technical and administrative approval was received from 
the US Centers for Disease Control and Prevention and the Office of the Global AIDS Coordinator, US 
Department of State. Informed consent to participate was not required as this study was solely based on secondary 
data analyses of de-identified routine service delivery data. Both as part of the ‘Analysis of existing aggregate 
data’ study and the ‘Optimal Models’ Collaboration, the Columbia University IRB Committee did not consider 
this study to be a human subject research, as there was no interaction with subjects and no intervention, and private, 
identifiable information was not collected. 
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Results 
PMTCT cascade in antenatal care 
A total of 916,280 women enrolled in ANC under Option B+ between July 2013 and December 2017. The 
proportion of women with a documented HIV status increased from 93% in 2013 to 96% in 2017 (Figure 1). The 
proportion of women who tested HIV-positive decreased from 8% to 6%. Among the HIV-positive women, the 
proportion of those who initiated ART at the first ANC visit increased from 32% to 60%. The proportion of women 
who had been on ART before ANC enrolment also increased from 10% to 35%. Overall, the proportion of HIV-
positive pregnant women on ART at the first ANC visit increased from 42% to 95% between 2013 and 2017.  
 
Attrition risk at 12 months following ART initiation 
A total of 44,377 HIV-positive women were included in this retrospective cohort analysis. Of these, ART was 
initiated in 31,186 women while they were pregnant (‘B+ pregnant’) and ART was initiated in 13,191 women 
based on immunological or clinical criteria (‘own health’) (Figure 2).  
Table 1 shows the baseline characteristics of the women included in the analyses. Overall, the median age at ART 
initiation was 26 years (interquartile range [IQR]: 21-32). More than 12% of the women had no education, 63% 
were unemployed and 56% were in a couple or married. The median gestational age at ART initiation for the ‘B+ 
pregnant’ women was 25 weeks (IQR: 19–29). The median follow-up time under ART was 13 months (IQR: 3-
24). In 44% of the women, ART was initiated between 2013 and 2014, in 31% in 2015, and in 25% in 2016.  
On comparing the two groups, the proportion of women who initiated ART at WHO clinical stage IV was higher 
in the ‘own health’ group (23% vs. 2% in the ‘B+ pregnant’ group). Among the women with available information 
(N=24,509), those in the ‘own health’ group had a lower median CD4 cell count than the ‘B+ pregnant’ group 
women: 240 (IQR: 128-348) vs. 386 (IQR: 234-572) cells/μL, respectively. In more than 90% and 36% of the 
women, ART was initiated on the same day of HIV diagnosis in the ‘B+ pregnant’ and ‘own health’ groups, 
respectively (Table 1).  
Table 2 describes the distribution of patients according to the health facility characteristics. More than 70% of the 
women were enrolled in public primary health facilities (type I). Only 53% had access to VL sampling at the 
health facility in which they received routine HIV care. Individual and/or group ART counselling was widely 
accessible (83%); however, more targeted approaches including support groups and peer education were less 
commonly provided (65% and 69%, respectively). Of 44,377 patients, 1,678 (4%) were enrolled in HIV care at 
the 12 facilities which did not have any information on facility-related characteristics. The baseline characteristics 
of the women included in the analyses were comparable to those who were excluded (N=11,737) (Supplemental 
Digital 2).  
Figure 3 describes the probability of retention by patient group and ART initiation year. The probability of 
retention at 12 months post ART initiation was significantly lower in the ‘B+ pregnant’ women than the ‘own 
health’ women, irrespective of year. From 2013 to 2016, the probability of retention increased from 64% (95% 
CI: 62-66) to 74% (95% CI: 73-75) for the ‘B+ pregnant’ women and from 71% (95% CI: 69-73) to 77% (95% 
CI: 73-75) for the ‘own health’ women.  
Of the 44,377 women included in the analyses, 22% (n=9,905), 29% (n=12,795) and 35% (n=15,326) dropped 
out of care by 3, 6, and 12 months post ART initiation, respectively. Of those who dropped out of care at 12 
months, 30% (4,576/15,326) did so immediately after their first visit, corresponding to the definition of NFU; 7% 
(1,011/15,326) died and 63% (9,739/15,326) were LTFU. On comparing the two groups of women, the proportion 
of those with an NFU status was significantly higher in the ‘B+ pregnant’ group than the ‘own health’ group: 11% 
(3,462/31,186) and 8% (1,114/13,191), respectively (P<0.0001). The proportion of women considered as non-
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retained in care (death and LTFU) was also significantly higher in the ‘B+ pregnant’ group than the ‘own health’ 
group, at 26% (7,978/31,186) and 21% (2,772/13,191), respectively (P<0.0001).  
We found a significant interaction effect between ART initiation year and patient group. Therefore, we presented 
the results stratified by ART initiation year (2013, 2014, 2015 and 2016) for both models (Tables 3 and 4).  
As Table 3 shows, the effect of patient group was different according to the year of ART initiation after adjustment 
for age at ART initiation, education level, employment, CD4 cell count at enrolment, same-day ART initiation, 
tuberculosis treatment at ART initiation, type of health facility and presence of a support group for HIV+ patients 
at the health facility. Women who initiated ART during pregnancy in 2013 were at a higher risk of having an NFU 
status than women who initiated for their own health, although no statistically significant difference was found. 
For the following years, women with ART initiation during pregnancy were less likely to have an NFU status than 
the ‘own health’ women with ART initiation during the same period; statistical significance was found only for 
those with ART initiation in 2015 (aOR: 0.77, 95% CI: 0.64-0.94, P=0.01) (Table 3). Our results were comparable 
after the exclusion of patients from sites without data on facility-related characteristics. 
Table 4 shows the risk of non-retention among women who completed at least one visit after ART initiation 
(N=39,801). Similar to the results of the previous analysis, we found a significant interaction between patient 
group and ART initiation year. After adjustment for age, employment status, CD4 cell count at enrolment, same-
day ART initiation as well as the availability of family planning services onsite, ‘B+ pregnant’ women showed a 
significantly higher risk of non-retention than women who initiated ART for their own health (aHR: 1.14, 95% 
CI: 1.03-1.25) when ART was initiated in 2013. The risk decreased during the subsequent years, with no 
statistically significant difference observed between the two groups. These findings did not change after the 
exclusion of patients from sites with no data on facility-related characteristics.  
 
 
Discussion  
This study assessed the effectiveness of the Option B+ strategy in two provinces in Mozambique over four years 
of the PMTCT programme implementation. We believe that our study makes a significant contribution to the 
literature by documenting in detail the progress made in implementation of the PMTCT Option B+ in a high HIV 
disease burden country in sub-Saharan Africa.  
In terms of the ANC cascade, we reported an improved HIV testing uptake at the first ANC visit, a reduction in 
the HIV-positivity rate, and an increase in the rates of ART initiation. We also found that the proportion of women 
already on ART at the first ANC visit increased, accounting for over 30% of HIV-positive pregnant women 
enrolled by 2017. These results provide evidence of the positive evolution of the Option B+ roll-out in 
Mozambique, contributing to better access to and acceptability of essential treatments.  
Over the four-year period, the overall retention rates at 12 months after ART initiation improved in both groups, 
at 74% and 77% of the women in the ‘B+ pregnant’ and ‘own health’ groups, respectively. Greater improvements 
were noted in the ‘B+ pregnant’ group, with retention rates that had increased from 64% in 2013 to 74% in 2017. 
Similar results were reported in a systematic review focusing on retention in HIV care under Option B+ in Africa, 
in which the pooled estimate was 76% at 12 months14. Despite the apparent progress, the overall attrition rate 
remains unacceptably high for both groups with one out of four women being lost to care within their first year of 
treatment; this highlights the importance of ensuring early and intensified quality ART adherence through 
counselling and peer support15.  
Interestingly, time effects came into play in the determination of the risks of attrition in our study. In the early 
years of Option B+ implementation (2013-2014), we did not observe a higher risk of immediate drop-out in 
Page 75 of 188 
 
 
pregnant women compared to women on ART for their own health, as observed elsewhere 7,8,16 . Conversely, in 
2015, the risk of immediate drop-out was significantly lower among the ‘B+ pregnant’ women than ‘own health’ 
women. The fact that several national efforts were implemented by the Ministry of Health with the support of 
other partners in 2015 may explain those results 17. In 2015, improvements in the quality of care in PMTCT-
related services were called for, and several tangible efforts were made, such as the provision of continuous 
training for MCH nurses in ART, increased frequency of supervision visits to health units, publication of the new 
PMTCT guideline handbook for healthcare workers and the establishment of a communication strategy for the 
elimination of the vertical transmission of HIV among girls and young women. Additionally, awareness on Option 
B+ was raised in the community and reinforced through Information Education and Communication material 
updates for Mother2Mother groups. As the expansion of ART and Option B+ services continued throughout 2016, 
the effects of such interventions may have ‘spilled-over’ to non-pregnant women, resulting in a similar low risk 
of immediate drop-outs as observed in 2016.  
The risk of non-retention was 12% higher in the ‘B+ pregnant women’ than ‘own health’ women when ART was 
initiated in the first year of programme implementation. This risk decreased over the years and was similar in both 
groups by 2016. Haas et al. reported similar findings in a cohort of women enrolled in Malawi’s Option B+ 
programme between 2011 and 2012 18: women in Option B+ had a higher risk of being lost to follow-up in years 
1 and 2 of ART than those who initiated ART for their own health. However, the retention rates did not change 
as the Option B+ programme matured. Our results suggest improvements achieved over time as the PMTCT 
Option B+ programme matured with better counselling including reinforced education messages about the benefits 
of ART during the first ANC visit and importance of adherence to long-term care during subsequent follow-ups. 
We observed that the initiation of ART on the same day as HIV diagnosis significantly increased both the risk of 
having an NFU status and non-retention, confirming that pregnant women may still experience considerable staff 
pressure to undergo immediate ART initiation without sufficient time to disclose to their partner or relative or 
reflect on their HIV sero-status and the implications of lifelong treatment 14,15,16,19. A greater degree of 
acceptability of lifelong treatment under Option B+ can be achieved with male-partner knowledge and support as 
well as strengthened community sensitization 20,21. 
The strengths of our study lie in the number of sites included, which resulted in the inclusion of more than 
40,000 eligible women in the analysis, increasing the statistical power and reliability of our results. In 
addition, coupling individual-level data with health facility-related characteristics provided a unique 
opportunity to identify actionable measures to improve the quality of care of PMTCT services. However, 
our study has several limitations that should be discussed. Firstly, the data did not allow us to verify if a 
woman with an LTFU status in a given health facility was actually being followed-up elsewhere. As the 
patients’ data were fully anonymised, ‘silent transfer’ could not be detected in a systematic manner, which 
may have caused the misclassification of the status of self-transferred patients as ‘LTFU’. It has been 
reported that accounting for self-transferred patients is likely to increase the estimates of patient retention 
22,23. Nevertheless, we assume that the rate of self-transfer is likely to be similar in both groups 
(nondifferential misclassification); thus, the association between the patient status and risk of attrition would 
not be affected significantly 24. Secondly, we analysed routine data for which nearly 7% of women did not 
have information on ART eligibility criteria. While routine health information systems are critical for 
programme evaluations, efforts to overcome the barriers of missing or inconsistent data are essential to 
enable the effective use of such data sources for policymaking, programme actions, and research 25,26.  
In conclusion, we demonstrated that the PMTCT Option B+ strategy in Nampula and Zambezia yielded 
positive results as the programme matured over four years, including the achievement of high HIV testing 
uptake and ART initiation rates in ANC. Improving women’s engagement in care remains a challenge. It is 
important to seek alternative service delivery models 27,28,29 to support the existing health system and prevent 
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potential defaulters to achieve the UNAIDS’ 95-95-95 targets for PMTCT and the virtual elimination of the 
MTCT of HIV.   
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Figure 1: Prevention of mother-to-child transmission of HIV (PMTCT) cascade of care, 
antenatal care sites, Nampula and Zambézia provinces, Mozambique 2013-2017 (n=86 
sites, 916,280 women). Source: DHIS2  
 
  
Source of data : DHIS2 aggregated facility reports; proportion of Pregnant women (PW) with known HIV status at 1st antenatal care (ANC) 
visit: numerator = # of pregnant women who received their test results (i.e. test results positive, negative and undetermined) plus those already 
known as HIV+, denominator= # PW enrolled in 1st ANC; Proportion of HIV+ PW in 1st ANC visit: numerator = # of PW HIV-positive, 
denominator = # with known HIV status; Proportion of HIV+ PW who initiated ART: numerator = # of PW HIV-positive who initiated ART at 
1st ANC visit, denominator = # of PW HIV-positive; Proportion of HIV+ PW already on ART: numerator = # of PW HIV-positive already 
receiving ART at 1st ANC visit, denominator = # of PW HIV-positive; Proportion of PW HIV+ on ART: numerator = sum of # of PW HIV-
positive who initiated ART  and # of PW HIV-positive already receiving ART at 1st ANC visit, denominator = # of PW HIV-positive.  
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Figure 2: Inclusion cascade of HIV+ women in the retrospective cohort analysis using 
electronic patient-level data, Nampula and Zambézia provinces, Mozambique 2013-2017, 
(n=86 sites).  
 
 
 
Source of data: electronic patient-level database (ePLD) merged with health facility characteristics data from the Program and Facilities 
Characteristics Tracking System (PFaCTS); Note: See definition of “B+ pregnant” and “own health” in Measurements section.   
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Table 1: Demographic, clinic-immunological and treatment characteristics of women 
included, Nampula and Zambézia provinces, Mozambique (n=86 sites, 44,377 women)  
 
Patient characteristics “B+ pregnant” 
(N=31,186) 
“Own health” 
(N= 13,191) 
Total 
(N=44,377) 
  Median age, years [IQR] 
  Age group (%) 
15-19 y 
20-24 y 
        25-34 y 
        35+y 
Education level (%) 
       None 
       Primary & above 
       No information 
Marital status (%) 
      Couple/married 
      Single 
      Widowed 
      Other/no info  
Employment status (%) 
      Unemployed 
      Working/student    
      No information 
25 [21 - 30] 
 
7,095 (23) 
9,346 (30) 
10,639 (34) 
4,106 (13) 
 
3,122 (10) 
20,985 (67) 
7,079 (23) 
 
19,367 (62) 
5,559 (18) 
884 (3) 
5,376 (17) 
 
21,280 (68) 
6,806 (22) 
3,100 (10) 
30 [24 - 39] 
 
1,193 (9) 
2,592 (20) 
4,898 (37) 
4,508 (34) 
 
2,179 (17) 
7,928 (60) 
3,084 (23) 
 
5,600 (42) 
4,496 (34) 
741 (6) 
2,354 (18) 
 
6,555 (50) 
5,191 (40) 
1,445 (11) 
26 [21 - 32] 
 
8,288 (19) 
11,938 (27) 
15,537 (35) 
8,614 (19) 
 
5,301 (12) 
28,913 (65) 
10,163 (23) 
 
24,967 (56) 
10,055 (23) 
1,625 (4) 
7,730 (17) 
 
27,835 (63) 
11,997 (27) 
4,545 (10) 
Clinical stage (%) 
       Stage I/II 
       Stage III 
       Stage IV 
n=30,027 
24,700 (82) 
4,724 (16) 
603 (2) 
n=12,828 
3,808 (30) 
6,095 (47) 
2,925 (23) 
n=42,855 
28,508 (67) 
10,819 (25) 
3,528 (8) 
CD4 testing, median [IQR] 
      CD4 cell count 
CD4 cell count group (%) 
      <200 
      200-349 
      350-499 
      >=500 
n=15,076 
386 [234 - 572] 
 
2,992 (20) 
3,667 (24) 
3,462 (23) 
4,955 (33) 
n=9,433 
240 [128 - 348] 
 
3,822 (41) 
3,295 (35) 
1,262 (13) 
1,054 (11) 
n=24,509 
319 [183 - 496] 
 
6,814 (28) 
6,962 (28) 
4,724 (19) 
6,009 (25) 
Follow-up pre-ART (days), median [IQR]  
Follow-up under ART (month), median [IQR]  
0 [0 - 1] 
13 [3 - 24] 
6 [0 - 32] 
               14 [4 - 25] 
0 [0 - 15] 
13 [3– 24] 
Year of ART initiation (%)    
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Patient characteristics “B+ pregnant” 
(N=31,186) 
“Own health” 
(N= 13,191) 
Total 
(N=44,377) 
      2013 
      2014  
      2015  
      2016  
4,045 (13) 
9,929 (32) 
9,693 (31) 
7,519 (24) 
1,661 (13) 
3,746 (28) 
3,996 (30) 
3,788 (29) 
5,706 (13) 
13,675 (31) 
13,689 (31) 
11,307 (25) 
ART regimen (%) 
     TDF-3TC-EFV 
     AZT-3TC-NVP/EFV 
     D4T-3TC-NVP/EFV 
     Other 
     Non specified 
 
24,105 (77) 
2,111 (7) 
124 (.4) 
4,751 (15) 
95 (.3) 
 
10,673 (81) 
  1,588 (12) 
222 (2) 
599 (5) 
109 (1) 
 
34,778 (78) 
3,699 (8) 
346 (1) 
5,350 (12) 
204 (.5) 
Same day ART initiation (%) 28,953 (93) 4,812 (36) 33,765 (76) 
On TB treatment (%) 740 (2) 1,401 (11) 2,141 (5) 
IQR: Interquartile range; ART: anti-retroviral treatment; TDF: Tenofovir; 3TC: Lamivudine; EFV: Efavirenz; AZT: Zidovudine; NVP: 
Nevirapine; D4T: Stavudine; TB: tuberculosis. Note: See definition of “B+ pregnant” and “own health” in Measurements section. P 
values of statistical tests are not presented, as all tests are highly significant, despite the Bonferroni correction (corrected a = 0.05/13 = 
0.004). 
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Table 2: Health facility characteristics, Nampula and Zambézia provinces, Mozambique 
(n=86 sites, 44,377 women)*   
 “B+ pregnant” 
(N=31,186) 
“Own health” 
(N= 13,191) 
Total 
(N=44,377) 
Health facility and services    
PMTCT option (%) 
       New B+ site 
        Switched from option A to B+ 
        No PMTCT services 
       No information  
Type of Health Facility (%) 
        Public I (HC clinic) 
        Public II (dist./prov. hosp.) 
        Public III (teaching/nation. ref. hosp.) 
        No information 
 
186 (1) 
29,342 (94) 
288 (1) 
1,370 (4) 
 
22,924 (74) 
6,432 (21) 
460 (1) 
1,370 (4) 
 
65 (1) 
12,589 (95) 
229 (2) 
308 (2) 
 
9,023 (68) 
3,401 (26) 
459 (4) 
308 (2) 
 
251 (1) 
41,931 (94) 
517 (1) 
1,678 (4) 
 
31,947 (72) 
9,833 (22) 
919 (2) 
1,678 (4) 
Location (%) 
Urban-city 
Semi-urban 
         Rural 
        No information 
 
12,787 (41) 
4,923 (16) 
12,106 (39) 
1,370 (4) 
 
3,958 (30) 
1,866 (14) 
7,059 (54) 
308 (2) 
 
16,745 (38) 
6,789 (15) 
19,165 (43) 
1,678 (4) 
Laboratory services    
Location cd4 testing (%) 
        Blood sample & test at HF 
        Blood sample at HF /test at other HF 
        Not available 
        No information  
 
8,117 (26) 
19,190 (62) 
2,509 (8) 
1,370 (4) 
 
5,531 (42) 
6,774 (51) 
578 (5) 
308 (2) 
 
13,648 (31) 
25,964 (58) 
3,087 (7) 
1,678 (4) 
Location of viral load sampling# (%) 
        Not available at HF and/or referred to another 
HF 
        Available onsite 
        Missing 
 
12,695 (41) 
17,092 (55) 
1,399 (4) 
 
6,430 (49) 
 6,453 (49) 
308 (2) 
 
19,125 (43) 
23,545 (53) 
1,707 (4) 
Other service availability on site    
Type of ART counseling (%) 
        None 
        One on one 
        Group 
        Both 
        Missing 
 
3,913 (13) 
3,282 (10) 
2,433 (8) 
20,188 (65) 
1,370 (4) 
 
2,024 (16) 
1,869 (14) 
901 (7) 
8,089 (61) 
308 (2) 
 
5,937 (13) 
5,151 (12) 
3,334 (7)                
28,277 (64) 
1,678 (4)                       
ART counselling by outreach worker (%)    
        No 
        Yes 
        Missing  
25,475 (82) 
4,341 (14) 
1,370 (4) 
10,403 (79) 
2,480 (19) 
308 (2) 
35,878 (81) 
6,821 (15) 
1,678 (4) 
Support group services:  
Support groups (%) 
Peer educator program (%) 
 
20,191 (65) 
22,110 (71) 
 
8,748 (66) 
8,418 (64) 
 
28,939 (65) 
30,528 (69) 
Action after missed visits for ART patients: 
Call/SMS (%) 
Home visits (%) 
 
23,551 (76) 
27,370 (88) 
 
9,840 (75) 
11,649 (88) 
 
33,391 (75) 
39,019 (88) 
HF: health facility; ART: anti-retroviral treatment. Note: See definition of “B+ pregnant” and “own health” in Measurements section. P values of 
statistical tests are not presented, as all tests are highly significant, despite the Bonferroni correction (corrected a = 0.05/12 = 0.004). * 1,678 
women with no information on health facility characteristics (12 Health facilities). 
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Figure 3: Twelve-month probability of retention in HIV+ women after ART initiation, by 
status and period of ART initiation, Mozambique 2013-2017 (n=86 sites, 44,377 women).   
  
 
 
  
 
ART: anti-retroviral treatment; 95%CI: 95% confidence interval. Note: See definition of “B+ pregnant” and “own health” in Measurements section. 
Log-rank test for equality of survivor functions, by patient status (‘B+ pregnant” vs. “own health”): for women initiating ART in 2013: p<0.00001; 
for women initiating ART in 2014: p<0.00001; for women initiating ART in 2015: p<0.00001; for women initiating ART in 2016: p=0.002 
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Table 3: Factors associated with no follow-up after start of art, Logistic regression models, Nampula and 
Zambézia provinces, Mozambique (n=86 sites, 44,377 women)  
 Events 
n/N (%) 
Univariate model Multivariable model 
 OR 95% CI P Adjusted OR† 95% CI P 
Status of HIV+ women        
Year of ART initiation: 2013 
    Own health 
    B+ pregnant 
 
160/1,661 (10) 
531/4,045 (13) 
 
Ref. 
1.56 
 
- 
1.21– 2.00 
0.0005 
 
Ref. 
1.12 
 
- 
0.88 – 1.42 
0.37 
Year of ART initiation: 2014 
Own health 
B+ pregnant 
 
345/3,746 (9) 
1,325/9,929 (13) 
 
Ref. 
1.40 
 
- 
1.17– 1.67 
0.0002 
Ref. 
0.96 
- 
0.81 – 1.12 
0.6 
Year of ART initiation: 2015  
Own health 
B+ pregnant 
 
370/3,996 (9) 
1,075/9,693 (11) 
 
Ref. 
1.17 
 
- 
0.96 – 1.42 
0.12 
Ref. 
0.77 
- 
0.64 – 0.94 
0.01 
Year of ART initiation: 2016 
    Own health 
    B+ pregnant 
 
239/3,788 (6) 
531/7,519 (7) 
 
Ref. 
1.27 
 
- 
1.00 – 1.62 
0.06 
Ref. 
0.88 
- 
0.70 – 1.10 
0.3 
Socio-demographic maternal factors        
Age at ART initiation  
    35+y 
25-34 y  
20-24 y  
15-19 y 
 
684/8,614 (8) 
1,553/15,537 (10) 
1,330/11,938 (11) 
1,009/8,288 (12) 
 
Ref 
1.29 
1.45 
1.60 
 
- 
1.13 - 1.46 
1.19 - 1.77 
1.30 – 2.00 
0.0001 
 
Ref 
1.15 
1.29 
1.37 
 
- 
1.02 - 1.28 
1.10 - 1.51 
1.16 - 1.60 
0.0023 
Education level 
Primary and above 
No school education 
No information 
 
2,591 /28,913 (9) 
569/5,301 (11) 
1,416/10,163 (14) 
 
Ref.  
1.22 
1.64 
 
Ref. 
0.97 - 1.53 
1.32 – 2.04 
<0.00001 
 
Ref. 
1.33 
1.33 
 
- 
1.11 - 1.60 
1.17 - 1.52 
<0.00001 
Employment 
    Working 
    Unemployed 
     No information 
 
929/11,997 (8) 
2,867/27,835 (10) 
780/4,545 (17) 
 
Ref.  
1.36 
2.46 
 
Ref. 
1.13 - 1.65 
1.92 – 3.18 
<0.00001 
 
Ref.  
1.16 
1.56 
 
Ref. 
0.98 - 1.38 
1.26 – 1.92 
0.0001 
Page 84 of 188 
 
 
 
 Events 
n/N (%) 
Univariate model Multivariable model 
 OR 95% CI P Adjusted OR† 95% CI P 
Clinic-immunological maternal factors        
CD4 cell count 
       >=350 
       <350 
       Missing  
 
715/10,733 (7) 
922/13,776 (7) 
2,939/19,868 (15) 
 
Ref. 
1.00 
2.43 
 
- 
0.87 - 1.15 
2.00 – 2.95 
<0.00001 
 
Ref. 
1.07 
2.17 
 
- 
0.93 - 1.23 
1.78 – 2.63 
<0.00001 
Same day ART initiation 
       No  
       Yes 
 
737 /10,612 (7) 
3,839/33,765 (11) 
 
Ref. 
1.72 
 
- 
1.48 - 1.99 
<0.00001 
 
Ref. 
1.27 
 
- 
1.09 - 1.48 
0.002 
TB treatment at ART initiation 
       No  
       Yes 
 
4,473/42,236 (11) 
103/2,141 (5) 
 
Ref. 
0.43 
 
- 
0.34 - 0.53 
<0.00001 
 
Ref. 
0.48 
 
- 
0.38 – 0.61 
<0.00001 
Health facility factors        
Type of Health Facility 
        Public I (HF clinic) 
        Public II (dist./prov. hosp.) 
        Public III (teaching/nation. ref. hosp.) 
        No information  
 
3,661/31,947 (11) 
738/9,833 (8) 
58/919 (6) 
119/1,678 (7) 
 
Ref. 
0.62 
0.52 
0.59 
 
- 
0.49 - 0.79 
0.42 - 0.64 
0.42 – 0.83 
 
 
<0.00001 
 
Ref. 
0.75 
0.75 
0.64 
 
- 
0.61 - 0.92 
0.64 - 0.89 
0.44 – 0.91 
 
 
0.0007 
Support groups for HIV+ patients 
        No 
        Yes 
 
2,518 /21,321 (12) 
1,939 /21,378 (9) 
 
Ref. 
0.74 
 
- 
0.59 – 0.93 
0.002 
 
Ref. 
0.81 
 
- 
0.67 – 0.98 
0.03 
OR: Odds ratio; CI: confidence interval; TB: tuberculosis; ART: antiretroviral treatment; HF: health facility. Note: See definition of “B+ pregnant” and “own health” in Measurements 
section. 
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Table 4: Factors associated with non-retention 12 months after ART initiation, Cox regression models, Nampula 
and Zambézia provinces, Mozambique (n=86 sites, 39,801 women)  
 Events 
(n/PM) 
Univariate models Multivariable model 
 Crude HR 95% CI P Adjusted HR† 95% CI P 
Status of HIV+ women        
Year of ART initiation: 2013 
    Own health 
    B+ pregnant 
 
375/13,435 
1168/29,290 
 
Ref. 
1.46 
 
- 
1.34– 1.60 
<0.0001 
Ref. 
1.14 
- 
1.03 – 1.25 
0.01 
Year of ART initiation: 2014 
Own health 
    B+ pregnant 
 
702/32,126 
2,450/78,296 
 
Ref. 
1.38 
 
- 
1.28– 1.48 
<0.0001 
Ref. 
1.06 
- 
1.97 – 1.15 
0.21 
Year of ART initiation: 2015  
Own health 
    B+ pregnant 
 
707/34,800 
2,360/80,398 
 
Ref. 
1.29 
 
- 
1.20 – 1.39 
<0.0001 
Ref. 
1.00 
- 
0.91 – 1.07 
0.78 
Year of ART initiation: 2016 
Own health 
    B+ pregnant 
 
721/33703 
1,685/66,195 
 
Ref. 
1.24 
 
- 
1.15 – 1.35 
<0.0001 
Ref. 
0.96 
- 
0.88 – 1.05 
0.40 
Socio-demographic maternal factors       
Age at ART initiation  
    35+y 
25-34 y  
20-24 y  
15-19 y 
 
1,546/76,064 
3,326/132,009 
3,031/95,915 
2,265/64,254 
 
Ref. 
1.22 
1.54 
1.69 
 
- 
1.15 - 1.30 
1.44 - 1.63 
1.58 - 1.80 
<0.00001 
 
Ref 
1.16 
1.40 
1.50 
 
- 
1.09 - 1.23 
1.32 - 1.50 
1.40 - 1.60 
<0.00001 
Employment 
Working 
Unemployed 
No information 
 
2,403/105,545 
6,842/227,764 
923/34,935 
 
Ref. 
1.26 
1.13 
 
- 
1.20 - 1.32 
1.04 – 1.23 
<0.00001 
 
Ref. 
1.15 
1.05 
 
- 
1.10 - 1.21 
0.97 - 1.14 
<0.00001 
Clinic-immunological maternal factors       
CD4 cell count  
     ³ 350 
 
2,464/95,336 
 
Ref. 
 
- 
 
<0.00001 
 
Ref. 
 
- 
<0.00001 
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 Events 
(n/PM) 
Univariate models Multivariable model 
 Crude HR 95% CI P Adjusted HR† 95% CI P 
     < 350 
     Missing 
2,790/121,574 
4,914/151,333 
0.88 
1.20 
0.84 - 0.93 
1.14 - 1.27 
0.98 
1.18 
0.93 - 1.04 
1.12 - 1.24 
Same day ART initiation 
     No  
     Yes 
 
2,020/93,946 
8,148/274,298 
 
Ref. 
1.37 
 
- 
1.31 – 1.45 
<0.00001 
 
Ref. 
1.20 
 
- 
1.22 - 1.27 
<0.00001 
Health facility factors        
Family planning services (%) 
    Available onsite  
    Not available at HF  
 
3,727/153,767 
6,441/214,477 
 
Ref. 
1.30 
 
- 
1.08 - 1.57 
0.007 
 
Ref. 
1.29 
 
- 
1.07 – 1.55 
0.007 
          PM, Person-Months; CI, confidence interval; HR, Hazard ratio; ART: anti-retroviral treatment; HF: health facility.  
†Ratios from multiple Cox regression allowing for clustering by health facility.  See definition of “B+ pregnant” and “own health” in Measurements section. 
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Supplemental Digital 1: National Antiretroviral Therapy ART-eligibility 
Guidelines from 2013 to 2017, Mozambique Ministry of Health.  
 
 
 WHO stage CD4 cell count not 
available 
CD4 cell count available 
2013 through 2016 
 I/II Do not initiate ART Initiate ART if CD4≤ 350 cells/μL 
 III Initiate ART Initiate ART independent of CD4 count 
 IV Initiate ART Initiate ART independent of CD4 count 
2016 through 2017 * 
 I/II Do not initiate ART Initiate ART if CD4≤ 500 cells/μL 
 III Initiate ART Initiate ART independent of CD4 count 
 IV Initiate ART Initiate ART independent of CD4 count 
Abbreviations: WHO, World Health Organization; ART, antiretroviral therapy. 
 
*A phased implementation of the “Test & Treat all” approach started in late 2016 in 12 high-burden districts 
which scaled up to reach 65 districts by December 2017.  
 
  
Page 88 of 188 
 
 88 
Supplemental Digital 2: Comparison of main characteristics of women 
included vs. excluded, Nampula and Zambézia provinces, Mozambique 
(n=86 sites, 56,114 women) 
 
Patient characteristics Excluded 
(N=11,737) 
Included 
(N=44,377) 
Total 
(N=56,114) 
Median age at enrolment, years [IQR] 28 [23 - 36] 26 [21 - 32] 27 [22 - 33] 
CD4 at enrolment (%) 
N=5,316 
367 [203-574] 
N=23,405 
328 [187-511] 
N=28,721 
335 [189-522] 
WHO clinical stage (%) 
     Stage 1-2 
     Stage 3 
     Stage 4 
N=6,828 
4,839 (71) 
1,769 (26) 
220 (3) 
N=42,855 
28,508 (67) 
10,819 (25)  
3,528 (8) 
N=49,683 
33,347 (67) 
12,588 (25) 
3,748 (8) 
ART treatment  
      Follow-up under ART (m), median [IQR] 
 
12 [5 - 25] 
 
13 [3 - 24] 
 
13 [3 - 24] 
     TB treatment at ART start (%) 497 (4) 2,141 (5) 2,638 (5) 
Cohort outcome at 12m after ART start (%) 
      Dead 
      Transfer out 
      No follow-up 
      Alive and retained in care with ART 
      Alive and retained in care with no ART 
      Lost to follow-up 
 
160 (1) 
255 (2) 
367 (3) 
7,875 (67) 
1,230 (11) 
1,850 (16) 
 
1,011 (2) 
1,722 (4) 
4,576 (10) 
23,290 (53) 
4,039 (9) 
9,739 (22) 
 
1,171 (2) 
1,977 (3) 
4,943 (9) 
31,165 (55) 
5,269 (9) 
11,589 (20) 
PMTCT site (%) 
       New option B+ site 
       Old option A site 
       No PMTCT services  
       Missing information 
 
113 (1) 
10,509 (90) 
215 (2) 
900 (7) 
 
251 (1) 
41,931 (94) 
517 (1) 
1,678 (4) 
 
364(1) 
52,440 (94) 
732 (1) 
2,578 (5) 
Type of Health Facility (%) 
       Public I (HF clinic) 
       Public II (dist./prov. hosp.) 
       Public III (teaching/nation. ref. hosp.) 
       No information 
 
9,643 (82)     
1,130 (10)  
64 (1) 
900 (7)      
 
31,947 (72) 
9,833 (22) 
919 (2) 
1,678 (4) 
 
41,590 (74) 
10,963 (20) 
983 (2)         
2,578 (4) 
Location (%) 
Urban-city 
Semi-urban 
       Rural 
        No information 
 
6,025 (51) 
1,610 (14)  
3,202 (27) 
900 (8)           
 
16,745 (38) 
6,789 (15) 
19,165 (43) 
1,678 (4) 
 
34,065 (40) 
13,373 (15) 
35,379 (40) 
4,688 (5) 
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Patient characteristics Excluded 
(N=11,737) 
Included 
(N=44,377) 
Total 
(N=56,114) 
Point of service providing ART (%) 
      Only HIV clinic 
      HIV clinic & all MCH services  
      HIV clinic & not all MCH services 
      No information 
 
79 (1) 
3,596 (31)        
7,162 (61)         
900 (7)                                          
 
2,336 (5) 
12,551 (28) 
27,812 (63) 
1,678 (4)
 
2,415 (4) 
16,147 (29) 
34,974 (62) 
2,578 (5) 
IQR: Interquartile range; WHO: World Health Organization; TB: tuberculosis; MCH: mother and child health; CI: 
confidence interval; HR: Hazard ratio; †Ratios from multiple Cox regression. All p values of statistical tests are < 0.0001 
except for the variable PMTCT site (p=0.015).   
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5.1.3 Results of additional analyses  
The post-partum period is known to be a high-risk period of drop-out. In the ePLD database, it 
was not possible to assess the exact date of delivery as the information was not reported in the 
electronic file. Nevertheless, in our cohort, 61% (19,150/31,186) of the ‘Option B+ pregnant’ 
women had information on gestational age. The median gestational age at ART initiation in 
these women was 25 weeks (IQR:19–29) which corresponds to 6 months of pregnancy. 
Therefore, assessing the 12-month ART retention would include up to 9 months of post-
partum. The Kaplan-Meir survival curves show that retention rates dropped significantly within 
the first 3 months after ART initiation, suggesting that the most difficult period for retaining 
women in Mozambique is at the early stage of ART treatment.  We also examined whether 
timing of ART initiation varied according to the gestational age and we did not find any specific 
trends.  
To provide insights on late post-partum retention outcome, we also evaluated the 24-month 
retention estimates. We included women who enrolled in HIV services in whom ART was 
initiated any time between July 1, 2013 and December 31, 2015, and with follow-up data until 
December 31, 2017 (i.e. at least 24 months of theoretical follow-up). Of 44,377 women 
included, 29,112 (66%) were analysed: 21,046/31,186 (67%) for ‘B+ pregnant’ and 
8,066/13,191 (61%) for ‘own health’ women. The probability of being retained in care at 24 
months significantly varied overtime for both groups of patients. For the ‘B+ pregnant’ women, 
the probability of retention at 24 months after ART initiation increased from 49% to 52% when 
ART was initiated in 2013 and 2014, respectively; then this probability decreased to 46% when 
ART was initiated in 2015. For women starting ART for their own health, similar trends in 
retention were observed over time with significantly higher results (Figure 5.2).       
In the manuscript, we included HIV-positive women initiating ART during pregnancy to 
characterize Option B+ enrolment and to compare with non-pregnant women initiating ART 
for their own health. We excluded women who initiated ART during breastfeeding (n=280) 
and those already on ART before pregnancy (n= 7,599).  
As the table 5.1 shows, women initiating ART while breastfeeding (‘B+ BFW’) had a median 
age at ART initiation of 25 years (IQR: 22 – 30), 38% were in WHO stage 3 or 4, and their 
median CD4 cell count was 303 cells/mm3 (IQR: 221-411). Only half of them initiated ART 
on the same day of HIV diagnosis. Among the ‘B+ BFW’ women who had information on the 
date of delivery (64%, 179/280), the median time of start of ART after birth was 46.5 days 
(IQR: 0-186). The probability of retention in care at 12 months after ART initiation was 80% 
with no significant difference by year of ART start (log-rank test, p=0.27) (Figure 5.3).  
For HIV+ women who initiated ART before diagnosis of pregnancy, age at ART initiation was 
29 years (IQR: 23 – 37). The median time between ART initiation and pregnancy detection 
was 2 months (IQR: 28 - 137) and median gestational age was 26 weeks (IQR: 19-31). Sixty-
one percent were WHO stage 1 or 2 and median CD4 cell count was 320 cells/mm3 (IQR: 174-
509). The majority of this group were enrolled in primary care health facility in an urban 
setting. The probability of being retained in care at 12 months post-ART initiation significantly 
improved over the years increasing from 68% when ART was initiated in 2013 to 84% when 
ART was initiated in 2016 (log rank test,  p<0.00001) (Figure 5.3). 
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Figure 5.2: Estimated Kaplan Meir survivor curves for retention over time for HIV+ women up to 24 
months after ART initiation, by status and period of ART initiation, Mozambique 2013-2017 (n=86 
sites, 29,112 women).  
 
Note: Log-rank test for equality of survivor functions, by patient status (‘B+ pregnant” vs. “own health”): for women 
initiating ART in 2013: p<0.00001; for women initiating ART in 2014: p<0.00001; for women initiating ART in 2015: 
p<0.00001; for women initiating ART in 2016: p<0.00001.  
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Table 5.1: Principal characteristics of B+ breastfeeding women (‘B+ BFW’, n=280)  and of women 
already on ART before diagnosis of pregnancy (n=7,599), Nampula and Zambézia provinces, 
Mozambique (n=86 sites) 
 
Patient characteristics B+ BFW 
(N=280) 
Already on ART before 
diagnosis of pregnancy 
(N=7,599) 
Median age at ART initiation, years [IQR] 25 [22 - 30] 29 [23 - 37] 
Marital status (%) 
      Couple/married 
      Single/widowed 
      Other/no info  
 
187 (67) 
65 (23) 
28 (10) 
 
3,513 (46) 
2,565 (34) 
1,521 (20) 
Education level (%) 
       None 
       Primary & above 
       No information 
 
35 (13) 
195 (69) 
50 (18) 
 
833 (11) 
5,246 (69) 
1,520 (20) 
Employment status (%) 
      Unemployed 
      Working/student    
      No information 
 
198 (71) 
65 (23) 
17 (6) 
 
4,660 (61) 
2,242 (30) 
697 (9) 
CD4 cell count (%) N=201 303 [221-411] 
N=3,623 
320 [174-509] 
WHO clinical stage (%) 
     Stage 1-2 
     Stage 3 
     Stage 4 
     Missing 
 
139 (50) 
88 (31) 
20 (7) 
33 (12) 
 
4,632 (61) 
1,629 (22)  
185 (2) 
1,153 (15) 
ART treatment  
      Follow-up under ART (m), median [IQR] 
 
12.7 [3.9 – 21.3] 
 
9.9 [4.9 – 18.5] 
      Same day ART initiation 142 (51) - 
     TB treatment @ ART start (%) 12 (4) 478 (6) 
PMTCT site (%) 
       New B+ site 
       Switched from Option A to B+ 
       No PMTCT services  
       Missing information 
 
1 (0) 
268 (96) 
1 (0) 
10 (4) 
 
56 (1) 
6,849 (90) 
133 (2) 
561 (7) 
Type of Health Facility (%) 
       Public I (HC clinic) 
       Public II (dist./prov. hosp.) 
       Public III (teaching/nation. ref. hosp.) 
       No information 
 
206 (74)     
51 (18)  
13 (5) 
10 (4)      
 
6,392 (84) 
615 (8) 
31 (1) 
561 (7) 
Location (%) 
Urban-city 
Semi-urban 
       Rural 
        No information 
 
100 (36) 
28 (10)  
142 (50) 
10 (4)           
 
4,584 (60) 
785 (10) 
1,669 (22) 
561 (8) 
Point of service providing ART (%) 
      Only HIV clinic 
      HIV clinic & all MCH services  
      HIV clinic & not all MCH services 
      No information 
 
23 (8) 
58 (21)        
189 (68)         
10 (4)                                          
 
7 (0) 
2,084 (27) 
4,947 (65) 
561 (7) 
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Figure 5.3: Estimated Kaplan Meir survivor curves for retention over time for HIV+ women up to 12 
months after ART initiation, by status and period of ART initiation, Mozambique 2013-2017 (n=86 
sites, 280 B+ BFW  and 7,599 women already on ART before diagnosis of pregnancy) 
 
Note: Log-rank test for equality of survivor functions, by year of ART initiation (2013/2014 vs. 2015/2016): for ‘B+ 
breastfeeding’ women: p=0.27; for women already on ART before diagnosis of pregnancy : p<0.00001.  
 
5.1.1 Discussion 
The results of the manuscript combined with the additional analyses presented here provide a 
broader picture of the successes and challenges of Option B+ implementation in Mozambique. 
Over the course of 4 years, Option B+ PMTCT program showed performance improvement 
for pregnant women initiating ART in ANC, women initiating ART for their own health and 
those already on ART before diagnosis of pregnancy detection. Women already on ART before 
pregnancy detection showed similar patterns of retention than ‘B+ pregnant’ women although 
probabilities of retention in care was higher in this group then in the ‘B+ pregnant’ group. It is 
possible that a proportion of these women may have been misclassified as not being ‘B+ 
pregnant’ due to delayed detection of pregnancy. This calls an earlier and more systematic 
screening of pregnancy and an improvement in reporting of test results in the HIS.  
The ‘B+ BFW’ women have a particular behaviour pattern. We can hypothesise that when 
breastfeeding women are initiated on ART, the benefit of ART on preventing vertical 
transmission to their HEI outweigh their desire to drop out of care. The timing of ART initiation 
for many of them corresponded to the first or second vaccination visit of their child. This calls 
for a better integration of HIV care and MCH services (with post-partum care or immunization 
for example) with early detection HIV infection for women who have already given birth. In 
addition, rapid treatment initiation to obtain rapid viral suppression is of paramount importance 
to reduce the risk of vertical transmission to less than 5%.   
As presented previously, the major drop-outs occur in the first 3 months of ART initiation for 
which the majority of our ‘B+ pregnant’ cohort corresponds to the last trimester of pregnancy. 
0
.2
5
.5
.7
5
1
0 1 2 3 4 5 6 7 8 9 10 11 12
Time on ART (months)
Women already on ART before pregnancy
Women on ART before diagnosis of pregnancy 
0
.2
5
.5
.7
5
1
0 1 2 3 4 5 6 7 8 9 10 11 12
Time on ART (months)
95% CI 95% CI 95% CI 95% CI
yart = 2013 yart = 2014 yart = 2015 yart = 2016
B+ breastfeeding women
0
.2
5
.5
.7
5
1
0 1 2 3 4 6 7 8 9 10 11 12
Time on ART (months)
95% CI 95% CI 95% CI 95% CI
2013 2014 2015 2016
B+ breastfeeding women
Probability of retention at 12m  
- ART initiation in 2013: 73% [95%CI: 43-98] 
- ART initiation in 2014: 87% [95%CI: 75-93] 
- ART initiation in 2015: 82% [95%CI: 67-90] 
- ART initiation in 2016: 73% [95%CI: 61–82] 
Probability of retention at 12m  
- ART initiation in 2013: 68% [95%CI: 63-72]  
- ART initiation in 2014: 72% [95%CI: 69-74] 
- ART initiation in 2015: 78% [95%CI: 76-80] 
- ART initiation in 2016: 84% [95%CI: 82–86] 
Page 96 of 188 
 
 96 
The delicate period around delivery can be challenging. Major physiological changes, excess 
fatigue when performing daily household chores can contribute to disengagement from care. 
Pre- and post-partum depression remains often undiagnosed but has been increasingly reported 
as a major factor contributing to disengagement from care[58]. In addition, women often move 
to their parents or in laws’ location to give birth and/or for nursing further increasing the risk 
of dropping out of care for both the mother and her new-born.  
As the ‘Test and Treat all’ strategy expands, an increasing number of women is expected to be 
on ART when they become pregnant, as we have observed in our analysis. The steady 
improvement of retention in care over time observed in our cohorts is certainly a positive 
outcome, however healthcare providers will face challenge for ensuring viral suppression in 
these women throughout both pre-natal and post-natal care. Accelerated efforts are thus needed 
to improve immediate (i.e. first three months) and long-term retention seeking innovative ways 
of delivering a patient tailored care to women and their children if we are to reach eMTCT in 
Mozambique. 
 
5.2 Interventions to improve PMTCT outcomes under option B+ strategy: a 
systematic review 
5.2.1 Introduction  
In the first work of the thesis, we evaluated the effectiveness of the PMTCT Option B+ 
programme in two high HIV burden provinces in Mozambique over the first four years of 
program implementation. The results showed achievement of high HIV testing and ART 
initiation rates in ANC with challenges remaining in improving immediate engagement in care 
and long-term retention in care.  
The lack of PMTCT engagement in care of women has been reported specifically under the 
Option B+ strategy. The barriers are predominantly women-specific such as younger maternal 
age [49,59], same day ART initiation [54,109–112] or missing CD4 cell count at ART 
initiation;  poor birth outcome (miscarriage or stillbirth) was also associated to increased risk 
of lost-to-follow [113] as well as lack of confidentiality [111], perceived or self-stigma [50–
52]; finally, lack of disclosure to partner or family has been frequently reported as a reason for 
dropping out of care [53,59,113]. Other health system and programme implementation 
challenges have also been identified such as lack of client friendly services or health workers 
insufficiently training on Option B+ or long waiting time at the clinic [51,53,54,112,113]. 
Therefore, interventions aimed at individual and health system constraints should help improve 
women’s engagement in PMTCT care. Such interventions are even more so needed, since 2016 
with the scale-up of the “test and treat” strategy,  to address the additional challenge of the 
significant increase in patient volume at health facility level. This increase has in turn further 
diminished the quality of services offered in the last few years and triggered the need to 
promote further decentralization of services to the community level [114–116].      
While previous PMTCT Options A and B provided anti-retroviral medication for a limited 
time, the added challenge in Option B+ is to maintain HIV-positive women under lifelong 
ART. Thus, under Option B+, specific interventions to improve women’s retention in care 
should cover not only short term but also have a long term post-partum effect to sustain 
engagement in care guaranteeing the expected benefits of viral load suppression, lower risk of 
HIV transmission to uninfected male partners and lower risk of MTCT of HIV in subsequent 
pregnancies. This systematic review focuses on specific interventions to improve PMTCT 
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outcomes under Option B+ with a special focus on women’s retention in care and infant testing 
uptake.  
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ARTICLE SUMMARY SECTION  
Abstract 
Objective: To systematically review interventions aiming to improve maternal retention and 
infant testing uptake in the prevention of mother-to-child transmission (PMTCT) programmes 
under the Option B+ strategy. 
Design: Systematic review 
Methods: Electronic databases and grey literature were searched to identify studies published 
from January 2010 to December 2018. Study outcomes were maternal retention in care at 6, 
12, and 24 months since antiretroviral therapy (ART) initiation and uptake of early infant 
diagnosis (EID) (age 4–8 weeks) and final infant testing (age 12–18 months). Outcomes were 
summarised according to intervention type. 
Results: Fifteen studies were included. Four studies reported on maternal retention through 
peer support, deployment of community health workers (CHWs), and point-of-care CD4 
testing, which yielded retention rates of 74–79%, 61–78%, and 70–74% at 6, 12, and 24 months 
since ART initiation, respectively. The rates were not significantly different from those 
reported in a standard-of-care context. Twelve studies reported on outcomes related to infant 
testing uptake through peer support, CHW outreach, SMS, healthcare provider-oriented 
strategies, or a combined package of interventions. The proportions of HIV-exposed infants 
tested were 49–94% and 68–95% for age 6–8 weeks and 12–18 months, respectively. A high 
infant testing uptake was observed under combined interventions (>94% at ages 2 and 18 
months). High heterogeneity in study outcomes was observed, mostly due to important 
variability in definitions. Both maternal and infant outcomes were likely to be overestimated 
because the outcomes were measured without considering consistency in maternal 
engagement. 
Conclusions: A combined package of interventions could effectively address different barriers 
to maternal engagement. Outcome definitions should be standardised to reduce inter-study 
heterogeneity and enable correct comparability of results for clear policy guidance. Indicators 
should be quality-based and process-oriented to allow precise understanding of maternal 
engagement to PMTCT care. 
 
Keywords: Systematic review; PMTCT; Option B+; retention; HIV-exposed infant; Early 
Infant Diagnosis; infant testing.  
 
Strengths and limitations of this study 
• This is a systematic review of interventions aimed at improving maternal engagement 
to care under the Option B+ strategy, with a particular focus on maternal ART 
retention and infant testing uptake. 
• Electronic databases such as MEDLINE, EMBASE, and Cochrane CENTRAL as 
well as grey literature were searched to identify relevant studies on outcomes of 
prevention of mother-to-child transmission under the Option B+ strategy. 
• The results of the review provide valuable data on maternal engagement in the 
PMTCT of HIV and can help in defining outcomes for clear policy guidance. 
• We identified studies in which insufficient information on the health system that 
delivered the interventions limited the generalisability of the results.  
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INTRODUCTION 
In 2013, the World Health Organization (WHO) revised its guidelines to recommend Option 
B+ as a strategy to prevent mother-to-child transmission (PMTCT) of HIV.[1] By providing 
all HIV-infected pregnant women with lifelong triple antiretroviral therapy (ART) irrespective 
of CD4 cell count, this new strategy aimed to ensure effective PMTCT and achieve viral 
suppression in mothers while simplifying service delivery. However, emerging evidence 
suggests higher drop-outs of women under Option B+ than in the general population of adults 
initiating ART for their own health.[2–4] Poor retention of mothers in PMTCT programmes 
and low uptake of infant HIV testing can be considered as an indicator of suboptimal 
performance of PMTCT programmes under Option B+, which represents a threat to the target 
of the Joint United Nations Programme on HIV/AIDS (UNAIDS) of reducing the number of 
newly infected children to <20,000 by 2020.[5] Various interventions have been tested to 
improve mother-infant engagement in care. In this study, we aimed to systematically review 
these interventions with a particular focus on their effectiveness on maternal retention in care 
at 6, 12, or 24 months since ART initiation as well as uptake of early infant diagnosis (EID) 
(4–8 weeks of age) and final infant testing (12–18 months of age). 
 
METHODS 
Electronic databases (MEDLINE, EMBASE, and Cochrane CENTRAL trials) were searched 
to identify relevant papers using combinations of the following terms: PMTCT, HIV, Option 
B+, retention, lost (or loss) to follow-up, and early or final infant HIV diagnosis 
(Supplementary Table 1). Bibliographies of relevant articles were reviewed to identify 
additional studies. In addition, grey literature including those available in Google Scholar and 
abstracts from international conferences were searched. We included papers published between 
January 2010 and December 2018 in English, French, or Portuguese. When studies had 
comparative data on interventional and standard-of-care settings, only data related to the 
intervention group were extracted. If multiple publications were found to be related to the same 
data source, the publication with the most complete data was selected. 
Study outcomes were maternal ART retention and infant testing uptake under Option B+. For 
maternal ART retention, we searched for papers that reported a proportion of HIV-positive 
women who remained in care at 6, 12, and 24 months after ART initiation. For infant testing 
uptake, outcomes were defined as the proportion of infants who received EID at 4–8 weeks 
and those tested at 12–18 months of age. Outcome definition and its methodologies were study-
specific. When necessary, we contacted authors to obtain additional information. 
We used a modified version of the Cochrane data extraction form to report the characteristics 
and outcomes of included studies.[6] A narrative synthesis of the results was generated 
according to the types of interventions.[7] We judged that the data were not suitable for meta-
analysis due to variability in study contexts and methodologies used. To assess the quality of 
evidence, we used the Evidence for Policy and Practice Information and Co-ordinating Centre 
(EPPI) approach.[8,9] The approach had four criteria: trustworthiness, appropriateness, 
relevance, and overall weight. Each criterion was assessed using the Jadad scale, with a score 
between 0 and 5.[10,11] A score of 0 or 1 was considered as ‘low’, 2 as ‘medium,’ and 3–5 as 
‘high’ quality.  
L.A. performed the literature searches and extracted the data. S.A. verified the selection process 
and checked the eligibility, inclusion, and exclusion criteria for 15% of a random sample of 
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included and excluded studies. Where discrepancies were found, a final decision was obtained 
by consensus. 
 
 
RESULTS 
Overview of the characteristics of included studies 
We identified 229 eligible records (Figure 1). After removing duplicates, we screened the titles 
and abstracts of 201 records and retained 88 for full-text review. Of these, 74 were excluded 
for not being relevant to Option B+ (n=43), for not reporting our study outcomes (n=15), for 
lack of information on the timing of the outcome measure (n=13), and for being without 
interventions (n=3). Finally, a total of 14 articles were included in our review, and these articles 
represented 6311 HIV-positive pregnant or breastfeeding women and 1920 HIV-exposed 
infants (HEIs) who have been exposed to at least one type of intervention to improve PMTCT 
outcomes. All studies were conducted in sub-Saharan Africa except for one which was 
undertaken in India (Supplementary Table 2).[12] There were seven cluster-randomised 
controlled trials,[12–18] six cohort studies,[19–23] one pre/post-quasi-experimental study,[24] 
and one cross-sectional evaluation.[25] Additional information on the included studies is 
available in Supplementary Table 3. 
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Figure 1 Flow chart of study selection and inclusion 
 
 
 
Overview of the interventions undertaken 
We identified various strategies that were used to improve maternal ART retention and infant 
testing outcomes within the context of Option B+ (Supplementary Table 2). There seemed to 
be two types of barriers that the strategies attempted to address. The first barrier included 
patient-level factors such as lack of awareness, HIV-related stigma and discrimination, and 
transport cost. The second barrier was related to the health system such as limited human 
resources and suboptimal quality of care. Community-level interventions through peer 
educators or community health workers (CHWs) seemed to be a frequent approach for 
addressing patient-level barriers.[13,14,19,24] These interventions supported women by 
improving treatment literacy, providing psychosocial support, and encouraging disclosure and 
adherence to treatment. In addition, to improve patient awareness and patient-healthcare 
provider communication, interventions called mHealth (mobile health) were largely deployed, 
which used telephone calls and/or SMS to remind mothers of their clinical 
appointments.[15,16,23] To strengthen the capacity of healthcare services, point-of-care (POC) 
CD4 testing was used to facilitate turnaround time for CD4 test results.[17] Moreover, 
148 records identified through database 
search
201 records screened
88 full-text articles assessed for eligibility
14 eligible studies included
81 additional records identified through other 
sources
113 records excluded 
- 27 not relevant to Option B+ 
- 38 relevant to Option B+ but not reporting our study 
outcomes 
- 7 with timing of outcome not defined or not adequate 
- 40 no intervention 
- 1 different study populations 
74 full-text articles excluded 
- 43 not relevant to Option B+ 
- 3 without intervention 
- 15 Option B+ but not studied outcomes 
- 13 timing of outcome not defined  
28 duplicates excluded 
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continuous quality improvement (CQI) was used to support utilisation of data to monitor 
progress and improve decision-making.[18] Similarly, mentorship programmes for PMTCT 
service providers offered guidance and support to improve the quality of services.[25] Certain 
studies used a combination of interventions. One such example was the postnatal clubs (PNCs), 
where several health services were integrated and made accessible simultaneously.[20] In 
another setting, SMS reminders were sent to mothers combined with economic incentives such 
as stipends for food and transport.[21] A church-driven educational programme provided 
opportunities for free laboratory screening.[22] Finally, a package of services known as 
COMBIND (COMmunity home Based INDia) included the deployment of community-based 
outreach workers (ORWs), enhanced patient-provider communication, and mHealth strategies 
to effectively address both patient- and health service-level factors simultaneously.[12] Figure 
2 illustrates the study outcomes of retention in care and infant testing by type of interventions. 
 
Figure 2 Outcome results by type of interventions for ART retention of HIV-positive women 
and infant testing for HIV-exposed infants (n=14 studies) 
  
 
 
 
 
 
 
 
 
 
Phiri (CBS)
Phiri (FBS) 
Phiri (CBS)
Phiri (FBS)
Phiri (CBS; alternative)
Phiri (FBS; alternative)
Atanga
Kim
Joseph (alternative 2)
Joseph (alternative 1) 
Joseph 
Joseph (laternative 2)
Joseph (alternative 1)
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 6 12 18 24
%
  A
RT
 re
te
nt
io
n
Time on ART (months)
ART retention
Page 104 of 188 
 
 104 
 
 
Outcome synthesis by type of interventions 
Patient-oriented strategies 
Peer support 
Three studies reported maternal ART retention outcomes through peer support programmes. 
In Cameroon, community peer educators were employed to track women who had missed 
appointments, leading to 69% of women being retained at 12 months since ART initiation.[19] 
In Malawi, a study assessed how facility-based and community-based peer support influenced 
maternal retention and infant testing outcome. In both models, ‘mentor mothers’ provided one-
on-one patient education and visit reminders and organised support groups at the health facility 
or in the community.[13] These mentor mothers were HIV-positive women who recently 
underwent PMTCT and were on ART. For maternal retention outcome at 12 months since ART 
initiation, the facility-based model yielded higher results than the community-based model: 
78% vs. 75%, respectively. At 24 months, however, the results were better with the 
community-based model than the facility-based model: 74% vs. 70%, respectively. For infant 
testing uptake at 6–8 weeks post-partum, both approaches led to similar outcomes: 68% 
(community-based) and 69% (facility-based). At 12–18 months post-partum, the facility-based 
model showed a much better outcome than the community-based model: 80% vs. 68%, 
respectively. In Zimbabwe, the mentor mother programme was used both at the health facility 
and in the community which led to 67% of HEIs being tested at 6–8 weeks of age.[14] 
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Community health workers 
One study reported results of interventions on CHWs. In Malawi, a CHW followed, on average, 
35–50 HIV-positive women to ensure that women adhere to the entire PMTCT process, starting 
from HIV testing to the final confirmation of the serostatus of the infant. This intervention led 
to a 6-month maternal retention of 79%.[24]  
 
mHealth 
Two studies reported infant testing outcomes under the mHealth strategy. In South Africa, 
mothers received telephone calls and weekly SMSs as a support to remain in care from pre-
delivery to 6–8 weeks post-partum.[23] This intervention led to a 76% increase in infant testing 
by 6–8 weeks of age. In the TextIT (Texting to Improve Testing) study in Kenya, women 
received a series of tailored messages for a specific time point during pregnancy or post-
partum, in a language of their choice.[16] This highly personalised approach has led to 
extremely high results, reaching 91% of HEIs being tested by 6–8 weeks of age. Similarly, an 
HIV infant tracking system (HITSystem) in Kenya tracked HEIs from enrolment to final HIV 
diagnosis, monitoring key interventions including EID and timely notifications of results by 
SMS to facilitate rapid ART initiation in case of positive testing.[15] This intervention yielded 
a high uptake, and 85% of HEIs were tested by 18 months of age.  
 
Healthcare-oriented strategies 
Four studies reported maternal and infant outcomes through strategies designed to improve the 
quality of healthcare. A study in Zimbabwe focused on the loss of patients between uptake of 
biological testing and delivery of test results and assessed the effects of POC CD4 testing on 
maternal retention in care at 6 and 12 months from ART initiation.[17] The retention was 74% 
and 61%, respectively. In Nigeria, a specific assessment was undertaken for CQI, which 
enabled an improved understanding of the drivers of low retention in care, leading to 49% of 
HEIs tested between 6 and 10 weeks of age.[18] In Malawi, PMTCT service providers 
participated in a national mentorship programme where a team of mentors provided hands-on 
training on data collection, testing procedures, documentation, and patient tracking.[25] This 
comprehensive training package has led to 70%, 73%, and 66% of HEIs being tested at 2, 12, 
and 24 months of age, respectively. 
 
Combined interventions 
Four studies reported the outcomes related to infant testing within the context of an intervention 
package. The PNCs in South Africa were formed by 2–10 mother-infant pairs who met monthly 
or quarterly until 18 months post-partum.[20] The women in the PNCs had access to integrated 
maternal, child, and HIV health services including mental health, nutrition advice, and early 
childhood development support.[26] The PNCs have yielded very positive results, and the 
proportion of HEIs tested reached 97% and 95% at 9 and 18 months of age, respectively. 
In Zambia, the intervention package consisted of enhanced counselling for ART adherence, 
SMS reminders on clinic appointment, and provision of stipends for food and transport 
equivalent to US$6 per visit.[21] Mothers were enrolled during pregnancy and followed until 
18 months post-partum. This package of interventions led to the high uptake of infant testing: 
95% and 87% by 6–8 weeks and 18 months of age, respectively. 
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In Nigeria, the Healthy Beginning Initiative (HBI) was used to improve infant testing. In this 
initiative, women received information on healthy habits delivered by lay health workers while 
participating in a baby shower at a local church.[22] In addition. these women were offered 
free laboratory screenings for HIV, hepatitis B, and sickle cell genotype. With this initiative, 
the uptake of infant testing reached 62% at 6–8 weeks and 71% at 18 months of age. Finally, 
the PMTCT programme in India used a combination of different interventions (COMBIND), 
including counselling by ORWs, provision of educational material for PMTCT as well as the 
use of an mHealth application for ART adherence, exclusive breastfeeding, postpartum care, 
and the need for EID.[12] The proportion of infants tested with EID at 6 weeks of age was 
81%, and those tested with infant HIV testing at 12 and 18 months of age was 73%. 
 
Assessment of quality of evidence 
Based on the EPPI criteria, we assessed the quality of evidence of the 15 studies included in 
this review. Six studies were considered as having a high quality overall,[12–15,17,18] six 
were medium,[16,19,21–23] and three were low[20,24,25] (Supplementary Table 4). The high-
quality studies provided sufficient information on key characteristics of the programme settings 
as well as methodologies, and the results seemed generalisable to other similar settings. 
Moreover, these studies used the recommended international definition of infant testing uptake. 
For the remaining studies, lower classifications were assigned due to insufficient information 
on study context, outcome definition, and study design. 
 
DISCUSSION 
We systematically reviewed interventions that aimed to improve maternal engagement to care 
in the context of Option B+, with a particular focus on postpartum retention and uptake of 
infant testing. Our results have shown that numerous attempts have been made in different 
settings yielding various outcomes. The Option B+ strategy presents an additional challenge 
since the women who are enrolled are required to remain in care under ART for life under the 
Option B+ strategy unlike in previous PMTCT options. 
We identified four studies that reported the effects of interventions on maternal retention. 
Through peer approach, deployment of CHWs, and enhanced access to POC CD4 testing, the 
reported retention rates ranged 74–79% at 6 months, 61–78% at 12 months, and 70–74% at 24 
months after ART initiation, respectively. The pooled estimates on retention under Option B+ 
in Africa, reported by Knettel et al.  within a context of standard of care were 72.9% (95% CI: 
66.4–78.9) at 6 months and 76.4% (95% CI: 69.0–83.1) at 12 months after ART initiation.[27] 
Thus, the rates found in our study were not significantly higher than those in a non-
interventional setting, suggesting that interventions might not automatically guarantee 
improved retention outcomes. Studies have shown that loss to care is caused by different factors 
including non-disclosure of patient’s HIV status,[14,17,28–32] stigma or fear of 
discrimination,[19,33,34] lack of involvement of partner and social support,[18,36,34] and lack 
of money for transport.[19,28,29] In addition, ART-related side effects[33] or perinatal 
depression[35,36] could explain why women drop out of care, especially in the post-partum 
period. Moreover, health system-related issues including long waiting hours,[30,37] long 
turnaround time for infant PCR (polymerase chain reaction) test result,[38] or inadequate 
opening hours of health services[28,29,37] can discourage women from remaining in care. 
Because of such complexity behind maternal disengagement, interventions need to be carefully 
designed and address a pathway to improvement. While our review did not find any studies 
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that investigated the effectiveness of the combined approach on maternal retention, it 
confirmed the potential benefits of such an approach on infant testing uptake. One study using 
a package of interventions had achieved extremely high infant testing outcomes, reaching 
>90% of HEIs being tested by 18 months of age.[20]  
Our review found that infant testing outcome reported by the 11 studies varied significantly: 
49–94% by 6–8 weeks of age and 68–95% by 12–18 months of age. Such variability might be 
attributed to the different nature of the intervention, small sample size,[23] or particular context 
in which the study was undertaken.[20,22,23] In addition, comparison of the study results was 
constrained by heterogeneity in outcome definitions (Supplementary Table 5). In most studies, 
retention in care was based on point retention defined as whether women came to the clinical 
appointment at a specific time point.[19] Other studies took into account the level of 
consistency in clinical attendance by considering the gap between two clinical appointments 
(e.g. for >60 days)[13] or the number of visits done on time.[17] We found that these 
differences in outcome definition directly influenced retention estimates. Phiri et al. reported 
that retention estimates fluctuated by 20% depending on the definitions used.[13] Moreover, 
Joseph et al. have highlighted considerable fluctuation in retention estimates depending on the 
threshold used in terms of timeliness of scheduled visits.[17] Currently, there is no consensus 
on the definition of retention in PMTCT programmes.[39–42] While retention can be simply 
defined as being present at a given appointment, such definition tends to overestimate retention 
rates by failing to take into account the process of care that is necessary to reach the ultimate 
goal of elimination of mother-to-child transmission of HIV. In addition, we note that only one 
study reported long-term maternal retention (i.e. 24 months after ART initiation). Option B+ 
has a particular challenge of retaining women on lifelong ART in a sustainable manner. As an 
increasing number of countries adapt this new strategy, the impact of different interventions 
on long-term retention merits further investigation. 
Similarly, infant testing outcomes were measured very differently. Some studies used a total 
number of HIV-positive women enrolled as a denominator,[12,14,15,23] while others used the 
number of live births[16,18,21,22] of HEIs alive at a specific time point.[13,20] Postnatal 
deaths were excluded from the denominator in certain studies, while they were accounted for 
in others. In our review, only three used the number of infants born to HIV-infected women as 
a denominator, in accordance with the official recommendation by the WHO.[43] From the 
programme point of view, however, the proportion of infant testing uptake might not represent 
the true value of engagement to care. Additionally, process indicators in the continuum of care, 
such as timely enrolment of HEIs, initiation of co-trimoxazole prophylaxis, and rapid 
turnaround time of test results should be taken into account to define engagement. In this 
context, the definition used by Finocchario-Kessler et al. seems to provide an alternative 
approach as it incorporates the notion of receiving complete EID services by 18 months. 
Unsurprisingly, engagement was reduced when such a complex definition was used, and the 
reported rate reduced from 85% to 60%, suggesting overestimation of engagement to care when 
a simple definition of HEIs tested by 18 months of age was used.[15] 
While we found potential benefits of the combined approach, it is worth noting that 9 out of 15 
studies were rated as having a medium to low quality of evidence. Such a low rating was mainly 
due to insufficient information on the health system in which the interventions were delivered. 
Effectiveness of an intervention depends largely on the local context where its feasibility and 
acceptability are determined.[19,44] Thus, it was not possible for us to fully understand the 
underlying mechanism that ensures effectiveness in certain interventions, limiting our ability 
to generalise the study results to other settings. 
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CONCLUSIONS 
Ensuring maternal engagement throughout the continuum of care is critical in achieving the 
goal of elimination of HIV/AIDS by 2030. Our review has suggested that a package of 
interventions could effectively address the different barriers to maternal engagement. Outcome 
definitions should be standardised to ensure correct comparability of results for clear policy 
guidance. Moreover, quality-based and process-oriented indicators should be used to allow a 
precise understanding of maternal engagement.  
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Legend for Figure 2 
 
Study legends: = peer and mentor support; = community health workers and lay workers; 
 = mHealth; = provider-oriented strategies; = combined interventions 
 
Notes: Joseph (alternative 1) corresponds to the study definition requiring 75% of visits to be on time; 
Joseph (alternative 2) corresponds to the study definition requiring 100% of visits to be on time. Phiri 
(CBS) corresponds to community-based support intervention arm; Phiri (FBS) corresponds to the 
facility-based support intervention arm. Phiri (CBS; alternative) corresponds to the community-based 
support intervention arm using the trial definition of retention (i.e. alive and on ART without any gap 
in care >60 days after a scheduled visit among those who started ART); Phiri (FBS; alternative) 
corresponds to the facility-based support intervention arm using the trial definition. Finocchario-
Kessler (intention to treat) corresponds to percentage of HEIs who received complete EID services 
until 18 months post-partum defined by the receipt of all indicated age-specific interventions until 18 
months post-partum (for HIV-negative infants) or ART initiation (for HIV-positive infants); 
Finocchario-Kessler (per protocol) corresponds to the percentage of HEIs tested by 18 months of age. 
All other definitions presented in the graphs are those of the Ministry of Health national guidelines. 
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SUPPLEMENTARY MATERIAL 
Supplementary Table 1 Literature search strategy 
 
Search 
set 
Medline/PubMed  Other databases 
1 (Infectious AND disease AND transmission 
AND vertical) OR (vertical infectious disease 
transmission) OR (vertical AND transmission) 
OR (vertical transmission) 
 (HIV-positive pregnant) OR (HIV-positive 
breastfeeding women) 
2 INFECTIOUS DISEASE TRANSMISSION, 
VERTICAL 
 vertical infectious disease transmission 
3 Sets 1-2 combined with ‘OR’  Sets 1-2 combined with ‘OR’ 
4 HIV OR human immunodeficiency virus   Prevention of Mother-To-Child Transmission or 
PMTCT 
5 HIV  (mother-to-child-transmission) OR (MCH) 
6 HIV INFECTIONS  Sets 3-5 combined with ‘OR’ 
7 INFECTIONS/THERAPY  HIV-exposed infant 
8 Sets 4-7 combined with ‘OR’  (early infant diagnosis) OR (EID) 
9 (Infant test) OR (infant testing) OR (early infant 
diagnosis) OR (HIV-exposed infant) 
 final infant HIV diagnosis 
10 INFANT  Sets 7-9 combined with ‘OR’ 
11 DIAGNOSTIC TECHNIQUES AND 
PROCEDURES 
 (option B+) OR (option B-plus) OR (option B plus) 
12 Sets 9-11 combined with ‘OR’  Retention 
13 RETENTION IN CARE OR (retention)  intervention 
14 (intervention) OR CLINICAL STUDY  Sets 3, 6, 11, 12 and 13 combined with ‘AND’ 
15 (option B+) OR (option B-plus) OR (option B 
plus) 
 Sets 6, 10, 11, 12 and 13 combined with ‘AND’ 
16 Sets 3, 8, 13, 14 and 15 combined with ‘AND’   
17 Sets 3, 8, 12, 14 and 15 combined with ‘AND’   
In addition, other electronic databases were searched: Embase, ScienceDirect, Web of Science, and 
Cochrane databases. 
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Supplementary Table 2 Summary of study characteristics of included studies (n=14 studies) 
 
No. Name of the article Country (location and sites) Study design Year of Option B+ 
initiation 
Study enrolment 
Sample size Interventions to increase retention or reduce FU 
Peer and mentor support 
1 Atanga 2017[49] Cameroon; 5 sites (Kumba Health 
District, South West region) 
A prospective cohort study 2012 
2013 (Oct)-2014 
(Dec) 
268 HIV-positive pregnant and 
breastfeeding women 
Team of peer educators (PE) trained to implement community follow-up of 
clients and especially tracking cases of women missing their clinic 
appointments and getting them back to care (telephone calls or home visits) 
2 Phiri 2017[117]a Malawi (3 of the 5 health zones: 
Central West, South East, and 
South West) 
A 3-arm stratified cluster-
randomised controlled trial 
2011 
2013 (Nov)-2014 
(Nov) 
1269 HIV-positive women 
(pregnant=1094, 
breastfeeding=175)  
Intervention comparing facility-based and community-based models of peer 
support with SOC: 
- SOC: participants received routine HIV care according to Malawi MOH 
guidelines 
- Facility-based peer support: women received SOC and met with ‘mentor 
mothers’ (i.e. women living with HIV who recently underwent PMTCT and were 
on ART) who provided one-on-one support at each clinic visit, led weekly 
clinic-based support groups, and contacted women within 1 week of a missed 
appointment – model adapted from the mothers2mothers model of clinical 
service delivery 
- Community-based peer support: women received SOC and met with ‘expert 
mothers’ (i.e. women living with HIV who recently underwent PMTCT and were 
on ART) who conducted routine home visits to study participants 
to provide HIV education and clinic visit reminders; led monthly community-
based support group meetings; were responsible for contacting women in 
the community within 1 week of a missed scheduled clinic visit.  
3 Foster 2017[118]b Zimbabwe – Eastern region 
(Mutare and Makoni Districts of 
Manicaland Province); 27 clinics 
A cluster-randomised controlled 
trial 
2013 
2014 (July)-2015 
(Oct) 
348 HIV-positive PW (188 
intervention arm, 160 SOC arm) 
The mother support groups (MSGs) was established in 14 clinics randomly 
selected. The HIV-positive mothers conducted the MSGs and mentor other HIV-
positive mothers at health facilities or in communities; meetings were planned 
to function twice / month; attendance was from enrolment to 6 months 
postpartum; MSG meeting reminders were sent to members, including an 
additional reminder to mothers who missed a meeting.  
Community health workers and lay workers 
4 Kim 2015[119]c Malawi (Area 25 and Kawale, 2 
large urban health centres, 
Lilongwe) 
A pre/post quasi-experimental 
study 
2011 
2011 (Oct)-2013 
(Mar) 
For the 6-month ART outcomes: 
984 HIV-positive PW newly 
initiated on ART after PMTCT 
enrolment (225 pre-Option B+ and 
759 post-Option B+)  
Community health workers (CHWs):  
1 CHW assigned to each HIV-positive pregnant woman at PMTCT enrolment. 
Each CHW follows an average of 35-50 patients: longitudinal care support 
throughout the full PMTCT cascade. Other CHW responsibilities include facility-
based health talks, nutritional assessments at clinic visits, and HIV testing and 
counselling. Standard VHW is no VHW accompaniment.  
mHealth 
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No. Name of the article Country (location and sites) Study design Year of Option B+ 
initiation 
Study enrolment 
Sample size Interventions to increase retention or reduce FU 
5 Schwartz 2015[120] South Africa; 1 site (Witkoppen 
Health and Welfare Centre, 
Johannesburg) 
A prospective pilot intervention  2012d 
2013 (May-Jun) 
50 HIV-positive PW pre-
intervention and 50 HIV-positive 
PW post-intervention 
Text messages and calls from a case manager (CM) who provided support and 
motivation for participants to remain in care (senior HIV lay counsellors with 
previous PMTCT counselling experience) 
Weekly pre-scripted text messages to the participants’ cell phones, which 
continued until 6 weeks postpartum (or up to 8 weeks if the participant did not 
return for the 6-week clinic visit), plus 1 pre-delivery and 2 post-delivery 
telephone calls made by the CMe 
6 Finocchario-Kessler 
2018[121] 
Kenya (6 public hospitals: 2 pre-
urban and 4 urban) 
A cluster-randomised trial 2012f 
2014 (Feb)-2015 
(Dec) 
690 MIPs (392 for HITSystem, 298 
for SOC) 
HIV Infant Tracking System (HITSystem): a web-based intervention linking 
providers of early infant diagnosis, laboratory technicians, and mothers and 
infants to improve outcomes for HEIs; infants are tracked regularly throughout 
the EID cascade of services from enrolment until final HIV status if established 
(up until 18 months post-partum).  
 
7 Odeny 2018[122] Kenya, Nyanza region, western 
region, 5 health facilities (mix of 
rural and urban settings) 
A parallel-cohort randomized 
controlled trial  
2012f 
2012 (April – Oct)  
187 HEIs in the intervention 
group, 181 HEI in the control 
group; 510 HEI in the ineligible for 
RCT group 
TextIT (Texting to Improve Testing): text intervention (a 2-way theory-based 
text messaging system); 14 text messages tailored for specific points during 
pregnancy and the postpartum period 
Provider-oriented strategies 
8 Joseph 2017[113] Zimbabwe (3 provinces, 32 sites) A 2-arm cluster-randomised 
controlled trial 
2013 
2014 (Jan)-2015 
(Jun) 
1150 HIV-positive PW (n=547 in 
SOC, n=603 in POC Plus) 
POC CD4 testing of HIV-positive PW before ART initiation + CD4 count-specific 
counselling, retraining on the use of POC CD4 and quality assurance of the POC 
CD4 instruments themselves 
Sites randomised to the ‘POC Plus’ arm were provided with POC CD4 devices. 
Healthcare workers were trained on their use and participated in a quality 
assurance programme throughout the trial period. In addition, they were 
trained to provide specific counselling using a predefined script that 
emphasised how ART will maintain high CD4 counts and how low CD4 counts 
need ART to improve immune system response 
9 Oyeledun 2017[123]g Nigeria, northern part (Benue and 
Kaduna states); 32 facilities (20 
primary and 12 secondary health 
level) 
A cluster-randomised controlled 
trial 
2016 
2014 (Jul) -2016 
(Oct) 
403 HEIs (194 HEIs in control 
group, 209 HEIs in the 
intervention group) 
Continuous quality improvement (CQI): a health system’s intervention 
methodology that uses serial reviews of local facility data to understand the 
primary and secondary drivers for low retention in care among HIV-positive 
mothers. The breakthrough series (BTS) is a specific short-term CQI approach 
(6-15 months) that brings together teams from several health facilities 
(‘collaboratives’) to jointly review progress and share solutions in a focused 
topic area 
10 Stillson 2018[124] Malawi (expansion from 5 
districts in the southern region to 
national scale – 400 HFs) 
A national mentorship programme 
evaluation 
2011 
2016 (April)-2018 
None specified A national mentorship programme for PMTCT service providers: reviewing and 
strengthening patient flow, testing procedures, and documentation practices; 
use of a mentorship checklist and facility-specific data sheets to identify areas 
for improvement; deployment of mentors to HFs (teams of 3) 
The programme first focused on health facilities with a high volume of patient 
flow, then gradually scaled up to other sites. This resulted in nearly every site in 
the country receiving at least one mentorship visit, with most receiving at least 
3 visits 
Combined interventions 
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No. Name of the article Country (location and sites) Study design Year of Option B+ 
initiation 
Study enrolment 
Sample size Interventions to increase retention or reduce FU 
11 Nelson 2018[125] South Africa (Khayelitsha, Town 2 
clinic) 
A retrospective cohort analysis 2015 
2016 (Jul)- 2018 
(Jun) 
335 mothers (18 high-risk) and 
340 infants 
Differentiated model of care using postnatal clubs (PNCs) formed according to 
the infants’ dates of birth into clubs of 2-15 MIPs and held at regular intervals 
until 18 months of age 
PNCs were adapted from the adult ART adherence club model to provide 
double integration of care (maternal health, child health, and HIV services) and 
components of the first 1000 days (mental health, nutrition advice, and early 
childhood development activities) for HIV-positive mothers (stable and high 
risk) and their HIV-exposed uninfected infants 
12 Ngoma 2015[126] Zambia (Chelstone Public Clinic, 
Lusaka) 
A prospective observational cohort 
study 
NS 
2008 (Dec)-2009 
(Dec) 
HEIs: 231 live births Women received adherence counselling, text message reminders for clinic 
visits and stipends for food and transport (30,000 kwacha, equivalent to US$6 
per visit). 
13 Pharr 2016[127] Nigeria; 40 churches, Enugu State A nested cohort study of HEIs 
within the HBI trial (A 2-arm 
cluster randomized trial) 
2016h 
2013 (Jan-Sept) 
69 HEI (live births) Healthy Beginning Initiative (HBI): congregation-based baby shower 
intervention delivered by lay health advisors at local churches (intervention) 
vs. a clinic-based approach (control) on HIV testing 
Intervention arm: provision of an educational programme that included healthy 
habits and information about important laboratory screenings during 
pregnancy. Additionally, participants were offered free integrated laboratory 
screenings during the baby shower, including tests for HIV, hepatitis B, and 
sickle cell genotype 
14 Suryavanshi 2018[128] India, four districts of 
Maharashtra (Pune, Thane, 
Sangli, Satara) 
A cluster-randomised controlled 
trial 
2014 
2015 (Apr)-2017 
(Mar) 
1191 women: 640 women 
assigned to 60 ORWs (COMBIND 
arm), 551 women to 56 ORWs 
(SOC arm) 
COMmunity home Based INDia (COMBIND) PMTCT intervention using 4 
combined interventions: 
1) Specialised ORW interactive motivational counselling training 
2) Use of an mHealth open-source platform called eMOCHA to facilitate 
communication with ORWs and women using educational videos and smart 
form-based counselling scripts 
3) Strategic feedback to ORWs 
4) Targeted feedback to HIV-positive women 
 
aThe PMTCT Uptake and Retention (PURE) study. 
bInformation on PMTCT programme protocol and ART regimen was extracted from the MOH national guidelines (Ministry of Health and Child Care, Zimbabwe. 
Operational and Service Delivery Manual for the Prevention, Care, and Treatment of HIV in Zimbabwe. Harare, Zimbabwe: Ministry of Health and Child Care 2014. 
www.differentiatedcare.org (accessed 25 Mar 2017). 
cThe Tingathe programme. 
dOption B+ was not yet the standard of care in South Africa at the time of this study. 
eAdditional telephone calls were made to the participant if requested by free-of-charge ‘Please call me’ text messages. 
fIn settings with the capacity to initiate and monitor triple therapy in HIV infected pregnant women.  
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gThe Lafiyan Jikin Mata or ‘Excellent Health for Mothers’ study. Information on PMTCT programme protocol and ART regimen was extracted from Oyeledun B, Oronsaye 
F, Oyelade T, et al. Increasing retention in care of HIV-positive women in PMTCT services through continuous quality improvement-breakthrough (CQI-BTS) series in 
primary and secondary health care facilities in Nigeria: a cluster randomized controlled trial. The Lafiyan Jikin Mata Study. J Acquir Immune Defic Syndr 2014;67(Suppl 
2):S125–31. 
hOption B+ was implemented at study sites in 2013, but national policy approved in 2016. 
ART: antiretroviral therapy; HEIs: HIV-exposed infants; HFs: health facilities; mHealth: mobile health; MIPs: mother-infant pairs; MOH: Ministry of Health; ORWs: 
community-based outreach workers; PMTCT: prevention of mother-to-child transmission; POC: point of care; PW: pregnant women; SOC: standard of care  
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Supplementary Table 3 Description of key programme characteristics of included studies 
  
Name of the article Aim or objectives (primary and secondary) Study settings Inclusion criteria for study participants Exclusion criteria for study 
participants 
Peer and mentor support 
Atanga 2017[49] To assess linkage and retention in care along the Option B+ 
PMTCT cascade 
MCH services on-site with >90% ANC population coverage; study sites 
were pilot sites for Option B+ using task-shifting (midwives and nurses 
prescribed ART). Peer educator providing community follow-up and 
tracking LTFU 
HIV-positive PW and BFW: including treatment-naïve 
women and women who had initially started Option A 
and consented to be switched to Option B+. 
Age was not an exclusion criterion, but adolescents 
needed parental consent 
Women coming from other districts 
Phiri 2017[117] To evaluate whether facility- and community-based peer 
support by women with similar experience would improve 
uptake and retention of mothers and infants in Option B+ 
programme compared with the national SOC at 2 years post-
initiation of treatment 
Sites were eligible if they provided Option B+ services, did not have other 
PMTCT interventions or research activities beyond the Malawi national 
standard of care and were expected to have at least 20 women eligible 
for Option B+ in a 6-month period (27 sites selected, 7 sites/zone, 3 
zones) 
Baseline assessment of selected sites reported that defaulter tracing was 
rarely if ever, occurring in any of the facilities. Most facilities had few or 
no health surveillance assistants (HSAs) and lay health providers who 
were trained in PMTCT 
Authors reported that in intervention sites, in both facility- and 
community-based models, support groups were poorly attended 
 
Women: 15 years or older, known previously or newly 
tested HIV-positive and ART-naïve 
HEIs: all infants born to women in the study were 
enrolled at birth or at maternal enrolment if 
breastfeeding 
None specified 
Foster 2017[118] To evaluate whether MSGs newly established in clinics 
improved HIV-exposed infants’ (HEIs) and their HIV positive 
mothers’ retention rates in postnatal follow-up and other 
programme outcomes. 
Selected clinics located within rural communal and commercial farming 
areas. Study sites were considered as early learning sites for Option B+.  
PMTCT retention in the ANC period was 100% at sampled sites; but at 
delivery, 43% of HIV-positive mothers were not recorded as having 
delivered at the clinic; only 53% of HEI underwent an early DNA PCR test 
for HIV; the number of HEI visiting clinics for postnatal review declined 
progressively with duration of follow-up 
HIV-positive, 18 years or older, lived in the clinic 
catchment area, and were under 35 weeks of 
gestation 
None specified 
Community health workers and lay workers 
Kim 2015[119] To compare service uptake and antenatal outcomes 
throughout the PMTCT cascade from the identification of 
HIV-infected PW at ANC to infant delivery pre- and post-
Option B+ implementation 
Two large urban centres in the capital city where the Tingathe 
programme operated. High ANC coverage (96% for at least 1 ANC visit); 
high volume of deliveries (15,000 deliveries/year) 
The Tingathe programme started 2 years before the national Option B+ 
implementation: HIV service programme that uses dedicated CHWs as 
CMs to support women to navigate the multiple steps in the PMTCT 
cascade 
Only HIV-positive PW enrolled in the Tingathe ANC 
programme 
Those known to have been 
transferred out or receiving ART 
outside health facilities (18 pre- and 
51 post-patients) for the 6-month 
outcomes among the women newly 
initiating ART 
mHealth 
Schwartz 2015[120] To assess the acceptability, feasibility, and potential for scale-
up of a mobile phone-based case management intervention 
piloted at a primary health centre implementing Option B+ in 
South Africa 
WHWC, a high-volume non-governmental primary health clinic in the 
capital city which serves an urban township and surrounding areas. 
WHWC sees 680 PW a month, 33% of which are HIV-infected. Option B+ 
was piloted at the site approximately a year before a national roll-out 
All HIV-positive PW ³ 36 weeks’ gestation owning a 
cell phone, being able to read text messages in English 
and willing to receive text messages and calls from a 
CM. Moreover, both women already on ART at the 
time of pregnancy and women not yet ART-initiated at 
time of pregnancy were eligible for this study 
None specified 
Page 120 of 188 
 
 120 
Name of the article Aim or objectives (primary and secondary) Study settings Inclusion criteria for study participants Exclusion criteria for study 
participants 
Finocchario-Kessler 
2018[121] 
To evaluate the efficacy of the HITSystem on key outcomes of 
EID 
 
Government-funded sites; provision of a comprehensive package of 
PMTCT services including EID and ART services; at least one dedicated 
EID provider; and maintained medical files for HEIs 
Rate of mobile phone use in Kenya was estimated at 90% (2016) 
HIV-positive mothers aged 18 years or older, with an 
HEI presenting for their first EID appointment through 
the MCH department, and who presented for EID care 
when their infant was younger than 24 weeks 
Mothers enrolled in EID services who 
did not meet the eligibility criteria 
Odeny 2018[122] To determine whether interactive text messages improved 
rates of clinical attendance and early infant testing 
A mix of rural and urban settings. Health facilities supported by Family 
AIDS Care and Education Services (FACES). These health facilities offer 
PMTCT services including testing for infant HIV infection, using a specific 
family model of HIV care and treatment[129] 
Women 18 years of age or older, pregnant at ³28 
weeks’ gestation (or had delivered on the day of 
enrolment), enrolled in the PMTCT programme, 
planning to remain in the study area, had access to a 
mobile phone and reported ability to read or have 
someone who read text messages on their behalf 
Women who reported sharing phones 
were ineligible unless they had 
disclosed their HIV status to the 
person sharing the phone 
Provider-oriented strategies 
Joseph 2017[113] To evaluate the impact of POC CD4 testing with CD4 count-
specific adherence counselling (POC Plus) vs. SOC on 
retention in care among HIV-positive PW initiating ART 
Sites were excluded if[130]: 
• No women had been initiated on ART in 2012 
• ART initiation rates were ³80% 
• Fewer than 24 women tested HIV-positive in ANC in 2012 
• Previous or existing POC CD4 capacity 
• Routine data were internally inconsistent (poor quality) 
• Challenging geographical access 
HIV-positive, ART-naïve PW attending their ANC 
booking 
Already having initiated ART or for 
false pregnancies 
Oyeledun 2017[123] To examine whether a BTS-CQI intervention can improve 
retention in care, defined as attendance at 6 months 
postpartum while not missing previously scheduled visits, 
among mothers living with HIV who have started lifelong ART 
Eligible facilities: existing PMTCT services for >6 months, regularly 
identified >1 pregnant woman per month, provided onsite delivery and 
postpartum care, and had at least 2 trained community health extension 
workers 
HIV-positive women whose gestational age was 34 
weeks or less, who were ART-naïve and who agreed to 
start lifelong ART 
None specified 
Stillson 2018[124] To increase testing uptake across routine milestones for HIV-
exposed children through national mentorship 
The mentorship consisted of a half-day in-service guided mentorship for 
PMTCT service providers 
The goal of the mentorship: to identify and address specific facility-level 
barriers to testing uptake and service provision, while strengthening 
documentation practices 
Sites were initially identified based on testing volume during the first 4 
rounds of mentorship, after which sites with lower volumes and 
performance were prioritised over higher-performing sites. This resulted 
in nearly every site in Malawi receiving at least one mentorship visit, 
with most receiving at least 3 visits 
Programme evaluation; no inclusion criteria No exclusion criteria 
Combined interventions 
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Name of the article Aim or objectives (primary and secondary) Study settings Inclusion criteria for study participants Exclusion criteria for study 
participants 
Nelson 2018[125] To analyse and describe maternal and child data collected 
during PNC intervention 
 
The aims of the PNCs are the improvement of retention in 
care and the following health outcomes for the MIPs: HIV VL 
suppression, vaccination coverage, and infant HIV testing 
uptake 
Postnatal PMTCT estimated at 4.3% at 18 months 
The study site was a peri-urban informal settlement, the ANC HIV 
prevalence estimated to be 33% (2015) 
Access to postnatal services, uptake of infant HIV testing and maternal 
retention in care postpartum were poor 
Integrated MCH services included one-stop shops, clinical visit at every 
session, pre-packed medicine, experienced nurse (ART, MCH) 
Integration of HIV and non-HIV care included VL, FP, and Pap smear for 
mothers, and HIV testing, growth monitoring, feeding support, and 
immunisations and IMCI for children 
A PNC included 2-15 MIPs 
HIV-positive mothers and HEIs:  
- Women stable on ART 
- ‘High-risk’ women with high VL or other 
characteristics based on the South Africa risk of 
treatment failure programme [131] 
- HEIs already tested as HIV-positive 
- Mothers with active tuberculosis 
- Mothers who refused to have their 
ART care in the same clinic as the 
baby 
Ngoma 2015[126] To assess the efficacy and safety of continued breastfeeding 
while the mother receives combined ART 
The study site was an urban public clinic in the capital city 
Services provided: reproductive health services which include PMTCT, 
FP, voluntary male circumcision and voluntary counselling. User fees 
were removed in 2013[132] 
Age 15 years and older, HIV-positive, confirmed 
pregnancy with the ability to initiate cART at 14-30 
weeks’ gestation, intention to do EBF for 6 months, 
ability to give informed consent and ability to attend 
follow-up visits 
Previous cART, known major illness 
likely to influence pregnancy outcome 
or leading to increased risk for 
adverse events from cART or 
continuing therapy with medications, 
which are contraindicated for co-
administration with 
ritonavir/lopinavir 
Pharr 2016[127] To report the impact of the HBI on rates of antiretroviral 
prophylaxis, EID, HIV status and linkage to care among 
infants born to HIV-infected mothers 
40 churches were defined as study sites with church attendance 
approaching 90% and an extensive network of faith-based institutions 
Each church had a health team (HT) comprising the priest, women’s and 
men’s group leaders, and 2 volunteer health advisors, 1 of whom is 
trained to perform venepuncture. Prevention, education, Treatment, 
Training and Research-Global Solutions (PeTR-GS) conducted training 
workshops for all study staff and church-based volunteer health advisors 
PW attending study churches None specified 
Suryavanshi 2018[128] To assess the impact of a novel mHealth and community 
health worker empowerment intervention on the uptake of 
the 4 key components of PMTCT: 
1. ART at delivery 
2. EBF for 6 months 
3. NVP prophylaxis for infants up to 6-12 weeks 
4. EID at 6 weeks and at 6, 12 and 18 months 
Maharashtra is the second largest state in India (population of >123 
million) and has one of the highest HIV prevalence in the country 
Community ORWs were trained to help navigate barriers to uptake of 
the PMTCT programme. ORWs were peer women and were identified in 
the community through local advertisement. They were former PMTCT 
clients. These ORWs were supervised by the PMTCT coordinators of that 
district level 
ICTCs identified HIV-positive women, who were then linked to ORWs. 
Each ICTC may have >1 ORW working in the project catchment area, 
depending on the HIV burden. Every public ANC clinic had an attached 
ICTC 
ORWs accompanied HIV-positive PW to the ART centre for registration, 
supported the women with monthly home visits during pregnancy and 
attended during labour and immediately afterwards, as well as up to 18 
months post-delivery[133] 
Mothers above 18 years of age and who provided 
consent for participation 
None specified 
 
ACT: Accelerating Children on Treatment initiative; ANC: antenatal care; ART: antiretroviral therapy; BFW: breastfeeding women; BTS-CQI: breakthrough series-
continuous quality improvement; cART: combination antiretroviral therapy; CHWs: community health workers; CM: case manager; EBF: exclusive breastfeeding; 
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EID: early infant diagnosis; FP: family planning; HBI: Healthy Beginning Initiative; HEIs: HIV-exposed infants; HFs: health facilities; HITSystem: HIV Infant 
Tracking System; ICTC: integrated counselling and testing centre; IMCI: integrated management of childhood illnesses; LTFU: lost to follow-up; MCH: mother and 
child health; MIPs: mother-infant pairs; MSF: Médecins Sans Frontières; MSGs: mothers support groups; NVP: nevirapine; ORWs: community-based outreach 
workers; PMTCT: prevention of mother-to-child transmission; PNC: postnatal clubs; POC: point of care; PW: pregnant women; SOC: standard of care; VHWs: 
village health workers; VL: viral load; WHWC: Witkoppen Health and Welfare Centre.  
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Supplementary Table 4 Weighting of studies by quality, according to the 4 EPPI criteria [134] 
 
Name of the article A 
Trustworthiness 
B 
Appropriateness 
C 
Relevance 
D 
Overall weight 
Peer and mentor support 
Atanga 2017 Low Medium High Medium 
Phiri 2017 High High High High 
Foster 2017 High High High High 
Community health workers and lay workers 
Kim 2015 Low Low High Low 
mHealth 
Schwartz 2015 Low Low High Medium 
Finocchario-Kessler 2018 High High High High 
Odeny 2018 High Medium High Medium 
Provider-oriented strategies 
Joseph 2017 High High High High 
Oyeledun 2017 High High High High 
Stillson 2018 Low Low High Low 
Combined interventions 
Nelson 2018 Low Low High Low 
Ngoma 2015 Low Medium High Medium 
Pharr 2016 Medium Medium Medium Medium 
Suryavanshi 2018 High High High High 
 
A = The trustworthiness of the results judged by the quality of the study within the accepted norms for undertaking the particular type of 
research design used in the study (methodological quality). B = The appropriateness of the use of that study design for addressing the systematic 
review’s research question (methodological relevance). C = The appropriateness of focus of the research for answering the review question 
(topic relevance). D = Judgement of the overall weight of evidence (WoE) based on the assessments made for each of the criteria A-C. Each 
of the 4 criteria was scored using the Jadad scale[135,136]: a score of 0 or 1 was considered as ‘low’ quality, a score of 2 was described as 
‘medium’, and scores of 3-5 were considered ‘high’ quality. 
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Supplementary Table 5 Definition of outcomes of interest (n=14 studies) 
 
Name of the article Definition of outcome 
Peer and mentor support 
Atanga 2017[49] Retention in care: % women who had started on lifelong Option B+ ART and attended clinic visits at 12 months or who were transferred out but known to continue ART following 
tracing information 
Phiri 2017[117]a 1) ART retention in care at 1 and 2 years from ART initiation:  
MOH definition: being alive and in care at 1 or 2 years regardless of earlier outcomes 
Trial definition: alive and on ART without any gap in care >60 days after a scheduled visit among those who started ART 
2) % of HEIs tested at 6 weeks, 12 and 24 months: 
Numerator: number of HEIs alive and tested at 6 weeks, 12 and 24 months 
Denominator: number of HEIs alive at 6 weeks, 12 and 24 months (deaths excluded from denominators) 
Foster 2017[118]b EID performed at 6 weeks (±2 weeks): 
Numerator: number of HEIs tested at 6 weeks 
Denominator: number of women enrolled 
Community health workers and lay workers 
Kim 2015[119]c % alive on ART at 6 months after ART initiation: definition not specified. Note: women defined as lost to follow-up were those who did not return to care for >60 days and could 
not be traced 
mHealth 
Schwartz 2015[120] % of HEIs receiving PCR at 6 weeks (pre- and post-intervention period): 
Numerator: number of HEIs tested 
Denominator: total number of HIV-positive PW women enrolled 
Finocchario-Kessler 2018[121] % of HEIs with complete EID retention until 18 months postpartum: 
Numerator: number of HEIs who received complete EID services 
Denominator: number of MIPs enrolled (deaths and documented transfers were excluded from the denominator) 
Complete EID retention: receipt of all indicated age-specific interventionsd until 18 months postpartum (for HIV-negative infants) or ART initiation (for HIV-positive infants) 
Odeny 2018[122] % of HEIs tested (median time from birth to HIV virologic testing was 7 weeks): 
Numerator: number of HEIs tested 
Denominator: number of HEI live birthse (deaths, stillbirths, and documented transfers were excluded from the denominator) 
Provider-oriented strategies  
Joseph 2017[113] POC CD4 testing.  
Study definition (75% on-time): 
1) % of HIV-positive PW retained on ART after 6 months (see the definition for 12 months) 
2) % of HIV-positive PW retained on ART after 12 months: having had an ART refill visit a minimum of 335 days post-ART initiation and on-time attendancef for at least 75% of 
scheduled ART refill visits, up to and including the 12-month visit 
Study definition (100% on-time): strictest definition, requiring all visits to be on time 
MOH definition: only 1 visit after 6 or 12 months post-ART initiation 
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Name of the article Definition of outcome 
Oyeledun 2017[123]g Quality improvement. % of HEIs born to enrolled mothers and tested by DBS/PCR between 6 and 10 weeks of age 
Denominator: live births with the exclusion of miscarriages, unknown delivery status, stillbirth, and neonatal death 
Stillson 2018[124] HF staff mentorship. % of HEIs tested at 2, 12 and 24 months 
Numerator: number of known HEIs with a test result recorded 
Denominator: total number of HEIs enrolled in the PMTCT programme from a given birth cohort (deaths and loss to follow-up are included in the denominator) 
Combined interventions 
Nelson 2018[125] Uptake of infant RHT at 9 and 18 months: 
Numerator: number of infants who underwent RHT at 9 and 18 months 
Denominator: number of HEIs attending visits at 9 and 18 months 
Ngoma 2015[126] % of HEIs who underwent PCR by 6-8 weeks, 12 months and 18 months: 
Numerator: number of infants tested 
Denominator: number of live births 
Pharr 2016[127] % of HEIs tested with EID at 6-8 weeks of age and with RHT after 18 months: 
Numerator: number of infants tested 
Denominator: number of live births 
Suryavanshi 2018[128] % of infants tested: EID at 6 weeks, infant HIV testing at 12 months and infant HIV testing at 18 months 
Numerator: number of live-born infants tested for HIV at 4-time points 
Denominator: number of HIV-positive women enrolled 
 
aThe PMTCT Uptake and Retention (PURE) study. 
bInformation on PMTCT programme protocol and ART regimen was extracted from the MOH national guidelines (Ministry of Health and Child Care, 
Zimbabwe. Operational and Service Delivery Manual for the Prevention, Care, and Treatment of HIV in Zimbabwe. Harare, Zimbabwe: Ministry of Health 
and Child Care 2014. www.differentiatedcare.org (accessed 25 Mar 2017). 
cThe Tingathe programme. 
dEligible services comprised initiation of co-trimoxazole for opportunistic infection prophylaxis, PCR testing and return of results to the hospital, notifying 
the mother of the PCR results, and initiation of ART (HIV-positive infants only). And retesting at 9 and 18 months (HIV-negative infants only) 
eCalculated using available data. 
fA visit was considered on time if the actual visit occurred before, on or up to 14 days after the next scheduled visit date. Any woman with a gap in care for 
>90 days was considered not retained. In addition, deaths and outward transfers were not considered retained. 
gThe Lafiyan Jikin Mata or ‘Excellent Health for Mothers’ study. Information on PMTCT programme protocol and ART regimen was extracted from 
Oyeledun B, Oronsaye F, Oyelade T, et al. Increasing retention in care of HIV-positive women in PMTCT services through continuous quality improvement-
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breakthrough (CQI-BTS) series in primary and secondary health care facilities in Nigeria: a cluster randomized controlled trial. The Lafiyan Jikin Mata 
Study. J Acquir Immune Defic Syndr 2014;67(Suppl 2):S125–31. 
DBS/PCR: dried blood spot polymerase chain reaction; EID: early infant diagnosis; HEIs: HIV-exposed infants; MIPs: mother-infant pairs; MOH: Ministry 
of Health; POC: point of care; PCR: polymerase chain reaction; RHT: rapid HIV antibody test. 
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5.2.3 Discussion   
The results of this work suggest that PMTCT Option B+ programs need to incorporate a package of 
interventions to support retention in care and infant testing uptake addressing the various barriers to 
engagement in care of the mother-infant pair. This recommendation is based on the hypothesis of 
acting on different types of barriers and at different time points in the continuum of care will produce 
more favorable outcomes than acting on a single time point using one type of intervention [137,138]. 
Therefore, the package of interventions should not only aim at changing the behavior of patients and 
their communities but also change the organization of care providing a more integrated approach 
carrying health care services away from an already overcrowded facility-based system to a more 
mother/infant-centered approach at community level. In addition, interventions to improve retention 
in care are equally applicable to women initiating ART at PMTCT enrolment as to women already 
on ART while becoming pregnant. Even more so for the latter group as these women should be more 
stable patients who can receive a more differentiated model of care [12].   
In our systematic review, only one eligible study reported on long term retention beyond 12 months 
of ART. Therefore, future research analyzing the impact of interventions to improve PMTCT 
outcomes should report on long term retention outcomes (i.e. >24 months after ART initiation) to 
account for the additional challenges of retaining women under lifelong ART after the end of the 
PMTCT period. We also found that all interventions which have been evaluated to date have limited 
impact on engagement in care for women enrolled under Option B+ suggesting that women prioritise 
their health care in ways that programmes do not yet understand. The results for this review can best 
be adapted to local context using informative research. Particularly, for the Mozambican context, 
further qualitative research is needed to address the particular local health system and socio-cultural 
challenges faced by women, such as migration, lack of tracking of women between clinics, for 
example. Results of such research can then help inform the specific intervention needed to improve 
their engagement in care.  
Finally, in this systematic review we also highlighted the plethora of definitions used to characterize 
women retained in care and the absence of use of the international recommended definition of infant 
testing. Based on these findings, from a programmatic stand-point to measure engagement in PMTCT 
care we recommend incorporating the element of completeness of follow-up in the measurement 
metrics of retention and infant testing.  
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5.3 Measuring retention in care for HIV-positive pregnant women in Prevention of 
Mother to Child Transmission of HIV (PMTCT) option B+ programs. The 
Mozambique experience.  
 
5.3.1 Introduction  
The first work of the thesis consisted in estimating retention rates in two high HIV burden provinces 
in Mozambique over the course of 4 years of Option B+ programme implementation. We observed 
low retention rates in pregnant women enrolled in PMTCT care. The second work highlighted the 
great heterogeneity of definitions used in the literature when defining women retained in care under 
Option B+ programmes and its impact on result interpretation. This third work is a sensitivity analysis 
of our cohort analysis by estimating the effect of different definitions of retention in care. We discuss 
here the advantages and limitations of each definitions in the context of engagement in care for HIV+ 
pregnant women initiating ART under Option B+ in Mozambique.   
The manuscript was submitted to the BMC Public Health journal on the July 2019.   
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Abstract 
Background: Failure of retention of HIV-positive pregnant women on ART leads to increased 
mortality for the mother and her child. This study evaluated different retention measures intended to 
measure women’s engagement along the continuum of care for prevention of mother-to-child 
transmission (PMTCT) option B+ services in Mozambique. 
Methods: We compared ‘point’ retention (patient’s presence in care at 12-months post-antiretroviral 
treatment (ART) initiation or any time thereafter) to the following definitions: alive and in care at 12 
months post-ART initiation (Ministry of Health); attendance at a health facility up to 15 months post-
ART initiation (World Health Organisation); alive and in treatment at 1, 2, 3, 6, 9, and 12 months 
post-ART initiation (Inter-Agency Task Team); and alive and in care at 12 months post-ART 
initiation with ≥75% appointment or on-time adherence during follow-up (‘appointment adherence’ 
and ‘on-time adherence’ retentions). Kaplan-Meier survival curves were produced to assess 
variability in retention rates. We used ‘on-time adherence’ retention as a gold standard to estimate 
sensitivity, specificity, and proportion of misclassified patients. 
Results: Considering the ‘point’ retention definition, 16,840 HIV-positive pregnant women enrolled 
in option B+ PMTCT services were identified as ‘retained in care’ 12 months post-ART initiation. 
Of these, 60.3% (95% CI 59.6–61.1), 84.8% (95% CI 84.2–85.3), and 16.4% (95% CI 15.8–17.0) 
were classified as ‘retained in care’ using MOH, WHO, and IATT definitions, respectively, and 1.2% 
(95% CI 1.0–1.4) were classified as ‘retained in care’ using the ‘ ≥75% on-time adherence’ definition. 
All definitions provided specificity rates of ≥98%. The sensitivity rates were 3.0% with 78% of 
patients misclassified according to the WHO definition and 4.3% with 54% of patients misclassified 
according to the MOH definition. The ‘point’ retention definition misclassified 97.6% of patients. 
Using IATT and ‘appointment adherence’ retention definitions, sensitivity rates (9.0% and 11.7%, 
respectively) were also low; however, the proportion of misclassified patients was smaller (15.9% 
and 18.3%, respectively). 
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Conclusion: More stringent definitions indicated lower retention rates for PMTCT programmes. 
Policy makers and programme managers should include attendance at follow-up visits when 
measuring retention in care to better guide planning, scaling up, and monitoring of interventions. 
 
 
Keywords: PMTCT, option B+, retention, sensitivity, specificity 
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Background 
Retention in prevention of mother-to-child transmission of HIV (PMTCT) care has both individual 
and public health consequences. At the mother-infant pair level, being in care contributes to higher 
maternal antiretroviral therapy (ART) adherence, better viral suppression, and ensures better post-
natal care, including full ART prophylaxis and complete infant testing to HIV-exposed infants (HEI) 
(1,2). In contrast, failure to be retained in care can lead to delayed or inconsistent use of antiretroviral 
medications, higher rates of maternal viral load failure, and increased morbidity and mortality for the 
mother and her child (3–5). In addition, recent publications have reported an upward trend in acquired 
drug resistance to first-line ART across low- and middle-income countries, principally due to sub-
optimal viral suppression (6–8). Therefore, non-achievement of viral suppression can lead to a higher 
risk of HIV transmission and secondary infections with acquired drug resistance strains and is, 
therefore, considered a public health threat (9). 
When referring to retention in care, publications often consider ‘point’ retention, which is defined 
in relation to a patient’s presence in care at a certain time point. For women and children enrolled in 
PMTCT services, attendance at a clinic at a certain time point is often considered to be full 
retention over this time period. While such a simple definition is useful, it has been demonstrated 
for HIV-infected adults that between one- and two-thirds of patients are not in regular care (10). 
Therefore, regularity of attendance is an important parameter to consider if quality engagement in 
care is to be evaluated (11). 
To address shortcomings in this simple definition, attempts to better measure retention in care in 
PMTCT services have been made (12,13). In 2014, a World Health Organisation (WHO) 
monitoring and evaluation working group published consolidated strategic information guidelines 
and proposed that retention in care of HIV-infected pregnant and breastfeeding women was 
equivalent to attendance at a health facility at 12-months post-initiation of ART, or at any time up 
to 3 months later (12). The 12-month time point was agreed to align with the adult ART monitoring 
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guidelines; however, it fails to address the ongoing risk period associated with continued 
breastfeeding beyond 12 months. In 2015, the Inter-Agency Task Team (IATT) on Children and 
HIV and AIDS defined maternal retention as ‘the proportion of HIV-positive pregnant and/or 
breastfeeding women on ART alive and in treatment at 1, 2, and 3 months post-ART initiation 
(early retention), and then at 6, 9, and 12 months post-ART initiation’, where retention was 
considered as a continuous engagement (13). Despite such efforts, there is no consensus on what 
constitutes ‘retention in care’, with no gold standard determined. In 2010, Mugavero et al. provided 
a synopsis of five commonly used definitions of retention in HIV care and treatment services, 
ranging from a simple count of the number of missed visits to a more complex medical visit 
performance measure that incorporated elements of appointment consistency and gaps in care (10). 
While that study provided important insights on methodological and conceptual strengths and 
limitations of each definition, no comparative analysis of these definitions has been undertaken. 
In this study, we aimed to evaluate different measures of retention that could reflect more 
accurately the nature of women’s engagement along the PMTCT care continuum. We hypothesised 
that ‘point’ retention’ might overestimate the level of engagement in care of women enrolled in 
PMTCT programmes, and that programme outcomes in a high HIV-burden country such as 
Mozambique would be better evaluated when the level of attendance of scheduled visits during 
follow-up was taken into account. More specifically, the objectives of this analysis were to: i) 
assess the variability of different measures of retention at 12 months post-ART initiation under 
PMTCT option B+ programmes using different definitions of retention in care; ii) compare the 
sensitivity and specificity of the different definitions in detecting women fully engaged in care at 12 
months post-ART initiation; and iii) discuss the programmatic implications of each definition in the 
context of PMTCT option B+ programmes. 
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Methods 
Setting 
Data for the present analyses were extracted from electronic patient-level databases (ePLD) from 86 
Ministry of Health (MOH) facilities providing PMTCT option B+ and HIV care and treatment 
services in Nampula and Zambézia provinces in Mozambique. The programmes were supported by 
ICAP at Columbia University through funding from the United States President’s Emergency Plan 
for AIDS Relief (PEPFAR). 
Officially adopted in 2013, the option B+ strategy in Mozambique uses a ‘one-stop-model’ and ‘Test 
and Treat’ approach where pregnant and breastfeeding women are counselled and tested in mother 
and child health (MCH) services and, if found HIV-positive, are started on lifelong ART that same 
day. HIV care and treatment are integrated within MCH services and ART provision is administered 
by nurses. For HIV-positive pregnant women, a second consultation occurs within the first week post-
ART initiation, and a monthly clinical follow-up is conducted during the first 6 months of ART, 
followed by bi-monthly follow-ups during breastfeeding until 12 months of treatment and bi-annually 
thereafter until the end of breastfeeding. ART counselling and drug pickup are conducted on a 
monthly basis for the first year of treatment. Routine viral load (VL) monitoring is recommended at 
3 and 12 months post-ART initiation and annually thereafter. HIV-positive women are followed in 
MCH services until the final HIV status of the exposed infant is determined (14). More detailed 
descriptions of the PMTCT programme settings and data sources are described elsewhere 
(manuscript, L Ahoua, 2019). 
The Mozambique provinces targeted for the study officially implemented option B+ in July 2013. Of 
all HIV-positive women who were enrolled in PMTCT option B+ programmes and who were started 
on ART between July 1st, 2013 and December 31st, 2017, we selected those who were considered as 
‘retained in care’ at 12 months post-ART initiation according to the ‘point’ retention definition (i.e. 
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patient alive and present in care at 12 months post-ART initiation, or any time thereafter) and with a 
follow-up time of at least 12 months under ART to allow complete assessment of engagement in care 
during the first year of treatment. These selected women constituted the basis of comparison for the 
subsequent analyses assessing variability in different definitions concerning retention measures. 
Comparing definitions 
The ‘point’ retention definition was compared against the following five definitions: MOH (15), 
WHO (12), IATT (13), ‘appointment adherence’ retention (10), and ‘on-time adherence’ retention 
(16) (Table 1). Similar to the ‘point’ retention definitions, the MOH and WHO retention definitions 
assess retention at a single time point. For women’s attendance at a clinic, we considered different 
types of visits including medical consultations, pharmacy drug refills, counselling, or laboratory 
analysis. This approach allowed us to consider HIV care as a holistic strategy, given that HIV care is 
provided in an increasingly team-based environment with non-prescribing healthcare professionals 
taking on expanded roles in direct patient care. Table 1 summarises the definitions of retention 
according to different measures and shows how failure events were accounted for in statistical 
analyses. 
Statistical analysis 
Women’s appointment adherence, as well as their on-time adherence to scheduled visits, were 
expressed as percentages, median, and interquartile range [IQR]. Women’s retention status was 
classified into a binary outcome (retained vs. not retained in care) using a 75% threshold for clinical 
attendance. Each woman contributed to the analyses from the date of ART initiation to the first 
occurrence of a failure event, as described in Table 1. To allow sufficient time to analyse clinical 
attendance within the first year of treatment, we only included women who initiated ART up until 
December 31st, 2016 and for whom the theoretical follow-up time under ART was ≥12 months. 
Kaplan-Meier survival curves were produced to estimate retention in care at 3, 6, 9, and 12 months 
post-ART initiation using each of the definitions described above. We assessed variability in the 
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different measures of retention between respective definitions used. We did not consider 
‘appointment adherence’ retention for the survival analysis, as this definition does not contemplate a 
time event, but rather a total number of visits completed during the observation period. 
We assessed sensitivity, specificity, and the proportion of misclassified women for each alternative 
definition of retention compared to the reference of an ‘ideal case scenario’ of full ‘on-time 
adherence’ retention, defined as a woman alive and in care 12 months post-ART initiation and  ³75% 
of scheduled visits attended on time (+/- 15 days). Sensitivity and specificity values were calculated 
with 95% confidence intervals. 
Results 
A total of 31,186 HIV-positive women were enrolled in the PMTCT option B+ programme initiating 
ART during the study period. Of these, 18,739 were considered as being retained in care at 12 months 
post-ART initiation according to the ‘point’ retention definition. We excluded 1,899 women with a 
follow-up ART time of <12 months. Finally, 16,840 women were included in this study. 
Of 16,840 women included, only 2,764 (16%) and 407 (2%) were considered retained at 12 months 
post-ART initiation when considering regularity and timeliness of appointment attendance, 
respectively (Figure 1). The occurrence of irregular (IATT’s definition) and delayed (‘on-time’ 
definition) clinical attendance was documented as early as 2–3 months post-ART initiation. The 
median frequency of appointment adherence to scheduled visits for all women included was 66.7% 
(IQR 57.1%–80.0%) and the median frequency of on-time adherence was 40.0% (IQR 22.2% – 
52.9%). 
Figure 2 shows Kaplan-Meier survival curves for retention over time up to 12-months post-ART 
initiation using the different definitions. Among the 16,840 B+ pregnant women considered retained 
in care according to the ‘point’ retention definition, 84.8% (95% CI 84.2–85.3) were actually defined 
as retained in care when estimated using the WHO definition (i.e. attendance at a health facility up to 
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15 months post-ART initiation), 60.3% (95% CI 59.6–61.1) with the MOH definition (i.e. alive and 
in care at 12 months post-ART initiation), and 16.4% (95% CI 15.8–17.0) with the IATT definition 
(i.e. alive and on treatment at 1, 2, 3, 6, 9, and 12 months post-ART initiation), respectively. When 
using the ‘on-time adherence’ retention definition (i.e. alive and in care at 12 months post-ART 
initiation with at least 75% of on-time adherence during follow-up), only 1.2% (95% CI 1.0–1.4) 
were defined as retained in care. 
We considered the gold standard category to be the 407 women alive and in care 12-months post-
ART initiation with at least 75% on-time adherence. We calculated the sensitivity and specificity of 
other definitions to more accurately classify the women into a more suitable category of retention and 
determine the proportion of misclassified patients. While all definitions provided specificity rates of 
≥98%, the sensitivity to detect a patient actually retained in care with ≥75% of on-time adherence 
was <12% (Table 2). The WHO and MOH retention definitions provided the lowest sensitivity figures 
and the highest proportion of women misclassified as retained in care as follows: 3.0% sensitivity 
(95% CI 2.7%–3.3%) with 78% of patients misclassified according to the WHO definition and 4.3% 
sensitivity (95% CI 3.9%–4.7%) with 54% of patients misclassified according to the MOH definition. 
In addition, the ‘point’ retention definition misclassified 97.6% of patients. Although sensitivity rates 
were also low when using the IATT and ‘appointment adherence’ retention definitions, the proportion 
of misclassified patients was relatively smaller (15.9% and 18.3%, respectively). 
 
Discussion 
We analysed six different definitions of ‘retention in care’ for HIV-positive pregnant women enrolled 
in PMTCT option B+ programmes ranging from the most lenient definition using a ‘point’ retention 
approach to the most stringent definition using an ‘on-time adherence’ retention approach. Of the six 
definitions, three definitions assess retention at a single time point (‘point’ retention, WHO, and 
MOH). The IATT, the ‘appointment’ and the ‘on-time adherence’ retentions approaches reflect a 
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more continuous engagement in care, where follow-up visits between initiation of ART and the 
endpoint date are considered. 
As expected, we found that the more stringent the definition, the lower the probability for women to 
be defined as retained in care; and when levels of attendance to visits during follow-up were 
considered, estimates were even lower (85% and 60% when using the WHO and MOH definitions 
compared to 16% and 1% when using the IATT and ‘on-time adherence’ retention definitions). At 
the end of the first year, most women starting ART had not adhered to their scheduled visits, with 
median appointment adherence at 66% and median on-time adherence at 40% among the 16,840 
women considered as retained in care using the ‘point’ retention definition. Of these, only 16% and 
2% were actually defined as retained in care 12 months post-ART initiation, if we considered a 
threshold of ≥75% for appointment and on-time attendance, respectively. 
Initial visits in the first year of ART initiation are critical to ensure successful engagement in care, 
involving intensive counselling, peer support, conveying important preventive healthcare and risk 
reduction messages, and monitoring patterns of healthier behaviour for the women and their exposed 
children. This interaction between the health system and the HIV-infected women determines the 
likelihood of survival of the pair and the mother-to-child transmission of HIV. Adding the frequency 
and regularity of visits into the concept of retention increases the quality of the PMTCT programme 
evaluations, enabling a distinction to be made between women who attend for all or some care and 
treatment, and those who completely fail to adhere to scheduled visits and are therefore considered 
not to be engaged in care. 
Table 3 provides a summary of the advantages, limitations, and programmatic implications of the six 
measures of retention concerning the PMTCT option B+ programmes (10,11). Based on our results, 
the three-single time point measures, namely, the ‘point’, WHO, and MOH definitions, were a 
classical programmatic approach to measure retention in care under ART. While relatively easy to 
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use, they do not capture important milestones in the PMTCT context; for example, at delivery, at 2-
months post-partum for early infant diagnosis, or at the end of breastfeeding for the final HIV 
determination of the HIV-exposed infant. In addition, they do not consider visit consistency, which 
has been demonstrated to be significantly associated with ART adherence and viral suppression 
among HIV-positive adults (17,18). However, the three definitions that capture visit consistency 
along the continuum of care, namely, the IATT, ‘appointment’ and ‘on-time adherence’ definitions, 
were more complex to use as they included multiple clinic visits (repeated measures) occurring 
longitudinally over time. This could become extremely challenging in limited-resource settings where 
limited qualified human resources are available to document such information, data collection tools 
are not adapted to capture longitudinal follow-up, and there are numerous entry points where women 
are followed within the same health facility or between sites (11,19). To correctly capture patients’ 
follow-up, different data sources need to be combined or triangulated, for example, with counselling 
registers and with laboratory or pharmacy records. Electronic databases may help this process, but 
these are generally implemented in high volume and accessible sites and may not necessarily be 
representative of the entire country for national programmes. However, all three definitions enabled 
adding the concept of a continuum of care to point retention estimates. 
When considering ‘on-time adherence’ retention as the gold standard, all other definitions provided 
very low sensitivity rates to accurately detect patients retained in care, with high rates of misclassified 
patients. The WHO and MOH retention definitions provided the lowest sensitivity rates, that is, 3% 
and 4%, respectively. For the ‘point’ retention, WHO, and MOH definitions, which did not consider 
continuous follow-up in their calculations, the proportion of misclassified patients ranged from 54% 
to 97%. The ‘appointment adherence’ definition provided the highest sensitivity rate (11.7%), with a 
fairly low proportion of misclassified patients (18.3%) compared to all other definitions analysed. 
We found that the median time to first failure of correct follow-up was short (≤3 months), if visit 
attendance during follow-up was considered, which demonstrated the need to implement early 
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preventive measures to avoid patients on the PMTCT programme disengaging from care. Such 
strategies should focus on already well-known barriers to regular attendance, such as a lack of 
disclosure, poor staff attitudes, competing personal priorities, medication side-effects, or transport 
difficulties (16). 
While our definition of ‘on-time adherence’ retention represents the ideal situation in which an HIV-
positive pregnant woman enrols in a PMTCT programme and starts ART under option B+ should be 
considered as fully engaged in care to ensure an optimal viral response, it is perhaps too stringent for 
PMTCT programme evaluations. It is also time consuming to use on a routine basis and may not be 
compatible with current PMTCT service settings. Therefore, we recommend either using the IATT 
or the ‘appointment adherence’ retention definitions to better measure levels of engagement in care 
for mother-infant pairs. 
Our analysis had several limitations. To accurately evaluate attendance at scheduled visits, it is 
desirable to distinguish visits cancelled in advance (either by the patient or the care provider) from 
‘no show’ visits that are actually visits missed by the patient (10). Our data did not allow this 
distinction to be made as this information was not captured in the database. Therefore, our results 
may have underestimated the real values of women’s engagement in care when analysing 
‘appointment’ and ‘on-time’ adherence retentions. 
Some women, although defined as having a full attendance at scheduled visits, did not follow per se 
the recommended schedule of visits as per national guidelines. More frequent visits may indicate a 
more advanced HIV disease, problems in counselling that need to be addressed, or drug or laboratory 
reagent stock-outs (19). Less frequent clinical visits may reflect a stabilised disease stage or 
temporary silent transfers (i.e. women receiving ART services elsewhere for a short period of time). 
For this reason, we chose to use all scheduled visits, regardless of whether the visits fell into expected 
time intervals. We did not analyse treatment interruptions and gaps in care for similar reasons. Further 
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research is warranted to investigate the effect of a lack of observation of the recommended schedule 
of visits as per national guidelines on PMTCT programme outcomes. 
Finally, we analysed data from health facilities with ePLD in two provinces in Mozambique. 
Although these two provinces are among the most populated in the country, with large volumes of 
patients seen at health facilities, our results may not be generalisable to other regions in Mozambique 
or to other resource-limited settings. 
 
Conclusion 
Balancing the need to reflect correct attendance and capture the regularity of visits without 
involving complex computer processing of the available routine data can be a daunting task. In 
addition, applying more stringent definitions is likely to result in lower reported rates of retention in 
care for PMTCT programmes. However, policy makers and programme managers should consider 
systematically taking into account attendance at follow-up visits to better guide decision-making 
concerning planning or scaling up interventions for mother-infant pairs. A consensus on a 
practicable definition is urgently needed, based on data availability, clinic scheduling practices, and 
local analytical capacities. Without overall agreed guidelines, findings from different programmes 
and interventions cannot be satisfactorily compared. Finally, a retention indicator is used in 
modelling estimates for vertical transmission of HIV. Without accurate and correct estimates, it is 
not possible to evaluate programme achievements effectively in respect of elimination of mother-to-
child transmission of HIV. This consideration may become particularly important as recent 
programmatic data seem to indicate a stagnation in the achievements of PMTCT programmes 
worldwide, which suggests the need for revised global, national, and local strategies to end the HIV 
epidemic by 2030 (20). 
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Table 1: Retention definitions and methods of calculation. B+ PMTCT programme, Mozambique, 
2013-2017 
Type of retention 
 
Definition of a patient ‘alive and retained in care’ at 12 months 
post-ART initiation Failure event 
‘Point’ retention Alive and had a visit at the health facility 12 months post-ART 
initiation or if was known to have had a visit at a health facility 
any time after  
Death, LTFU, and transfer-out are counted if 
they occurred within the first 12 months post-
ART initiation 
WHO  Attendance at a health facility at 12 months post-ART 
initiation*, or at any time up to 3 months later 
Death, LTFU, and transfer-out are counted if 
they occurred within the first 15 months post-
ART initiation. 
Patients transferred out were right-censored at 
the date of transfer-out 
MOH  Attendance at a health facility at 12 months post-ART initiation* 
 
Death or LTFU are counted if either occurred 
within the first 12 months post-ART initiation 
Patients transferred out are excluded from the 
analysis 
IATT  Attendance at a health facility and on treatment at 1, 2, 3, 6, 9, 
and 12 months post-ART initiation # 
Death, LTFU, transfers-out and failure to attend 
either the 1-, 2-, 3-, 6-, 9-, or 12-month visit, 
whichever comes first 
Patients are right-censored at the date of the 1st 
failure event. 
‘Appointment adherence’ 
retention 
Attendance at a health facility at 12-months post-ART initiation 
* and ³75% of appointment adherence to scheduled visits 
‘Appointment adherence’ was estimated using the number of 
visits attended divided by the number of total scheduled visits 
during the 12-month observation period 
Not applicable 
‘On-time adherence’ 
retention  
Attendance at a health facility at 12 months post-ART initiation 
* and ³75% of ‘on-time attendance to scheduled visits 
A visit on time is defined as a visit that occurred within +/- 15 
days of the date of the expected scheduled visit 
‘On-time adherence’ is estimated using the number of visits 
attended on-time divided by the number of total scheduled 
visits. 
Unscheduled visits occurring before the date of appointment 
were not counted as missed visits 
Death, LTFU, transfer-out, and failure to attend 
a visit on-time, whichever comes first. 
Patients were right-censored at the date of the 
1st failure event 
ART, antiretroviral therapy; LTFU, lost to follow-up 
*For these definitions, we considered a window period of +/- 15 days around the theoretical date of 12-month post-ART initiation. 
# We allowed a +/-15-day window period for each stage of ART follow-up. Note: We did not consider ‘appointment adherence’ 
retention for the survival analysis, as this definition does not contemplate a time event but rather the total number of visits completed 
during the observation period. 
  
Page 145 of 188 
 
 
Table 2: Sensitivity and specificity of various definitions of retention in care among B+ HIV+ 
pregnant women defined as alive and retained in care according to the ‘point’ retention definition 
(n = 16,840). 
Retained in care 
according to type of 
definition 
(n = 16,840) 
Alive and retained in 
care with ³75% of visits 
in time 
(Gold standard) 
Sensitivity 
95% CI 
Specificity 
95% CI % of misclassification 
Yes No 
‘Point’ retention  407 16,433 - - 97.6% 
WHO  405 13,154 3.0% [2.7%–3.3%] 99.9% [99.8%–100%] 78.1% 
MOH  
407 9,093 4.3% [3.9%–4.7%] 100% [99.9%–100%] 54.0% 
IATT  249 2,515 9.0% [8.0%–10.1%] 98.9% [98.7%–99.0%] 15.9% 
‘Appointment 
adherence’ retention  407 3,076 11.7% [10.6%–12.8%] 100% [100%–100%] 18.3% 
Note: The ‘on-time adherence’ definition of retention is considered as the gold standard (n = 407 women 
retained in care at 12-months post-ART initiation and with ³75% on-time adherence to scheduled visits). The 
percentage of misclassified patients is calculated using the sum of patients incorrectly classified according 
to each definition divided by the total number of patients included in the analysis. 
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Table 3: Advantages, limitations, and programmatic practicality of six measures of retention in care for PMTCT option B+ programmes. 
Retention 
definition Advantages Limitations Programmatic practicality 
‘Point’ retention  Easy to measure 
Assessed at a single time point 
Provide a transversal picture of retention  
Does not consider visit consistency of the MIP 
Does not consider whether the women fully adhered to the 12-
month visit schedule 
Not aligned with important PMTCT milestones (i.e. delivery, EID, 
or final HIV testing)  
Programmatic definition of retention 
Achievable with simple health information systems 
(e.g. paper-based registers) 
WHO  Easy to measure 
Assessed at a single time point 
Provide a transversal picture of retention 
More specific in detecting patients adhering to the 12-
month visit (up to 15-months only) 
Does not consider visit consistency of the MIP 
Not aligned with important PMTCT milestones (i.e. delivery, EID, 
or the end of breastfeeding)  
As above 
MOH  Easy to measure 
Assessed at a single time point 
Provides a transversal picture of retention 
Considers whether the women fully adhered to the 12-
month visit schedule 
As above  Programmatic definition of retention 
Achievable with simple health information systems 
(e.g. paper-based registers) 
Cohort based approach for calculation 
IATT  Considers whether the women fully adhered to the 12-
month visit schedule 
Captures visit consistency 
Can be adapted to align with the follow-up of the MIP 
More complex to measure (ideally requires an ePLD or POC EMR) 
Not systematically aligned with national PMTCT follow-up 
guidelines but can be modified accordingly 
Probable need of data triangulation with other data sources (e.g. 
pharmacy, laboratory) and linkage with unique IDN 
Relevant in capturing visit consistency of the MIP, can 
be aligned with important PMTCT milestones 
Ideal if integrated POC testing services for the MIP are 
available 
Better alternative than single time point estimations 
‘Appointment 
adherence’ 
retention  
Considers whether the women truly adhered to the 12-
month visit schedule 
Capture visit consistency 
Measurable with paper-based longitudinal cohort based 
registers (total # of completed visits done/total scheduled 
visits) 
Does not capture the regularity or timeliness of completed visits 
Not aligned with important PMTCT milestones for the MIP 
Highly dependent on data completeness of denominator (# of 
scheduled visits) 
Need of data triangulation with other data sources (e.g. 
pharmacy, laboratory) and linkage with unique IDN 
Achievable with simple health information systems 
Better alternative than single time point estimations 
‘On-time 
adherence’ 
retention 
Considers whether the women fully adhered to the 12-
month visit schedule 
Ideal to capture correct levels of engagement in care for 
PMTCT (regularity and timeliness) 
Aligned with important milestones of PMTCT follow-up for 
the MIP 
More complex to measure (requires an ePLD or POC EMR) 
Highly dependent on data completeness of denominator (# of 
scheduled visits) 
Need of data triangulation with other data sources (e.g. 
pharmacy, laboratory) and linkage with unique IDN 
Time consuming activity not compatible with one-stop model 
PMTCT services in the absence of electronic databases 
Adapted for research purposes 
Not compatible with routine monitoring of retention 
in care of MIPs 
Note: EID, early infant diagnosis; EMR, electronic medical record; ePLD, electronic patient-level database; IDN, identification number; MIP, mother-infant pair; POC, point-of-care 
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Figure legends 
Figure 1. B+ pregnant women retained in care 12 months post-ART initiation: time to first 
failure event. 
 
Figure 2. Estimated Kaplan-Meier survival curves for retention over time, by retention 
definition. 
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* Note: Time until first failure event expressed in months, median, and interquartile range 
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Time to failure event 0 months 3 months 6 months 9 months 12 months 
WHO definition      
# at risk 16,840 16,838 15,359 14,793 11,448 
# events - 797 703 559 493 
# events (cumulative) - 797 1,500 2059 2,552 
Retention (95% CI) - 95.3% (94.9-95.6) 91.1% (90.7-91.5) 87.8% (87.3-88.3) 84.8% (84.2-85.3) 
MOH definition      
# at risk 15,750 14,743 13,834 12,829 6,099 
# events - 759 902 1,011 3,302 
# events (cumulative) - 759 1,661 2672 5974 
Retention (95% CI) - 93.4% (93.0-93.8) 87.7% (87.2-88.2) 81.3% (80.7-81.9) 60.3% (59.6-61.1) 
IATT definition      
# at risk 16,840 7,163 4,514 3,402 1,855 
# events - 5,937 2,649 1,112 637 
# events (cumulative) - 5,937 8,586 9,698 10,335 
Retention (95% CI) - 42.5% (41.8-43.3)  26.8% (26.1-27.5) 20.2% (19.6-20.8) 16.4% (15.8-17.0) 
On-time definition      
# at risk 15,232 8,508  4,907 3,265 154 
# events - 4,838 3,420 1,551 2,979 
# events (cumulative) - 4,838 8,258 9,809 12,788 
Retention (95% CI) - 54.8% (53.9-55.6) 32.2% (31.4-32.9) 21.8% (21.2-22.5) 1.2% (1.0-1.4) 
 
Note: Kaplan-Meier survival curves for retention over time are presented by retention definition for B+ HIV-
positive pregnant women up to 12 months post-ART initiation. 
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5.3.3 Discussion 
We demonstrated that measuring retention in care using ‘point retention definition’ does not 
reflect accurate level of engagement in care of women enrolled in PMTCT Option B+ program. 
Such definition of engagement fails to capture adherence to scheduled visits. It also highlights 
the health system’s inefficiency in incentivizing PMTCT clients to adhere to scheduled visits. 
Importance of attendance to scheduled visits and of adherence to treatment need to be 
emphasized at enrolment and throughout pre and post-natal care to achieve and ensure viral 
suppression. More flexible opening hours could also help patients living far away or women 
who have professional/economical/household commitments. This work has confirmed the 
findings of the literature review related to the heterogeneity of definitions used and the absence 
of international consensus.   
This study only relates to HIV-positive women starting ART in pregnancy. However, with 
expansion of Option B+ and ‘Test and Treat’ strategy the number of women already on ART 
before pregnancy is expected to increase. These women are also likely to be more stable patients 
then those newly initiated on ART. Additional analysis in the first work showed good levels of 
retention in women already on ART before diagnosis of pregnancy (up to 84% for those who 
initiated ART in 2016). Nevertheless, the importance of regular attendance to scheduled visits 
also applies to these women as a key to maintain viral suppression.   
Based on the results of the first part of the thesis, the median gestational age at ART start was 
25 weeks and for those with available information on the date of delivery (19,150/31,186, 
61.4% of ‘B+ pregnant women’ included), the median time between ART initiation and 
delivery was 3.6 months (IQR: 2.6 - 4.9). Therefore, a 12-month post-ART assessment of 
retention covers the time around delivery, known to be at increased risk of LTFU. Although not 
widely used in the literature, the IATT or the ‘appointment adherence’ retention definitions 
seems to be good alternatives to measure levels of engagement in care for mother-infant pairs. 
The added value of the IATT definition is that it assesses specific time points that can capture 
the period before and after delivery.   
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6 General discussion 
6.1 Work synthesis 
The aim of the PhD was to discuss, from a public health perspective, the programmatic 
challenges of engagement in care for PMTCT Option B+ strategy in sub-Saharan Africa, with 
the example of Mozambique. More specifically, we focused on three important programmatic 
aspects of engagement in care: retention in care of HIV-positive pregnant women initiating 
ART, HEI testing coverage and methods of measurements of retention in care with their 
potential operational impact. We also proposed some alternative definitions to better measure 
levels of engagement in care of the mother/infant pair enrolled under Option B+ programs.  
The first part of this work provides an update of the PMTCT situation in Mozambique over 
the course of 4 years of program implementation from 2013 to 2017. It evaluated the Option 
B+ care cascade in ANC and investigated the risk of attrition from a large sample of more than 
30,000 HIV-infected pregnant women on ART (‘B+ pregnant’). We noted substantial 
improvement in outcomes in the care cascade: the proportion of women with documented HIV 
status increased from 93% in 2013 to 96% in 2017; the HIV testing yield (i.e. the proportion of 
clients undergoing HIV testing who test positive) decreased from 8% to 6% and the ART 
coverage increased from 42% to 95%. We also noticed a substantial increase in women already 
on ART enrolling in ANC of more than a 3-fold in 5 years, suggesting that ART coverage in 
Mozambique in pregnant women will reach saturation. As the PMTCT program matures, an 
increasing proportion of women will already be on ART when pregnancy will be diagnosed. 
When comparing ‘B+ pregnant’ women and ‘own health’ women, the retention at 12 months 
after ART initiation improved in both groups reaching 74% and 77%, respectively. Greater 
improvement was noted in the ‘B+ pregnant’ group, as retention increased from 64% in 2013 
to 74% in 2016. Despite the seeming progress made, the overall attrition remained unacceptably 
high for both groups of women with 35% of women being lost to care within three months of 
treatment. In addition, year of ART initiation significantly impacted risks of attrition: this risk 
was 14% higher in ‘B+ pregnant’ women compared to ‘own health’ women when they initiated 
ART in the first year of program implementation. This difference in risk decreased over the 
years and reached similar levels in both groups by the end of the study period which suggest 
programmatic improvements achieved over time as the PMTCT Option B+ programme 
matured with better supervision and training of nurses on quality of care and counselling. And 
a greater degree of acceptability of lifelong treatment under Option B+ has been achieved; 
nevertheless we found that initiation of ART on the same day as HIV diagnosis significantly 
increased both the risk of having an NFU status and non-retention which indicates that women 
in Mozambique may still experience considerable staff pressure to undergo immediate ART 
initiation without sufficient time to disclose to their partner or relative or reflect on their HIV 
sero-status. Additional analyses showed that less than a half of women were retained in care 
24-months after ART initiation. Women who initiated ART before the diagnosis of their 
pregnancy had similar patterns of improvement in retention rates than ‘B+ pregnant’ women. 
Finally, we also revealed high rates of retention (80% at 12-month post ART initiation) for ‘B+ 
breastfeeding’ women with no significant difference over the years. The retention rates in the 
latter group were even better than for the ‘B+ pregnant’ women and women who initiated ART 
pregnancy was formally detected. If women initiate ART before pregnancy the rate of MTCT 
can be similar to that observed in high-income countries [139]. The challenge will remain for 
the incident HIV infection during late pregnancy (for those accessing ANC late in their 
pregnancy), perinatal and breastfeeding period, as mother not being on ART during pregnancy 
and late ART initiation is strongly associated with MTCT [140].  
Based on the gaps and challenges identified in this first part regarding persistent low retention 
rates of women enrolled in Option B+ in Mozambique, the next question would be to identify 
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what interventions could improve women’s engagement in care? We have seen that although 
ART coverage in ANC reaches 95%, the estimated MTCT rate remains still unacceptably high 
at 15% in 2018. While efforts have been made to improve PMTCT services in the antenatal and 
maternity settings, the postpartum and infant components of the continuum of care of PMTCT 
programs have not been receiving equivalent attention and follow-up of HIV-exposed infants 
remains sub-optimal. Hence, the need also to identify what potential interventions could 
improve the post-partum component of engagement in option B+ PMTCT measured by the 
infant testing uptake.  
 
The second work provides a critical overview of rates of maternal ART retention and HIV 
infant testing coverage when interventions to improve such outcomes are implemented. 
Fourteen studies were included, representing 6,311 HIV+ pregnant or breastfeeding women and 
1,920 HIV-exposed infants receiving an intervention to improve PMTCT outcomes. All but 
one study reported data from PMTCT programs implemented in Sub-Saharan Africa. A wide 
variety of interventions were examined: three used peer and mentor support, one used 
community health workers or lay workers, three used mHealth interventions, three used 
provider-oriented strategies and four used a package of interventions. The interventions 
analysed in our review did not seem to show any improvement in retention in care for pregnant 
and/or breastfeeding women when compared to settings where no intervention were 
implemented. Indeed, when no intervention is implemented, retention at 12 months after ART 
initiation  under Option B+ in sub-Saharan Africa is 76.4% (95% CI: 69.0–83.1) [141]. In our 
review, retentions estimates ranged from 61–78% at 12 months post-ART initiation. The 
highest results for infant testing uptake were obtained when a package of interventions was 
implemented. All these studies reported only on HIV infant testing outcomes and reported 
infant testing coverage above 70%. The major advantage of using of a combination of 
interventions is that it addresses simultaneously structural, biomedical, and behavioral barriers 
to MIP follow-up along the PMTCT continuum of care. Nevertheless, the remaining 30% of 
HEI who were not reached is substantial and demonstrates that follow-up of HIV-exposed 
infants during post-partum still remains a challenge in resource limited settings. These MIPs 
are probably those most vulnerable or hard to reach, experimenting frequent socio-economical 
barriers to access to care as previously mentioned, such as long distance, insufficient financial 
or social support, physiological and/or psychological changes related to the breastfeeding 
period.  The review also enabled to point out serious heterogeneity in definitions used to 
estimate program outcomes. We also highlighted the importance of combining retention with 
level of clinical attendance during women follow-up to provide a better representativeness of 
engagement along the continuum of care in PMTCT programs. Likewise, the ideal definition 
for infant testing is the one used by Finocchario-Kessler et al which estimated the proportion 
of HEI receiving complete EID services by 2 week or 18 months’ for HEI infant testing [121]. 
This definition allows to capture the important milestones an exposed-child should receive for 
correct PMTCT of HIV from enrolment after delivery to final HIV status determination, 
including initiation of co-trimoxazole prophylaxis and timely testing of HIV according to the 
national algorithm.  In the Mozambican context, the results of this literature review point out 2 
major findings. First, there is a need to explore the impact of a package of interventions to 
improve women retention in care specifically in the prenatal phase, focusing more on the most 
vulnerable and at risk women with low social-economical means and/or the most hard to reach. 
A package of intervention implemented at community level such as the PNCs or the combined 
package of adherence counselling, mHealth through text message reminders for clinic visits 
and stipends for food and transport could have the potential to improve women’s engagement 
in early ANC care [125,126]. For the postpartum phase, however, none of the package of 
interventions reviewed offered integrated family planning services which was found to be 
associated with the risk of attrition in our cohort analysis. Thus, further research will be needed 
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to evaluate in the specific context of Mozambique, the impact of a package of intervention 
including integrated family planning services on improving post-partum engagement in care. 
Second, the retention in care estimates from the first work are probably overestimating the 
levels of true engagement of pregnant women initiating ART in our cohorts. Thus, if we 
consider levels of timeliness and completeness of attendance at scheduled visits during the first 
year under ART, how would such heterogeneity of measurements metrics impact of 
programmatic interpretation of study outcomes? Are there any alternative definition that can be 
used to better capture level of engagement in follow-up care of women initiating ART under 
Option B+? These are the questions we tentatively responded to in the third work of this thesis.   
 
The third work has investigated the heterogeneity of definitions related to ‘retention in care’ 
for women enrolled under Option B+. It confirmed the findings of our systematic review 
highlighting the importance of combining appointment adherence with ART retention 
measurement to correctly evaluate levels of engagement in care, as using a ‘point retention’ 
definition most probably underestimates the true levels of  engagement in care of women on 
ART. Six different definitions of ‘retention in care’ were analysed and compared to the ‘point 
retention’ definition used in the second part of the thesis. The definitions ranged from the most 
lenient definition using a ‘point’ retention approach, where women were considered retained in 
care if they had a visit at 12-months post-ART initiation or later, to the most stringent definition 
of ‘on-time adherence’ retention which considered only those with a reported visit at 12-months 
post-ART initiation with at least 75% of scheduled visits done on-time during follow-up. The 
more stringent the definition, the lower was the probability for women to be defined as retained 
in care: 85% and 60% when using the WHO and MOH definitions compared to 16% and 1% 
when using the IATT and ‘on-time adherence’ retention definitions. By the end of the first year, 
many women initiating ART did not adhere to their scheduled visits: median appointment 
adherence was 66% and median on-time adherence was 40%. Based on these results, we 
recommend either using the IATT or the ‘appointment adherence’ retention definitions as 
alternatives to better measure levels of engagement in care for mother-infant pairs. These 
definitions should better capture visit consistency along the continuum of care, embracing the 
delicate period around delivery and the post-partum phase. Furthermore, the IATT definition 
can be modified and aligned to important milestones in the pregnancy/post-partum phases to 
better capture regular ANC and childhood immunization visits. The recent 2016 WHO 
guidelines on ANC recommend a minimum of eight contacts to reduce perinatal mortality and 
improve women’s experience of care [142]. Thus, for example, an alternative of the IATT 
definition would be “attendance at a health facility and on ART treatment at 10, 20, 26, 30, 34, 
36, 38 and 40 weeks of pregnancy, at delivery, and at 8 weeks, 3, 4, 9 and 18 months 
postpartum. Assuming that the woman either starts ART at first ANC visit or will already be 
on ART when she becomes pregnant (which the latter group is increasingly more frequent as 
observed on our first work).  
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6.2 Limitations and methodological challenges  
It was unfortunately not possible to measure maternal viral suppression and the full PMTCT 
cascade including vertical transmission due to unavailability of patient level VL test results in 
the database and absence of link between the clinical and laboratory HIS. In addition, although 
Mozambique national guidelines recommended a VL monitoring for HIV-infected 
pregnant/breastfeeding women under Option B+ at 3 and 12 months after ART initiation and 
annually thereon, very few patients actually received testing and had their test results entered 
in the ePLD: of the 31,186 ‘B+ pregnant’ women included, 23 (0.07%) had a result available 
in the database. 
No information on pregnancy outcomes or exposed infant related data were collected in the 
ePLD. Therefore, the paucity of post-partum information did not allow us to analyse these 
variables that could have influenced the interpretation of our results. The patient status (‘B+ 
pregnant’ vs. ‘own health’) can change over time due to multiple pregnancies; thus, our primary 
exposure variable could be considered as a time-varying variable. However, we considered the 
‘patient status” as a fixed variable for the following reasons: for the ‘B+ pregnant’ group the 
median number of reported pregnancies per woman was one pregnancy ([IQR: 1-3]), 42% 
(19,013/ 44,998) had missing information on actual date of birth and no information on duration 
of breastfeeding was collected. 
Although it was possible to distinguish between LTFU and death (if date of death was recorded 
in the patient file), we know that a significant proportion of deaths remain unreported in such 
limited resource settings where true outcomes of LTFU patients cannot be systematically 
ascertained [143]. For this reason, we chose to estimate factors associated with the combined 
event of LTFU and death (i.e. ‘non-retention’) after excluding patients transferred-out.  
Due to the nature of the paper-based registers and the lack of data triangulation between health 
facilities, if a woman attends more than one HIV or ANC clinic without providing voluntarily 
her HIV identification number, she will be considered as a new patient initiating ART. This 
often happens when she fears stigma and discrimination. As a mitigation action after merging 
KEY MESSAGES 
1) Between 2013 and 2017, we observed improved uptake of HIV testing (93% to 96%), improved ART 
coverage (42% to 95%) in ANC in Mozambique 
2) Improved 12 months retention in care for B+ pregnant women with an increase from 64% when ART was 
initiated in 2013 to 74% when ART was initiated in 2016 in Mozambique 
3) Overall attrition was unacceptably high with one out of four women being lost to care within the first three 
months of treatment in Mozambique 
4) A package of interventions has yielded better infant testing outcomes (>70% of HEI tested for HIV by 12-18 
months post-partum) compared to a single-based intervention under option B+ programs  
5) Importance of capturing attendance of scheduled visits during follow-up to better measure engagement in 
care along the PMTCT continuum. Proposed outcome definitions: ‘Attendance at a health facility and on 
treatment at 1, 2, 3, 6, 9 and 12 months post-ART initiation’ (IATT definition) or ‘attendance at a health facility 
at 12-months post-ART initiation and ³ 75% of appointment adherence to scheduled visits’ (‘appointment 
adherence’ definition) for maternal retention and ‘proportion of HEI receiving complete EID services by 2 
weeks or 18 months of age’ for HEI infant testing.  
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all 86 sites ePLD together, we searched for duplicate patients using the following data elements: 
sex, age (or date of birth), outcome status, date of outcome status, date of enrolment, last date 
of visit. If a duplicate was found, data was reviewed on a case by case basis and if applicable, 
merged into one single patient follow-up using the first HIV identification number attributed. 
This exercise is also routinely done at central level before quarterly reporting.  It is not possible 
to evaluate to what extent duplicate patients impact on study results. Nevertheless, we can 
assume that this proportion is similar in both patient groups. 
 
6.3 The PMTCT Option B+ care cascade: success and challenges  
Based on results from this thesis and available population-based surveys done in Mozambique, 
we have re-created a detailed PMTCT Option B+ cascade of care (Figure 6.1). Considering 
each step of the cascade, 93% of pregnant women have enrolled in the first ANC visit with high 
HIV testing uptake and ART initiation ³ 95% for those tested HIV-positive.  
However, numerous challenges remain. We observed that the first ANC visit is performed late 
in pregnancy, only at the beginning of the 3rd trimester and 14% of women dropped-out of care 
immediately after ART initiation, meaning they did not receive treatment. An estimated 55% 
of pregnant women complete their required four ANC visits and 73% of them delivery in the 
presence of a skilled birth attendant. There is a persistent low rate (74%) of retention in care 12 
months after ART initiation and only 40% of scheduled visits during follow-up are done on-
time. Finally, infant testing uptake remains low (52%) with an estimated MTCT rate of 15% in 
2018.  
The main successes of the program owed to the strong political will of the Mozambican 
government since 2011 to accelerate the response for elimination of MTCT through the 
development of a series of national policies; an accelerated expansion of PMTCT services at 
the health facility providing PMTCT services in MCH through a “one-stop model” and “test 
and treat” strategy. The integration of ANC and HIV services coupled with the task-shifting 
from clinicians to nurses of ART initiation, although programmatically challenging in the first 
years of program implementation has resulted in high uptake of HIV testing, improvement in 
ART coverage and a better acceptance of ART initiation in HIV-positive pregnant women over 
time.  
The challenges remain during follow-up of women and their HIV-exposed infants as shown in 
the cascade figure above. Lost-to follow-up occurs because of barriers such as low socio-
economical means that can be exacerbated during the post-partum period (i.e. depression, house 
chores or silent migration). In addition, weak health systems such as low supply and demand 
for early infant testing and poor health information systems are also contributing factors of the 
low performance of PMTCT Option B+ in the country. The heterogeneity of measurement 
metrics, without international consensus, makes it even more difficult to estimate correctly 
levels of engagement in care for pregnant women enrolled under ART. Finally, the follow-up 
across various MCH services is still the important missing component of an efficient HMIS to 
track correctly the MIP across the continuum of care.  Figure 6.2 summarizes the successes and 
challenges of PMTCT Option B+ in Mozambique.  
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Figure 6.1 : Summary of the PMTCT care cascade in Mozambique  
 
Note: figures for proportion receiving care are those from most recent data available; percentages presented are 
estimated percentages from the row above; EID testing coverage is calculated using the number of HIV+ pregnant 
women recorded in ANC during the period.   
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Figure 6.2 : Summary of the success and challenges of the PMTCT Option B+ program in Mozambique 
     
  
•HIV testing >90%
Restesting not implemented routinely; low partners' testing coverage : 48%
•ART coverage > 90%
35% of PW already on ART @ 1st ANC
Success
•Late access to ANC                                                                                                           
Median gestational age at ART initiation 25 weeks (IQR: 19–29 we) 
•Low retention & adherence to visits
Retention @ 12m: 74% ; median % of "on-time attendance": 40%
•Low supply and demand for EID testing:
National Lab coverage = 33% ; EID testing coverage @ 8 weeks: 52%
•Poor Health Information systems
Unknwon silent transfers; suboptimal measurement metrics; linkage of MIP across MCH 
services still missing; linkage lab results and patient data still missing
Challenges
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6.4 How far is Mozambique from virtual elimination of MTCT of HIV by 2030? 
Mozambique is still a stretch away from virtual elimination of vertical transmission of HIV 
(Table 6.1). Great efforts have been made, as discussed previously, but the Achilles’ Heel to 
achieving virtual eMTCT of HIV is the ‘leakage’ of women and infants during follow-up after 
ART is initiated in ANC with 3 major challenges directly linked to their engagement in care: 
1) sub-optimal retention of women after ART initiation, 2) low infant testing coverage and 3) 
a weak health information system to measure correctly PMTCT outcomes.  
 
Table 6.1 : Targets versus current situation in Mozambique in 2018: main indicators for validation of 
eMTCT of HIV 
WHO country validation criteria Target Mozambique achievement 
Number of cases of HIV per 100,000 live births < 50 cases NA 
Transmission rate in breastfeeding population < 5% 15% 
Access to ANC for pregnant women  >95% 93% 
Testing of HIV in pregnancy >95% 96% 
Treatment for pregnant women diagnosed with HIV >95% Receiving ART @ 1
st visit =95% 
Retained @ 12 m = 74% 
Note: ANC: antenatal care, NA: not available.  
Results for the indicator ‘Treatment for pregnant women diagnosed with HIV’ are the probability 
of retention as provided by the retrospective cohort analysis.  
 
6.5 The ‘last mile’ to achieve eMTCT in Mozambique  
As demonstrated through this work, engagement in care of the MIP is one of the major pillars 
to reach virtual eMTCT of HIV. There is no single risk factor that universally drives mother-
infant pair’s engagement in PMTCT care. Instead, the etiologies of disengagement are multi-
causal and multi-levels.  
Achieving the ‘last mile’ to reach eMTCT relies complementary strategies addressing 
simultaneously structural, biomedical, and behavioral barriers to the mother-infant pair care 
and treatment. These strategies combined would improve each step of the PMTCT cascade, 
sine qua none condition necessary to reduce the vertical transmission to less than 5%.  
In the spirit of the 2016 ‘Start Free, Stay Free, AIDS Free’ Super-Fast-Track framework, we 
address in this paragraph the feasibility of achieving virtual eMTCT in Mozambique by 2030 
proposing innovative strategies which have demonstrated effectiveness in improving the 
continuum of care in similar settings (Figure 6.3).    
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Figure 6.3: Innovative strategies to reach the ‘last mile’ for eMTCT in Mozambique   
 
 
 
 
 
 
 
Note: Testing strategies are also valid for breastfeeding women.   
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HIV diagnosis  
Significant numbers of women acquire HIV during pregnancy and while breastfeeding without 
being diagnosed. A meta-analysis of 19 studies showed that pregnancy and postpartum periods 
are times of persistent HIV risk, at rates similar to “high risk” cohorts[144]. MTCT risk was 
two to three times higher among women with incident versus chronic HIV infection in the 
postpartum period or in pregnancy and postpartum periods combined. In Mozambique, De 
Schacht et al. reported an estimated HIV incidence in postpartum women of 3.20/100 women-
years (95% CI: 2.30–4.46), with the highest rate among the 18- to 19- year-olds (4.92 per 100 
women-years; 95% CI: 2.65–9.15). In addition, of the new infections, 34% were identified 
during the first six months postpartum, 27% between 6 and 12 months and 39% between 12 
and 18 months postpartum[145]. 
In Mozambique, the first ANC visit occurs during the 3rd trimester, only 55% of pregnant 
women complete four ANC visits. In this context, a great number of HIV-negative pregnant 
and breastfeeding women are not being retested and may be unaware of the need to take 
additional precautions to avoid acquiring HIV. This represents missed opportunities to improve 
HIV testing coverage and is of major concern in a country with such high HIV disease burden. 
This highlights the increased risk of MTCT of HIV in pregnant women who are not engagement 
in care. The risk is particularly high for those newly infected due to the very high viremia 
associated with new HIV infection. The study from Mozambique reported a vertical 
transmission rate of 21% (95% CI: 5–36) among newly infected women[145].  Another study 
in Malawi presenting estimates of early MTCT of HIV in a nationally representative sample of 
HIV-exposed infants aged 4–12 weeks. The results showed higher risk of MTCT in women not 
on ART with an unknown HIV status during pregnancy compared to mothers on ART before 
pregnancy status was diagnosed (adjusted odds ratio 19.1, 95%CI:8.5–43.0)[140]. Furthermore, 
Mandelbrot L et al. showed that early access to PMTCT Option B+ services in ANC with rapid 
achievement of viral suppression reduces significantly the risk of vertical transmission: MTCT 
rate is 0.4% if ART is started in the first trimester, 0.9% if started in the 2nd trimester compared 
to 2.2% if started in the 3rd trimester. If the women is under ART at pre-conception, the MTCT 
rate drops to 0.2%[32]. Thus, in a country like Mozambique where fertility rate is high - 5.3 
children per woman, ANC coverage (at least 4 visits) if low - 49% and immunization coverage 
of children aged 12 to 23 months completely vaccinated  is sub-optimal at 65%, ART 
counselling for all HIV-positive women, and especially for those starting ART for their own 
health, should emphasize on the importance of engaging in regular PMTCT care and correctly 
adhering to ART throughout the pregnancy and breastfeeding period. 
The introduction of HIV self-testing has increased the uptake of testing among men, female sex 
workers, young adolescents  and first time testers in a variety of settings, including Malawi, 
Myanmar, the United Kingdom, and Zimbabwe[146–149]. Such intervention, especially in the 
community coupled with enhanced peer support and effective referral system through CHWs, 
could provide better access to HTC when access to health facility is  impractical[150]. HIV 
retesting with the option of self-testing should be a standard part of the basic package of services 
for antenatal and postnatal care in places that have a high prevalence of HIV and long distance 
to health facilities is a barrier to access to care. To best adapt this strategy in the Mozambique 
context, further formative research is needed to understand how best to implementation self-
testing at the community level for it to be acceptable and successful.  
Another HIV prevention strategy for women within sero-discordant couples is Pre-exposure 
prophylaxis (PrEP)[151]. Pregnancy is recognised as a period with increased HIV vulnerability.  
PrEP for pregnant and breastfeeding women taken daily reduces by 90% risk of transmission. 
Preventing HIV infection during pregnancy and breastfeeding has important implications for 
transmission to the child because women who seroconvert during pregnancy or breastfeeding 
are 18% and 27% likely to transmit the virus to their unborn child, respectively. Since 2016, 
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WHO recommends that women taking PrEP should continue taking PrEP at least during high-
risk period of pregnancy and breastfeeding[12,152]. In a country where the prevalence of sero-
discordant couples is 10%, PrEP could be an effective prevention strategy.  
Effective eMTCT requires quick detection of HIV infection in women and immediate initiation 
of ART to obtain rapid viral suppression. As reported above, pregnancy and postpartum periods 
are ‘high risk’ periods for acquiring the virus and vertical transmission can reach more than 
20%. A new emerging technology using Point-of-care recency tests (POC-RT), such as the 
Asante HIV-1 Rapid Recency Assay could be an innovative way for rapid detection of HIV 
incidence infection (< one year) in this group of ‘high risk’ women. The test combines HIV 
diagnosis and detection of recent HIV-1 infection in one testing device. It can be completed in 
20 minutes, making it a fast way to test individuals. The introduction of recency testing in 
routine HIV testing services was experienced in five countries in Central America by The 
Center for Disease Control and Prevention (CDC)[153,154]. It was shown to increase HIV case 
finding and linkage to services through index partner testing resulting in rapid response 
interventions. If used in MCH services, especially in ANC for partner case finding, recency 
testing can be advantageous in identifying populations, defined by behavior and/or geography, 
where current transmission is occurring. This could be further effective in high HIV burden 
locations where HIV testing yield in HTC services remain low.  
 
Retention in care of MIP 
A pooled analysis of the INSPIRE studies showed that scaling-up targeted interventions to 
improve retention would avert almost 3,000 infant infections annually in the 3 countries where 
the studies took place (i.e. Malawi, Nigeria, and Zimbabwe)[155]. Therefore, even the modest 
improvement of retention can translate into large numbers of infant infections averted. In 
Mozambique, under Option B+, women are immediately initiated on ART after HIV test 
results, under the ‘one-stop’ and ‘test and treat’ model. This has enabled to improve ART 
initiation reaching >95% of HIV-positive pregnant women on ART at first ANC visit. 
Therefore, ART initiation under Option B+ strategy may no longer be an issue but rather 
maintaining these women on ART through pregnancy, delivery and end of breastfeeding (which 
can be as long as two years post-partum) remains the principal public health challenge.    
Considering expansion of the ‘Test and Treat all’ policy, the substantial increase in the number 
of HIV-infected pregnant women already on ART and enrolled in ANC is observed; of these a 
proportion will be stable and virally suppressed. Additionally, the increased volume of PLHIV 
attending health services has put further strain on the already weak health system of the country: 
Mozambique has low levels of human resources for health with only 8 doctors and 27 nurses 
per 100,000 people. Consequences observed at health facility level has been long waiting hours, 
poor clinical attendance with suboptimal counselling. Factors all contributing to disengagement 
from care for the mother-infant pair.  
In the second work of this thesis, no single based intervention seems to improve ART retention 
for pregnant and breastfeeding women. The four studies which combined a package of 
interventions seemed to yield better infant testing outcomes than single-based interventions. Of 
particular interest are three studies which yielded the highest infant testing uptake: one used a 
differentiated model of care to provide integrated health care in the post-partum period and two 
others included mHealth interventions either to facilitate communication or provide reminders 
for clinical visits. Unfortunately, none of these studies have reported on women retention.  
Nevertheless, differentiated models of care is a promising solution especially for high volume 
sites[156]. The advantages are numerous: reduce burden on the health system and on the patient 
while ensuring a tailored client-centered service approach. In addition, less frequent visits can 
increase the likelihood of retention and can improve clinical outcomes[114,156,157]. The 
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model can vary from one setting to another, but in general patients receive multi-month drug 
prescriptions (i.e. 3 to 6 months) and enhanced community-based support by lay counsellors or 
peer educators. In the post-partum period, a package of combined services for both the mother 
and infant until the end of breastfeeding can also be delivered. WHO recommends that HIV-
positive pregnant and breastfeeding women stable on ART for at least 12 months with evidence 
of viral suppression should be eligible to receive such services as they have a very low risk of 
HIV transmission[32]. Such models have been tested in women enrolled in PMTCT Option B+ 
programs in South Africa and show promising results[125,158].  
This type of innovative service delivery models providing a MIP-tailored approach with 
integrate service delivery for both the mother and her newborn using a multipronged package 
of interventions to improve PMTCT outcomes can be adapted to the Mozambican context and 
can yield better levels of engagement in care. The objective being to improve retention in care 
while aligning to important women and child health care milestones, including rapid (or 
maintenance of) HIV VL suppression, regular attendance to ANC/post-partum visits, complete 
vaccination coverage, and infant HIV testing uptake.  For example, a package of intervention 
similar to the PNCs model from South Africa can be adapted [125]. The difference is that the 
package should be started at enrolment into PMTCT during pre-natal care and would offer: 
integrated MCH services included one-stop shops, clinical visit at every session by an 
experienced nurse (ART, MCH), pre-packed medicine, VL testing, integrated family planning 
services, and Pap smear for mothers, and HIV testing, growth monitoring, feeding support, and 
immunizations and IMCI for children. Peer support groups would also be offered in this 
package and tailored to the pre-/post-partum stage in which the women is. However, in this new 
model of care from South Africa, multi-months ART dispensing is proposed coupled with 
community-based distribution of ART, adherence clubs and longer intervals between clinical 
visits[159]. But, no data yet is available to help define which criteria to use for defining a ‘stable 
HEI’. Further research is thus warranted to better identify which infant can be safety enrolled 
and followed-up under such a strategy.    
For better child service integration, MIP clinical visits should be aligned with standard post-
natal care including immunization calendar, child nutritional assessments and timely infant 
testing. With an integrated service approach, infant testing can be offered to young children 
who present with illnesses using a specific screening tool for EID testing at EPI services, 
malnutrition services, in-patient ward or tuberculosis treatment sites[160,161]. However, a 
qualitative study in Tanzania that had explored the feasibility of integrating pediatric HIV 
prevention services with routine infant immunization visits revealed that perceived mandatory 
HIV testing, lack of confidentiality during testing and fear of stigma and discrimination were 
raised as a concern[162]. In a similar setting such as Mozambique, the success of such 
integrated services at health facility or community levels can be achieved only if confidentially 
of patients is guaranteed.    
A new challenge is posed by the introduction of DTG-based ART regimen recommended in 
2016 by WHO, particularly in pregnant and breastfeeding women. At the time of the publication 
of the first recommendations, the biological mechanisms that underlied between this new 
regimen and adverse outcomes in pregnancy and birth were not completely understood. An 
important potential safety concern was reported suggesting that DTG may be associated with 
an increased risk of neural tube defects among infants born to women receiving the drug during 
the periconception period in the TSEPAMO study in Botswana [21,163]. Thus, a note of caution 
was published in December 2018 for using DTG in women and adolescent girls of childbearing 
potential [13]: “Adolescent girls and women of childbearing potential who do not currently 
want to become pregnant can receive DTG together with consistent and reliable contraception”. 
In 2018, Mozambique has adopted the new WHO recommended DTG-based ART regimen and 
introduced it in a phased manner. Although, pregnant and breastfeeding women are not yet 
switched to the new regimen until further WHO guidance, an increased number of HIV-infected 
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women of childbearing age will already be on DTG-based regimen while becoming pregnant. 
Since then, a number of clinical trials, observational cohort studies, systematic reviews and 
drug safety monitoring data from Brazil, Botswana and northern countries have been published 
providing further insight into the association between DTG-based regimen and adverse birth 
outcomes. For example, data from the Antiretroviral Pregnancy Registry (APR) with most 
reports coming from North America and Europe, described central nervous system (CNS) 
defects and NTD in infants born to women receiving DTG as an integrase strand transfer 
inhibitor (InSTI). The authors reported a NTD prevalence of 0.40% (1 case in 248 births) for 
periconception DTG-based ART regimen [164]. Another clinical trial from Uganda and South 
Africa, the DOLPHIN-2 study, evaluated viral suppression at delivery in pregnant women 
initiating ART from 28 weeks gestation to DTG vs EFV plus 2 NRTIs [165]. The authors 
reported that DTG was well-tolerated and achieved more rapid virological suppression before 
delivery compared to EFV. Of 270 live births, congenital anomalies were reported in 17 infants 
(8 with DTG vs. 9 with EFV) up to 6 weeks of age; no NTDs were observed. Finally, additional 
data from the TSEPAMO study reported 5/1,683 NTDs among births to women receiving DTG 
at conception, bringing down the prevalence rate from 0.94% to 0.3% but still with a slight 
significative prevalence difference of 0.20% (95% CI: 0.01-0.59) compared to non-DTG based 
regimens [27]. Overall, NTD prevalence has decreased with increased exposure numbers, but 
it remains significantly higher than all other exposure groups. The NTD risk is thus not zero in 
the absence of drug but this risk is still relatively small. More recently, increased weight gain 
has been reported in patient receiving DTG-based regimens compared to those on NNRTI-
based regimens[166,167]. For example, two major large efficacy trials of DTG conducted in 
Africa, the ADVANCE trial [168] and the New Antiretroviral and Monitoring Strategies in 
HIV-Infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 trial [169] have 
demonstrated that DTG-based ART was noninferior to EFV-based treatment. However, in the 
ADVANCE trial, dolutegravir was unequivocally associated with excessive weight gain, 
particularly with TAF–emtricitabine. Patients treated with this regimen gained a mean of 6 kg 
with no leveling off at 48 weeks; 14% became newly obese. Similarly, in the NAMSAL trial, 
the incidence of obesity at 48 weeks was 12.3% in the DTG group, as compared with 5.4% in 
the EFV group.  Based on these new findings, WHO now recommends DTG-based ART for all 
and this recommendation includes women of reproductive potential [170]. Knowing drug side 
effects, such as weight gain, and adverse birth outcomes are factors of LTFU in PMTCT 
programs, this will require a more active pharmacovigilance monitoring of adverse outcomes 
and assessment of safety of such drugs for the mothers and their exposed children [171].  
 
Maternal viral load suppression 
Recent evidence suggests that VL testing should be undertaken more frequently during 
pregnancy and breastfeeding, with the goal of achieving suppression before delivery and 
maintaining suppression during breastfeeding. Proposed interventions include VL testing four 
weeks prior to delivery to set the stage for postpartum interventions in the event of high 
maternal VL, including targeted birth testing and enhanced ARV birth prophylaxis[12,172]. 
With low laboratory coverage, particularly in rural primary health care settings, an alternative 
option would be the use of Point-of-Care (POC) VL testing to monitor viral suppression. HIV-
positive women could be tested at the clinical visit and receive same-day results [173–176]. 
POC devices for virologic testing machines are likely to be too expensive to be placed at all 
primary care facilities. However, they would have the potential to greatly increase access to 
virologic testing by at least two approaches. Either they could be placed at intermediate level 
facilities (i.e. district “hubs”) so that patients could periodically be referred to those centers for 
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testing, or mobile labs could periodically be scheduled to visit primary health centers to offer 
such testing to eligible patients7.  
 
Improving HIV-pre-exposure prophylaxis for infant  
Using Nevirapine as a single-agent for PrEP in HIV-exposed uninfected infants has been 
demonstrated to significantly decrease HIV transmission through breastfeeding during the first 
6 months of life [177]. In 2016, Nagot et al. demonstrated in 4 sub-Saharan Africa settings that 
the use of lopinavir–ritonavir and lamivudine as an extended PrEP strategy through 
breastfeeding in HEI up to 50 weeks was safe and led to very low rates of HIV-1 postnatal 
MTCT of 1.4% and 1.5%, respectively [178]. Based on these findings, there is a potential to 
further extend infant ARV prophylaxis throughout breastfeeding exposure to reduce risk of 
HIV transmission and make breastfeeding safe [179]. In the context of Mozambique where we 
have highlighted that a substantial proportion of pregnant and breastfeeding women access late 
MCH services, or for whom HIV infection is diagnosed postnatally, maternal ART alone in 
such cases would be sub-optimal to prevent breastfeeding transmission [180]. Thus, longer 
course of infant PrEP throughout the breastfeeding period in this case should be evaluated for 
safety and efficacy as this strategy could be a potential intervention to help reach virtual 
elimination of HIV in the country [181]. 
 
Infant HIV testing  
Early infant diagnosis of HIV is one of the biggest challenges in PMTCT programs in 
Mozambique. On the demand side, programmatic data from 2018 shows only 91,776 HEI of 
the estimated 116,371 HIV+ pregnant women were enrolled in the at risk child clinic, and 
71,754 (78%) of them had a sample collected for PCR analysis within 8 weeks of age which 
represent an estimated population based coverage of 62%[94]. On the supply side, EID has 
been gradually expanded and by the end of 2018 was available in 1,401 health facilities (92% 
of PMTCT facilities with Option B+). However, national coverage of laboratories processing 
EID remains low: 135 of 400 laboratories in the country process VL/EID testing by end of 
2018. The long delay in returning test results often causes loss-to-follow-up of the MIP.  
In addition to low EID supply and demand challenges, children who acquire HIV in utero have 
increased risk of rapid disease progression and higher mortality rates than children who acquire 
HIV through breastfeeding, highlighting the need to provide treatment as early as possible after 
diagnosis confirmation[182]. Diagnosis at birth has shown to improve infant outcomes. South 
Africa is among the countries now conducting testing at birth and once the infant reaches 10 
weeks[183]. In a setting such as Mozambique where EID coverage is poor, at-birth testing could 
be a good option to reduce the HEI who are lost to care before 8 weeks of age. 
Similar to VL testing for HIV-positive pregnant women, increase in access to point-of-care 
technologies for EID (POC EID) would make a massive difference; increasing both rapid 
diagnosis of infants living with HIV and improve timely pediatric treatment initiation in a cost-
effective way. Jani et al. reported in 2017 testing outcomes of POC EID compared to the 
standard of care (SOC) using conventional laboratory testing in Mozambique[184]. In the SOC 
arm, the median turnaround time for conventional EID was 125 days whereas all results for 
infants tested by POC diagnostic were available at the health facility. Of the POC results, 99.5% 
were provided to the infant’s caregiver, compared to 65% of the SOC test results. In a UNITAID 
 
7 Since 2016 the MOH (MISAU) has been rolling out POC EID testing and training DPSs and health facilities 
workers to perform the test in Maputo Province, Gaza, and Sofala. Currently, approximately 5% of PMTCT health 
facilities are offering POC EID. 
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supported project, the routine use of POC EID in sub-Saharan African countries improved 
significantly the proportion of results with a turn-around time of less than 60 days compared to 
conventional testing methods (99.5% versus 11.8%). All results using POC EID were returned 
to the caregiver on the same day as the test was performed, compared to a median of 122 days 
with conventional methods; and 87% of HIV-positive children were initiated on ART within 
60 days compared to 13% using conventional testing methods[185]. The strategy has the 
potential to identify and fast-track ART initiation in infants especially in pediatric in-patient 
ward, malnutrition or tuberculosis services where HIV testing yield in children are the highest. 
As mentioned above, the success of such intervention can only be achieved if confidentially of 
settings are guaranteed to maintain patient privacy. 
While waiting for larger scale us of POC EID, another approach to enhance transportation of 
EID samples for conventional laboratory diagnostic is to use health facility ‘HUBs’. Based on 
a geographical mapping of health facility networks using Geographical Information System 
(GIS) and of quality of road access, regional referral hospitals, district hospitals and other health 
facilities are identified as sample transport ‘HUBs’ to receive samples and results at the sub 
district level. The ‘HUB’ model has been tested in Uganda and significantly improved referral 
network drastically reducing transportation costs by 62% and reducing turn-around times by 
46.9%[186]. This low-cost health system strengthening initiative could critically improve 
quality of laboratory and diagnostic services in Mozambique.  
Finally, a recent innovative strategy to enhance healthcare delivery is the use of drones for 
sample transportation or delivery of medicine to health care workers or patients. Drones are 
pilotless aircrafts that were initially used exclusively by the military but are now also used for 
various scientific purposes including healthcare service delivery. Their technical capabilities 
and ease of use can benefit access to health services in remote rural areas with difficult road 
access which otherwise would be impossible to reach in a timely manner[187]. In the context 
of PMTCT health care services, drone-aided delivery and pickup of blood samples have the 
potential to reduce transportation and the turn-around time for early infant testing. In Malawi, 
a private company partnered with UNICEF to pilot the transport of EID samples from a remote 
clinic to a central laboratory in the capital Lilongwe. The test flight showed promising results 
leading to a larger scale project with a cost comparison with road transport[188]. 
  
Passive or active immunization 
Finally, we have talked about virtual elimination of MTCT of HIV. Although efforts are crucial 
for Mozambique and other resources limited countries to attain UNAIDS’ ‘Global Plan’ targets, 
we should strive towards the complete elimination of MTCT of HIV, which will in turn 
accelerate towards the ultimate goal of an AIDS-free generation by 2030. Efforts to improve 
engagement in care of the mother/infant pair along the PMTCT continuum, addressing the gaps 
we have discussed, is the first step. Complete elimination through this mode of transmission 
will require additional measures[189,190]. Passive or active immunization of the mother and/or 
infant may enable to eradicate this form of transmission[191,192]. Few studies have analysed 
the combined strategies of ART with immunotherapy and showed promising results[193,194]. 
For example, the passive administration of broadly neutralizing antibodies (bNabs) to HIV-1-
exposed infants has the potential to further (and fully?) protect from postnatal HIV-1 
transmission[194]. Further research combining current preventive packages with vaccination 
or passive immunization is warranted to identify potentially efficacious interventions to help 
achieve the goal of a generation free of HIV by 2030.  
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Strengthen the Health Information System (HIS) for better data reporting  
PMTCT Option B+, compared to ART in the general adult population and to previous PMTCT 
Options A and B, have the unique particularity of intersecting two cascades: one for the 
prevention of HIV infection in children and another for the life-long care and treatment of 
mothers[61]. The HIS in resource poor settings such as Mozambique has thus an additional 
challenge to improve collection of accurate data on the continuum of care across service 
delivery sites with strong linkages of the mother–infant pair, especially to measure important 
impact indicators such as HIV incidence in pregnant and lactating women who were initially 
HIV negative, viral suppression in HIV-positive women and MTCT of HIV.   
In Mozambique, challenges persist to maintain a robust HIS system to track the mother-infant 
pair which also needs to mirror the more and more frequent changes in WHO and national 
PMTCT and HIV treatment guidelines. PMTCT interventions are provided through various 
service delivery points. Currently, the paper-based HIS at health facility limits the ability to 
analyse MIP outcomes using a longitudinal cohort approach. This can be easily done using an 
electronic patient-level database, as demonstrated in the second part of this thesis. However, 
patient-level retention in care is only monitored by partners who have ePLD allowing 
measuring this indicator with an estimated coverage of 80% of all PLHIV in treatment in the 
country. But even so, in the absence of means to track the MIP across various entry points of 
the health sector, which is currently the case, gaps in capturing the full follow-up picture will 
still remain. The use of an electronic medical record compiling longitudinal follow-up data 
coupled with a unique national health identifier code would facilitate tracking mother–baby 
pairs throughout the health care sector from pregnancy trough delivery and breastfeeding (both 
at community and facility levels)[195–199]. This follow-up should be done until at least two 
years post-delivery to measure final MCH outcomes and eMTCT criteria.  
As mentioned previously, the current lack of linkage between the laboratory HIS and clinical 
information does not allow to estimate maternal viral load suppression and MTCT rates. 
Transfer of automated laboratory data from the laboratory HIS into a database format that 
enables linkage to clinical and pharmacy data would enable for example to rapidly assess the 
viral load response to antiretroviral therapy, to investigate interference between laboratory tests 
and drugs, to study the risk of adverse drug reactions, and to take immediate action for treatment 
failure[200,201]. It would also enable to link infant testing results to the mother’s profile for 
MTCT transmission outcomes. Linkage should ideally be real-time using clinical, pharmacy 
and laboratory databases linked through the unique national health identifier code. This would 
require multiple software applications at different entry points across the health sector, all 
interoperating together. OpenMRS, the official national patient-level open-source platform 
since 2016 has the potential for interoperability with other open-source platforms such as 
OpenELIS (Laboratory Information System) and OpenLMIS (Logistics Management 
Information System)[202]. Developing such a framework for interoperability of health 
information systems could significantly improve PMTCT program monitoring.  
Global efforts have been made to have a common and harmonised M&E framework for 
monitoring progress for PMTCT programs with more emphasis on monitoring the impact of 
ART on MTCT and measuring the retention of pregnant women initiating ART and of mother-
infant pairs[203]. However, the lack of consensus and absence of alignment of definitions make 
comparison of PMTCT outcomes difficult across countries and settings[204–206]. National and 
international stakeholders and researchers need to commit to more standardised reporting 
methodologies to allow international comparisons of PMTCT indicators. Based on the results 
of this thesis and the importance of engagement in care of the MIP, we recommend using  
‘attendance at a health facility and on treatment at 1, 2, 3, 6, 9 and 12 months post-ART 
initiation’ (IATT definition)  (or its alternative definition as suggested in chapter ‘6.1  Work 
synthesis’) or ‘attendance at a health facility at 12-months post-ART initiation and ³75% of 
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appointment adherence to scheduled visits’ (‘appointment adherence’ definition) to define 
maternal retention and ‘proportion of HEI receiving complete EID services by 2 week or 18 
months’ for HEI infant testing. 
 
Reduce unintended incidence pregnancy 
In this work, we have focused on women already infected by HIV. However, family planning 
remains a core pillar of the four-pronged approach to comprehensive programming to prevent 
MTCT[207]. We have seen that in Mozambique, women are the most vulnerable population 
with nearly a quarter of new HIV infections occurring among young women aged 15–24 
years[1]. In addition, women's experiences and decisions regarding pregnancy are more 
influenced by social and cultural norms than medical advice[208]. Therefore, unmet needs in 
family planning remain high. In the 2015 IMASIDA survey, 49.6% of married women aged 
15-49 years reported having unmet need for modern methods of family planning and only 27% 
of them used any form of contraception[79]. Studies have found that pregnant adolescents and 
young women living with HIV were much less likely than their older peers to start ARV 
prophylaxis, and there is evidence that they also have poorer outcomes along the cascade of 
PMTCT services[209].  
In addition, the results of our first work highlighted the need for better integrated family 
planning services as in the absence of such services, the risk of attrition was significantly higher. 
In July 2019, following the new ART guidance for use of DTG-based regimen for all HIV-
positive patients including women of childbearing age, WHO released a specific tool for “HIV 
treatment and contraceptive services integration implementation” [210]. This tool provides 
guidance to ensure access to integrated, rights-based, client-centred, high-quality contraceptive 
care for women and adolescent girls living with HIV and receiving ART across the life-course 
in HIV treatment programmes.  
Thus, efforts to reduce the risk of MTCT by reducing the number of reproductive-age women 
acquiring the virus is a major HIV prevention strategy, especially for adolescent young women. 
To reach an AIDS free generation in Mozambique, both incidence of infection in women of 
childbearing age and unmet family planning needs should be reduced. Providing appropriate 
counselling, support and contraceptives to women to meet their family planning goals and 
spacing of pregnancies will optimise their health outcomes and reduce the number of infants 
exposed to or infected with HIV. 
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7 Conclusion 
This work has provided a comprehensive view of the level of engagement in care under the 
PMTCT Option B+ strategy from ANC enrolment of HIV-positive pregnant woman to final 
HIV testing of the exposed infant. Highlights of the gaps in optimal engagement care of the 
mother-infant pair and its consequences on achieving virtual elimination of MTCT of HIV have 
been discussed. To reach eMTCT, Mozambique’s government need to focus efforts to reinforce 
engagement in care of MIPs during follow-up, especially in the first 3 months after ART 
initiation in pregnancy.  
We highlighted the exponential benefit of a multipronged approach to provide a package of 
interventions to improve each step of the PMTCT cascade. Nevertheless, the cost-effectiveness 
and sustainability of such interventions should be considered by both the national HIV program 
and the international stakeholders for programmatic decision making and policy change.  
We also emphasized the importance for the international community to have a consensus 
approach for PMTCT programme outcomes measurement to allow national and international 
comparisons. If adherence to schedule visits is not considered, measurement of retention and 
infant testing will fail to accurately estimate program success. 
Engagement across the continuum of PMTCT care is dynamic and impacts individual and 
population-level outcomes. Efforts to retain women under lifelong ART, ensuring their HIV-
exposed infants receive the expected PMTCT services at the right moments along the 
continuum until final HIV status is determined, is the cornerstone of achieving an AIDS-free 
generation by 2030 in Mozambique.  
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8 Place of the PhD work in my personal scientific career 
This 4-year PhD work has enabled me to combine the application of rigorous epidemiological 
and biostatistical methods with the knowledge and built-up experience of my 16+ years of 
career working as a medical epidemiologist in resource-limited settings in sub-Saharan Africa. 
My professional interest is further confirmed in the use of quality data to produce evidence-
based results to help identify programmatic challenges and propose practical solutions. 
Focusing on infectious disease epidemiology, reproductive health and mother and child health 
has been and will always be my personal motivation. Thus, I will continue working as a public 
health professional, committed to high quality international development projects to improve 
human health and the well-being of the most vulnerable populations in world. 
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Titre : Prévention de la transmission du VIH de la mère à l'enfant au Mozambique: 
engagement dans les soins et défis programmatiques de la stratégie B+  
 
Introduction 
En 2015, l’Organisation Mondiale de la Santé a mis en œuvre des nouvelles lignes directrices 
sur la prévention de la transmission de la mère à l'enfant (PTME) du VIH. Appelée « Option 
B+ », cette stratégie recommande que toutes les femmes enceintes et allaitantes séropositives 
initient le traitement antirétroviral (TARV) et le continuent à vie. Cependant, à la lumière des 
défis programmatiques de sa mise en œuvre, de plus en plus d'inquiétudes se font jour quant à 
l'efficacité de cette stratégie pour réduire réellement la transmission verticale du VIH. On 
observe en particulier des niveaux sous-optimaux d’engagement et de suivi dans les soins chez 
le couple mère-enfant en Afrique sub-Saharienne.  
L'engagement dans les soins du VIH fait référence à un patient pleinement impliqué dans un 
processus de soins réguliers dynamique tout au long du continuum de soins du VIH avec 
l'objectif final de parvenir à la suppression virale permanente (1). Par conséquent, l'engagement 
dans les soins, trop souvent confondu avec la « rétention dans les soins », est vital pour les 
personnes vivant avec le VIH (PVVIH).  
Concernant en particulier les programmes de PTME, l'engagement dans les soins implique que 
la femme séropositive et son bébé soient considérés comme étant une seule et même entité ; les 
avantages potentiels du TARV peuvent être par conséquent  améliorés en réduisant le risque 
d'infection VIH de la mère à l’enfant. En outre, pour atteindre l’élimination virtuelle de la 
transmission mère-enfant (eTME), au moins 95% des femmes enceintes devraient bénéficier 
des soins de PTME. Dans ce contexte, l'engagement précoce et continu dans les soins de la 
période prénatale pour la mère jusqu’à 18 mois après la naissance pour le couple mère-enfant 
est essentiel pour les différentes étapes de la PTME tels que le contrôle rapide de la charge 
virale de la mère avant l'accouchement, le test de dépistage précoce de l’enfant à l'âge de 6-8 
semaines et le test définitif du VIH à 12-18 mois (2,3).  
Ainsi, le désengagement des soins de PTME a le même effet néfaste sur la suppression de la 
charge virale, que celui pour le traitement universel des femmes séropositives, mais à cela, 
s’ajoute en plus le risque d’échec de l’élimination de la TME du VIH. Dans un pays aux 
ressources limitées tel que le Mozambique, des interventions visant à améliorer l'engagement 
dans les soins des femmes inscrites dans les programmes de PTME dès le stade précoce de la 
grossesse est d’une importance primordiale si l’on veut que la stratégie Option B+ puisse 
permettre d'atteindre l'objectif de santé publique consistant à réduire le taux de TME à moins 
de 5% (4). 
 
Objectifs 
La thèse vise à mettre en évidence, du point de vue santé publique, les défis programmatiques 
relatifs à l'engagement dans les soins de la stratégie Option B+ en Afrique subsaharienne en 
utilisant l'exemple du Mozambique, un pays connu pour avoir l'une des prévalences du VIH les 
plus élevées au monde. Pour évaluer le niveau d'engagement dans les soins du couple 
mère/enfant, ces travaux ont porté sur trois aspects programmatiques de la stratégie Option B+: 
les résultats du programme de PTME avec un accent particulier sur la rétention maternelle sous 
TARV et le recours au dépistage du VIH chez l’enfant exposé, les interventions visant à 
améliorer les résultats de ces programmes et les méthodes de mesure de la rétention dans les 
soins et leur éventuels impacts programmatiques. 
Les objectifs spécifiques de la thèse sont les suivants: 
1. Quantifier le risque d'attrition associé à la raison de l'initiation du TARV (initiation 
de l’Option B+ dans la cadre de la PTME versus initiation pour la propre santé de 
la femme séropositive) au Mozambique ; 
2. Décrire les interventions visant à améliorer les résultats du programme PTME B+ 
avec un accent particulier sur la rétention sous TARV de la mère et le recours au test 
de dépistage du VIH chez l’enfant ; 
3. Évaluer l’impact des diverses définitions de « rétention dans les soins » sur 
l’interprétation des résultats programmatiques de la stratégie Option B+. 
 
Méthodes 
Pour répondre au premier objectif, une analyse empirique des données de routine des quatre 
premières années (2013-2017) de mise en œuvre du programme PTME Option B+ au 
Mozambique a été réalisée pour analyser les tendances annuelles des résultats 
programmatiques. Cette étude s'est focalisée sur la cascade des soins prénatals des femmes 
enceintes séropositives et sur leur rétention dans les soins à 12 mois après le début du TARV. 
Pour répondre au deuxième objectif, une revue systématique de la littérature axée sur les 
interventions visant à améliorer la rétention maternelle sous TARV et le dépistage du VIH pour 
les enfants exposés a été réalisée. Cette revue systématique vise à synthétiser les différents types 
d’interventions évaluées et à discuter de l’hétérogénéité des paramètres de mesure utilisés pour 
définir à la fois la rétention sous TARV et le recours aux tests de dépistage pour les enfants 
exposés ainsi que leur impact sur les résultats d’interventions. 
Pour répondre au troisième objectif, une analyse comparative utilisant six définitions 
différentes de « rétention dans les soins » a été réalisée pour mettre en évidence la variabilité 
des paramètres de mesure et discuter de leur impact sur l'estimation du niveau d’engagement 
dans les soins des femmes séropositives sous l'Option B+ au Mozambique. 
 
Résultats 
Manuscrit 1: « Cascade de soins de PTME et facteurs liés à l'attrition dans les quatre 
premières années suivant la mise en œuvre de l'Option B+ au Mozambique »  
Objectif: Évaluer l'efficacité du programme de PTME Option B+ dans deux provinces du 
Mozambique à charge de morbidité élevée du VIH durant les quatre premières années de mise 
en œuvre du programme. 
Méthodes: Nous avons évalué la cascade de la PTME dans les soins prénatals de juillet 2013 à 
décembre 2017 en utilisant des données agrégées des centres de santé et effectué une analyse 
de cohorte rétrospective avec des données individuelles des patientes. Nous avons comparé les 
taux de rétention après 12 mois de TARV entre les femmes séropositives ayant débuté un 
traitement dans le cadre de l’Option B+ (« enceintes B+ ») et les femmes non enceintes et non 
allaitantes ayant initié un traitement pour leur propre santé (« propre santé »). 
Résultats: Un total de 916 280 femmes enceintes ont été inscrites en consultation prénatale 
(CPN). La proportion de femmes ayant un statut VIH documenté est passée de 93% en 2013 à 
96% en 2017. La proportion de séropositivité a diminué de 8% à 6%, tandis que celle des 
femmes séropositives sous TARV passait de 42% à 95%. Parmi les 44 377 femmes 
séropositives ayant initié le TARV et incluses dans l'analyse de cohorte rétrospective, 35% ont 
été perdues de vue. Les femmes « enceintes B+ » débutant le TARV en 2015 étaient plus 
susceptibles de faire l'objet d'un suivi comparé aux femmes ayant commencé un traitement 
antirétroviral pour leur « propre santé » au cours de la même année (rapport de cotes ajusté: 
0,77, intervalle de confiance à 95% [IC95%]: 0,64 -0,94, p = 0,01). Il n'y avait pas de différence 
statistique significative entre les deux groupes au cours des autres années durant lesquelles le 
TARV avait été initié. Parmi les patientes qui ont initié le TARV en 2013 et qui sont revenues 
pour une visite de suivi après leur première visite (N=39 801), les femmes « enceintes B+ » 
présentaient un risque plus élevé de non-rétention que l'autre groupe (ratio de risque ajusté: 
1,14, IC95%: 1,03-1,25). Ce risque diminue au cours des années suivantes avec aucune 
différence observée entre les groupes. 
Conclusion: L’expansion du programme PTME Option B+ a donné des résultats positifs, 
notamment l’atteinte de taux élevés de dépistage du VIH et d’initiation du TARV dans les soins 
prénatals. Cependant, il reste encore des difficultés pour l’amélioration de l’engagement 
immédiat dans les soins et la rétention à long terme. La recherche de modèles alternatifs de 
prestation de services afin d’alléger les systèmes de soins existants et prévenir les perdues de 
vue est essentielle si l’on veut atteindre les objectifs 95-95-95 de PTME de l’ONUSIDA au 
Mozambique. 
 
Manuscrit 2: «Interventions visant à améliorer les résultats des programmes de 
prévention de la transmission du VIH de la mère à l’enfant dans le cadre de la stratégie 
Option B+: une revue systématique» 
Objectif: Examiner systématiquement les interventions visant à améliorer la rétention 
maternelle et le recours au dépistage de l’enfant dans les programmes de PTME Option B+. 
Méthodes: Les bases de données électroniques et la littérature grise ont été consultées pour 
identifier les études publiées entre janvier 2010 et décembre 2018. Les résultats évalués étaient 
la rétention maternelle à 6, 12 et 24 mois depuis le début du TARV, le recours au diagnostic 
précoce infantile chez le nourrisson (âgé de 4 à 8 semaines) et le recours au test VIH rapide 
chez l’enfant (âgé de 12 à 18 mois). Les résultats ont été résumés en fonction du type 
d'intervention. 
Résultats: 14 études ont été incluses. Quatre études ont rapporté des résultats relatifs à la 
rétention maternelle par le biais du soutien par des pairs, du déploiement d'agents de santé 
communautaires et par l’utilisation de tests CD4 au point de prestation de service. Ces 
interventions ont donné des taux de rétention de 74–79%, 61–78% et 70–74% à 6, 12 et 24 mois 
après l’initiation du TARV, respectivement. Les taux n'étaient pas significativement différents 
de ceux rapportés dans un contexte de soins standard (sans intervention). Douze études ont 
rapporté les résultats liés à l'utilisation de tests de dépistage infantile par le biais du soutien des 
pairs, de la sensibilisation promulguée par les agents de santé communautaire, d’envoi de SMS, 
de stratégies pour améliorer les services de santé donnés par le personnel de santé ou par le 
biais d'un ensemble d'interventions combinées. Les proportions d’enfants exposés au VIH testés 
étaient respectivement de 49 - 94% à l’âge 6-8 semaines et de 68 - 95% à l’âge 12 -18 mois. 
Un taux élevé de recours aux tests de dépistage infantile a été observé lorsque les interventions 
étaient combinées (> 94% des enfants exposés). Une hétérogénéité élevée des résultats a été 
observée, principalement en raison de la variabilité importante des définitions utilisées. Les 
résultats rapportés étaient probablement surestimés car mesurés sans tenir compte du niveau 
d’engagement dans les soins de la mère tout au long de son suivi. 
Conclusions: Un ensemble d'interventions combinées pourrait effectivement éliminer 
différents obstacles à l'engagement maternel. Les définitions doivent être normalisées afin de 
réduire l'hétérogénéité existante entre les études et de permettre une comparabilité correcte des 
résultats dans le but de formuler des orientations politiques et programmatiques claires. Les 
indicateurs doivent être basés sur la qualité et le processus de prestations de services afin de 
permettre une évaluation précise du niveau d'engagement de la mère et de son enfant tout au 
long du suivi dans les programmes PTME. 
 
 
 
Manuscrit 3: «Mesurer la rétention dans les soins pour les femmes enceintes séropositives 
dans le cadre des programmes PTME Option B+: l'expérience du Mozambique» 
Contexte: L'échec de la rétention dans les soins des femmes enceintes séropositives pour le 
VIH sous TARV entraîne une mortalité accrue pour la mère et son enfant. Cette étude a évalué 
différentes mesures de rétention destinées à mesurer l’engagement des femmes tout au long du 
continuum de soins pour la PTME Option B+ au Mozambique. 
Méthodes: Nous avons comparé la rétention dite « à un temps t » (présence de la patiente dans 
les soins à 12 mois après le début du TARV ou à tout moment par la suite) avec les définitions 
suivantes: vivante et suivie à 12 mois après l’initiation du traitement (Ministère de la Santé); 
fréquentation d'un établissement de santé jusqu'à 15 mois après l’initiation du traitement 
(Organisation mondiale de la santé); vivante et suivie sous traitement à 1, 2, 3, 6, 9 et 12 mois 
après l’initiation du traitement (Inter-Agency Task Team- IATT); et vivante et suivie à 12 mois 
après l’initiation du traitement avec une observance de 75% ou plus des consultations au cours 
au suivi (avec ou sans respect de la ponctualité des rendez-vous). Des courbes de survie de 
Kaplan-Meier ont été produites pour évaluer la variabilité des taux de rétention. Nous avons 
utilisé la rétention avec observance de 75% ou plus des consultations avec respect de la 
ponctualité des rendez-vous comme référence pour estimer la sensibilité, la spécificité et la 
proportion de patientes mal classées.  
Résultats: En tenant compte de la définition de la rétention dite « à un temps t », 16 840 femmes 
enceintes séropositives inscrites aux services PTME Option B+ ont été identifiées 
comme vivantes et suivies à 12 mois après l’initiation du traitement. Parmi celles-ci, 60,3% 
(IC95%: 59,6–61,1), 84,8% (IC95%: 84,2–85,3) et 16,4% (IC95%: 15,8–17,0) ont été classées 
comme «retenues dans les soins» en utilisant la définition du Ministère de la Santé, de l’OMS, 
et de l’IATT et 1,2% (IC95% : 1,0-1,4) ont été classées comme vivantes et suivies à 12 mois 
en utilisant la définition de rétention avec observance de 75% ou plus des consultations avec 
respect de la ponctualité des rendez-vous. Toutes les définitions donnaient des taux de 
spécificité ≥ 98%. Les taux de sensibilité étaient de 3% avec 78% de patientes classées 
incorrectement selon la définition de l'OMS et 4,3% avec 54% de patientes classées 
incorrectement selon la définition du Ministère de la Santé. Basé sur la définition de la rétention 
dite « à un temps t », 97,6% des patientes sont mal classifiées. En utilisant les définitions de 
rétention de l’IATT et celle avec observance de 75% ou plus des consultations, les taux de 
sensibilité étaient également faibles (9,0% et 11,7%, respectivement); Cependant, la proportion 
de patientes mal classées était moins importante (15,9% et 18,3%, respectivement). 
Conclusion: L’utilisation de définitions plus strictes produisait des taux de rétention dans les 
programmes de PTME plus faibles. Les décideurs et les responsables de programme devraient 
inclure l’observance aux visites de suivi lors de la mesure de la rétention dans les soins afin de 
mieux orienter la planification, l’expansion et le suivi des interventions. 
 
Discussion et conclusion générale 
Ce travail a fourni une vue d’ensemble du niveau d'engagement dans les soins dans les 
programmes PTME Option B+, depuis l'inscription de femmes enceintes séropositives à la 
consultation prénatale jusqu'au test final de l’enfant exposé au VIH. La mise en évidence de 
lacunes dans la prise en charge du couple mère-enfant et des conséquences néfastes sur l’atteinte 
de l’objectif d’élimination virtuelle de la TME du VIH, ont été discutés. Pour atteindre 
l’élimination virtuelle de la TME du VIH, le gouvernement du Mozambique doit concentrer ses 
efforts sur le renforcement de l’engagement dans les soins des couples mères-enfants au cours 
du suivi, en particulier au cours des trois premiers mois suivant l’initiation du traitement 
antirétroviral durant la grossesse. 
Nous avons mis en évidence l'avantage d'une approche pluridimensionnelle consistant à 
proposer un ensemble d'interventions visant à améliorer chaque étape de la cascade de la PTME. 
Néanmoins, la rentabilité et la pérennité de telles interventions devraient être prises en compte 
à la fois par le programme national de lutte contre le VIH et par les parties prenantes 
internationales impliquées dans les formulations de décisions stratégiques et changement de 
politique de santé. 
Nous avons également souligné l'importance pour la communauté internationale d'adopter une 
approche consensuelle pour mesurer les résultats des programmes de PTME afin de permettre 
des comparaisons nationales et internationales. Si l’observance des visites programmées au 
cours du suivi n'est pas prise en compte, la mesure des résultats ne permettra pas d'estimer avec 
précision le succès du programme. 
L'engagement tout au long du continuum de soins pour la PTME est un phénomène dynamique 
et a un impact sur les résultats programmatiques à la fois au niveau de l’individu et de la 
population. Les efforts visant à retenir les femmes sous TARV tout au long de leur vie, en 
veillant à ce que leurs enfants exposés au VIH reçoivent les services de PTME attendus au bon 
moment et ce jusqu'à la détermination du statut final du VIH, constituent la pierre angulaire de 
la réalisation d'une génération sans SIDA d'ici 2030 au Mozambique.  
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